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 Since the 1980s, the pharmaceutical and biotechnology industries have interacted 
in a pattern best described as a “helix of rhetorical transformation,” with each engaging in 
a recursive and interactive process of definition, description and ingratiation. The 
relatively recent emergence of the biotechnology industry has destabilized the older 
pharmaceutical industry, causing heightened activity of self-evaluation for each, as well 
as assessment by media, government, economic development agencies, investors, and 
others. 
 Although the two industries have much in common, their differences have set in 
motion a rhetorical helix that winds both toward and away from each other. Both 
industries have foundations built on the modern scientific method and share a mission to 
develop new drugs for humans and animals. At the same time, they are also made distinct 
by size (small biotechs versus “big pharma”), relative age, method of drug development 
(biology-based versus chemistry-based), product capabilities, and characterization of the 
employee base (innovative and risk-taking versus traditional and risk-averse).   
In the early 1900s, nascent pharmaceutical companies were keen to shed the 
image of drug manufacturing as alchemy and adopt a new definition that was grounded in 
scientific methodology.  Pub lic ingratiation soared mid-century with the development of 
life-saving penicillin but declined toward the end of the century, attributable to several 
high-profile drug failures as well as charges of excessive profiteering and immoral 
marketing practices.  Meanwhile, public response to biotechnology was rising since the 
newer industry represented greater potential for transformation—not only of the 
landscape of drug development, but of communities themselves.  
 The intricacies of the bio-pharma rhetorical helix—including the play between 
scientistic and dramatistic approaches to language—can be examined by using the 
framework of dramatism and specifically Kenneth Burke’s pentad of key analytical 
terms. Burke’s concepts serve as a systematic form of inquiry for understanding the 
biotechnology and pharmaceutical meta-narratives (including the mythology associated 
with Alexander Fleming, Francis Crick, and James Watson) that have emerged within a 
complex and volatile cultural environment of shifting modernism and postmodernism. 
They also provide a basis for predicting future constructions of the “biopharmaceutical” 
drama. 
George Lakoff’s work in metaphor (alone, and in collaboration with Mark Turner 
and Mark Johnson) is useful in understanding the potent imagery of the double helix, and 
Ann E. Berthoff’s observations of the writing process as a helix speaks to the usefulness 
of this structure in generating exciting and transformational new meaning. 
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CHAPTER I 
 
INTRODUCTION 
 
 
Transformation wields great power. As individuals, we can define who we are and 
describe those essential characteristics that make us unique. Our view of ourselves, 
however, may not necessarily align with the opinions of those around us. Thus, the ability 
to reinvent oneself, to change how others see us and react to us, is critical for the process 
of ingratiation. If I want to court your approval, to endear myself to you, then I may need 
to redefine myself or describe differently what I stand for. Politicians are no stranger to 
this process. Neither are corporations or industries. 
This process of defining, describing, and ingratiating oneself has been in play, 
recursively, for the modern pharmaceutical industry since its emergence in the early 
twentieth century and for the biotechnology industry since the 1980s. Of particular 
interest is the phenomenon whereby each industry seeks to reinvent itself in relation to 
the other, resulting in a kind of helical dance to curry public favor. Inherent in this 
“rhetorical helix” is the notion that definition and description are always in flux, always 
informed by culture, and always being negotiated by companies, industries, the media, 
the government, investors, and others. Some speak on behalf of biotech, others on behalf 
of “pharma,” and others for an amalgamation of the two. The ultimate prize is what 
rhetorician Kenneth Burke refers to as identification where two people (or two publics) 
share a way of life, acting together to form “common sensations, concepts, images, ideas, 
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[and] attitudes that make them consubstantial” (ROM 545). Burke explains the concept 
as follows: 
 
A is not identical with his colleague, B. But insofar as their interests are joined, A 
is identified with B. Or he may identify himself with B even when their interests 
are not joined if he assumes that they are, or is persuaded to believe so. .  . To 
identify A with B is to make A “consubstantial” with B. (ROM 544-545) 
 
 
In embracing (or rejecting) pharmaceutical or biotechnology industries, we are 
essentially embracing or rejecting each industry’s ability to transform us in some way – 
to provide jobs for our communities; to bring therapeutics to our medicine cabinets; to 
make us, by association, innovative and heroic, or greedy and staid. Automobiles, for 
example, hold a potential for personal transformation that is perceived by the buyer and 
validated through the rhetoric of advertising and the media. While all cars are designed to 
get us from one point to another, few will argue that an eco-friendly mini sedan that gets 
50 miles to the gallon is equivalent to a custom turbo-charged sports car with all- leather 
interior and a nine-speaker audio system. As auto manufacturers and advertisers know, 
the vehicles we choose to purchase can reflect not only who we are, but also who we 
hope to be. It is no coincidence that we associate James Bond with an Aston Martin and 
not a Honda Civic. 
Just as with cars, communities also hold potential for transformation—for the 
cities and towns themselves and, by extension, the citizens who live there. Media 
accounts are filled with stories of towns that reinvent themselves. Architectural historian 
William Morgan offers Bellows Falls, Vermont as an example of an old, industrial mill 
town that sought to shake off hard times by building a new historical center and a 
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“monumental and somewhat startling 145-foot- long and 32-foot-high steel bridge arching 
over the building” (B5). South Amboy, New Jersey, an old and rusty shore town, 
transformed itself into a “transit-oriented commuter village,” thanks to new railway and 
waterway transports (O’Keefe 67). And when Monterey, California—once the center of a 
bustling fishing and canning industry—slid into a seedy state of affairs in the early 1950s 
(infamously described by John Steinbeck in his novel, Cannery Row), it later resurrected 
itself with upscale restaurants, hotels, and a world-class aquarium. 
The three community transformations cited above are not simply examples of 
successful urban redevelopment, they are also examples of successful rhetorical 
transformation as community leaders re-defined their cities and towns. As a Cannery 
Row real estate website puts it: “The Good Life, that perfect combination of 
environment, treasures and experiences, is the definition of Cannery Row.” As Morgan 
writes, Bellows Falls’ steel bridge is not just a bridge, but a “powerful identity symbol” 
that “declares that Bellows Falls is renewing itself, and with a sense of style.” The real 
value of the bridge, he says, is as a metaphor that captures “the indomitable character of 
the city” (B5). 
But what of declining or stagnant communities that do not have the natural 
advantage of an ocean or the historical advantage of a Pulitzer-prize setting? For such 
communities, transformation—both literal and figurative—is possible through the 
acquisition of new industry. The biotechnology industry, with its perceived aura of 
youthfulness, innovation, and usefulness, stands out as a prime example. 
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Since the early 1980s, when it became clear tha t biotechnology was not just a 
scientific endeavor but a potentially profitable business enterprise as well, regional 
thought leaders scrambled to entice biotech companies to their parts of the country. In 
1984, for example, the State of North Carolina established The North Carolina 
Biotechnology Center, whose mission is to “provide long-term economic and societal 
benefits to North Carolina by supporting biotechnology research, business and education 
statewide” (2006 Annual Report 1). 
From 1984 onward, the rhetoric of transformation through biotech flowed several 
ways. Development organizations like the NC Biotech Center communicated the benefits 
of biotechnology to the media, the public, and local leaders. The biotechnology industry 
touted its capabilities and attributes to the government, the media, and the public. Those 
in academia and the corporate world weighed in as well. Everyone had an opinion about 
biotech and it was largely positive. Biotechnology was smart, new, and filled with 
enormous promise and potential—the key watchwords that surfaced from all sides of the 
discussion. Biotech, in other words, carried an aura of positive transformation. 
Particularly when compared to the older, larger, and “greedier” pharmaceutical industry, 
biotech fared very well indeed. By the end of the twentieth century, “big pharma,” as the 
large pharmaceutical companies came to be known, was suffering from a major image 
problem as the industry was accused of dishonest marketing practices, shoddy science, 
callous pricing, and worse. 
Big pharma’s reputation was not always negative. Like biotech, the 
pharmaceutical industry was once fresh, bright, and even heroic. And it, too, had the 
 
 
5 
power of transformation. In the early twentieth century, pharmaceutical company 
founders took great care to distance themselves from the alchemists of centuries earlier.  
In many ways, the emergence of the biotechnology industry (also called bio, as a 
comparable term to pharma) may have exacerbated the public’s ill- feeling toward 
pharmaceuticals. From a rhetorical perspective, pharma was old, whereas bio was young. 
Pharma was greedy; bio had yet to make a profit. Pharma was rooted in chemistry; bio, in 
biology. Pharma was a big, old-boy network that was closed to newcomers, whereas bio 
was the newcomer. Bio was accessible, even to a small city such as Winston-Salem, 
North Carolina, located mid-state in the Piedmont Triad region. At the end of the 
twentieth century, such a city couldn’t realistically hope to newly mint itself as a 
pharmaceutical hub. But it certainly could aspire to become a biotechnology center. Thus, 
Winston-Salem—a city once dominated by RJ Reynolds and “big tobacco”—began to lay 
down its agrarian mantle and pick up the banner of life science technology. It is but one 
story of many in the United States where a community has looked to biotechnology for 
change and implemented a transformative process through the deliberate and repeated use 
of potent biotech rhetoric and imagery. 
There is perhaps no image more evocative of biotechnology than the double 
helix—the structure of DNA first brought to public attention in the 1950s by James 
Watson and Francis Crick. Since then, the double helix structure has been elevated to 
icon status, finding its place not only in the halls of science but the galleries of art, 
fashion, and pop culture. Amy Harmon describes this phenomenon well:  
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With its extraordinary symmetry and blend of form and function, the double helix 
has supplanted the bomb-tainted atom as the standard symbol of science. Its 
celebrity status and multiple associations, the art historian Martin Kemp wrote in 
a recent issue of the journal Nature, make DNA the “Mona Lisa” of modern 
biology. 
 
But the double helix also resonates beyond science into the public consciousness. 
Along with the national flag, a Christmas tree or other venerable symbols, the 
double helix has become a visual shorthand for a range of emotions and beliefs 
about the nature of life. (A1) 
 
 
The double helix, in other words, has become what George Lakoff and Mark 
Turner would call a “basic conceptual metaphor,” whereby there now seems to be a 
“fixed correspondence between the structure of the domain to be understood” (in this 
case, new and innovative science) and “the structure of the domain in terms of which we 
are understanding it” (51). The structure in this case is a ladder of sorts: a tool that allows 
us to ascend, to reach new heights, albeit in a twisting and complex manner. 
In her pedagogical work, The Making of Meaning, Ann Berthoff calls models 
such as the double helix “picturable analogies that are aids to reflection” (7). She herself 
uses the double helix as a way to depict the process of written composition that works 
upward, downward and also in opposition to one another. 
For the study at hand, if we consider two strands of DNA, similar in composition 
but not a mirror image of one another and interacting in a manner that appears 
simultaneously to unite and divide, we can extend the metaphor to the biotechnology and 
pharmaceutical industries. The two strands of bio and pharma have wound their way 
through two separate eras, with the modern pharmaceutical industry emerging at the 
beginning of the twentieth century and the biotechnology industry several decades later. 
 
 
7 
Toward the end of the twentieth century, while the two metaphorical strands began 
winding ever closer toward one another, they were also pushed apart by a volatile and 
shifting cultural milieu. It is to be noted that discussion of biotechnology and 
pharmaceuticals in the chapters that follow is primarily reflective of U. S. culture and 
history. 
When pharma came into being, the new industry defined itself and, at the same 
time, was defined by others. Once defined, pharma (and others) attempted to establish the 
essential qualities of the industry—that is, its unique character and attributes. While 
conveyance of positive industry attributes resulted in ingratiation with the public at large, 
negative perceptions by the public spurred redefinition and/or re-description. Similarly, 
as the biotechnology industry emerged, it began its own process of definition, description 
and ingratiation. 
Thus, the rhetorical helix can be considered as operating in two ways. First, the 
rhetorics of definition and description operate as a helix within each industry, recursively 
functioning to establish and/or maintain ingratiation with the public. Second, the rhetorics 
of each industry operate as a helix in their competition for ingratiation with the public.  
Until bio came into being in the late 1970s/early 1980s, redefinition and re-
description for pharma was prompted by the industry’s early evolution. The new and 
young pharmaceutical companies defined themselves as modernists who carefully 
controlled the chemistry of their medicinal compounds. They were advocates of 
standardization who employed well-validated scientific processes to manufacture their 
products. Most important, they produced life-saving therapeutics, such as penicillin and 
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polio vaccine, that achieved near-mythic status. And although the pharmaceutical 
industry was always designed to be profit-making, its defining narrative for many 
decades was “deserved wealth.” Many of the early pharmaceutical companies relayed 
their rags-to-riches tales in which hard work and personal sacrifice was rightly rewarded.  
The emergence of the biotechnology industry destabilized the older 
pharmaceutical industry, forcing it to redefine and re-describe itself in relationship to this 
new entity. “Biotechnology was a rude shock to big pharma,” George Poste, the former 
head of research and development for pharmaceutical giant SmithKline Beecham, was 
quoted as saying (Glaser and Hodgson 240). In the same article, Poste said that action-
wise, the pharmaceutical company response was to bring biotechnology in-house, form 
alliances with biotech companies, or ignore it altogether. From a rhetorical perspective, 
pharmaceutical companies competed with biotech in the language they used, infusing 
their texts with words that conveyed vitality and innovation. 
For its part, biotechnology, as the second strand of the helix, had to differentiate 
itself from the pharmaceutical industry. The biotechnology industry’s public rhetoric 
positioned it as more youthful and risk-tolerant in contrast to pharmaceuticals, but of 
necessity, several similarities were drawn as well. After all, both industries are rooted in 
the modern scientific method and both are engaged in the science of health. Both have a 
professional employee base, a significant investment in research and a necessity for 
return on investment. 
The helix metaphor captures the essence of two industries caught up in a twisting, 
fraught and complex rhetorical relationship in which many parties play a role. PhRMA 
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(the Pharmaceutical Research and Manufacturers of America) speaks for the 
pharmaceutical industry, while BIO (the Biotechnology Industry Association) speaks for 
the biotechnology industry. While these organizations serve as guardian (and frequently 
author) of their industries’ meta-narratives, their roles are increasingly influenced by the 
cross-population of member companies. Many big pharmaceutical companies (e.g., 
GlaxoSmithKline, Pfizer) are members of BIO, while some PhRMA members (e.g., 
Genzyme Corporation, Celgene Corporation) describe themselves as biopharmaceutical 
companies. 
Other players attempt to sway the tenor of the pharma-bio conversation for their 
own reasons. Media outlets, for example, thrive on the tension of a good story. 
Consequently, newspaper and magazine articles frequently pit biotechnology against 
pharmaceuticals as a means of attaining narrative fulfillment. In the financial community, 
Ernst & Young, a professional services organization, issued its first biotechnology 
industry annual report in 1986, with the goal of helping to guide “a new industry based 
on a new technology in a world that is both enthusiastic and apprehensive about what 
they are doing” (Burrill 1). From the start, the organization asked whether biotechnology 
would stand alone or “gradually blend in with major pharmaceutical firms” (Burrill 1), a 
question that lent exc itement and drama to the bio /pharma play. 
In fact, the biotechnology-pharmaceutical engagement is theater at its best, a real-
life drama complete with heroes, villains, scapegoats and a host of other characters. One 
of the most well known names in the history of pharmaceuticals is Alexander Fleming, 
who is widely acknowledged for his discovery of penicillin. Fleming was awarded a 
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Nobel Prize for his discovery, knighted by a king and—half a century after his death— 
lives on in the popular psyche as a pioneer of health. By contrast, there is Howard Walter 
Florey, also a Nobel Prize winner for his work in penicillin and also knighted, but whose 
name lies in relative obscurity. 
Why is one name still vital today while the other is dormant? One clue may lie in 
the rhetoric that surrounds scientific endeavors. Fleming was associated most closely 
with biology and the concept of discovery through divine Providence. The Fleming story 
that is most popularly told in literature and in the press notes how the young Scottish 
researcher saw that Penicillium mold spores had fortuitously drifted through an open 
laboratory window, settled onto a plate of bacteria and killed them. Florey, on the other 
hand, represented biochemistry, and together with Ernst Chain worked with the 
government and major pharmaceutical companies to mass produce penicillin antibiotics. 
Thus, the drama of the penicillin story was marked by a showdown between biology 
versus chemistry; the single, heroic individual versus an anonymous team of big 
pharmaceutical scientists; and nature versus invention. Yet while one side of the story 
resonated with the public, the other did not. 
It is possible, and worthwhile, to analyze the intricacies of the penicillin story—
and the larger bio-pharma play as well—through the framework of Burkean dramatism 
and specifically Burke’s pentad of key analytical terms. Kenneth Burke saw language as 
more than a mere conduit for information; language, in his view, performs. As Burkean 
scholar David Blakesley elucidates, “Words act . . . to define, persuade, appease, divide, 
identify, entertain, victimize, move, inspire, and so on” (5). 
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Dramatism, for Burke, was a way of understanding the human motives behind the 
words, with his overarching question as follows: “What is involved when we say what 
people are doing and why they are doing it?” (GOM xv). 
If we lived in a world with no ambiguity, then nothing would exist between the 
extremes of black and white, good and bad, small and large, or old and new. What people 
are doing would be obvious, and why they are doing it would be equally obvious. 
However, we do not live in such a world, and people’s motivations for what they do are 
often hazy. And, more to the point of Burke’s question, how we see other people and how 
we interpret their actions are also fraught with complexity. When we tell the story of 
Alexander Fleming and, in the doing, ignore or downplay the story of Howard Florey or 
Ernst Chain, what exactly is involved? Are we trying to persuade people that biology is 
more valuable than chemistry? Do we feel that a lone hero is more inspirational than a 
large team? Or is Fleming’s story just simpler to tell, or perhaps more entertaining? 
Similarly, Francis Crick and James Watson were widely celebrated for unlocking 
the “secret code” of the double helix and DNA, while Rosalind Franklin—who did much 
of the groundbreaking work—went largely unacknowledged. Was the suppression of her 
name (and failure to award her a Nobel Prize) a plot against uppity female scientists? An 
oversight? A reflection of the times? 
And, in the biotech world, what of the well-publicized feud between Francis 
Collins, head of the government-funded Human Genome Project (HGP), and Craig 
Venter, founder of a privately funded venture?  Both men were committed to identifying 
all of the genes in human DNA, but one felt that the ensuing knowledge should belong to 
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the public, while the other felt that such knowledge should be the property of its 
discoverer. How were these men characterized in the popular press, and how does it 
speak to our values? 
Rather than trying to corral the complexity of human motivation, Burke suggests 
five key terms to set it free. Burke’s pentad of terms—act, scene, agent, agency, and 
purpose—are designed to reveal ambiguity, to unfold the myriad possibilities of how we 
use language and how we are used by it. According to Burke, these terms can then be 
examined at length: 
 
We want to inquire into the purely internal relationships which the five terms bear 
to one another, considering their possibilities of transformation, their range of 
permutations and combinations—and then to see how these various resources  
figure in actual statements about human motives. (GOM xviii) 
 
 
The concept of transformation is integral to the study at hand. If the 
pharmaceutical industry has been transformed from hero to villain, then how has 
language been complicit in this change? If the biotech industry is perceived as an agent of 
transformation for languid towns, how does language factor in? 
I suggest that it is critical to look at rhetorical transformation at each stage of the 
bio-pharma helix, using Burke as the primary guide and Lakoff and Turner as well as 
Berthoff as important sources of illumination. 
I begin, in Chapter II, by using a provocative statement made by the president of 
the animal rights group People for the Ethical Treatment of Animals (PETA) to compare 
the dramatistic approach to the nature of language, which sees language as act, with the 
scientistic approach, which sees language as definition. Although the two approaches, in 
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Burke’s words, “are by no means mutually exclusive” (LSA 44), they are very different 
in how they direct one’s attention. Whereas the scientistic approach derives its power 
through a process of naming and definition, the dramatistic view of language openly 
acknowledges the “suasive nature” of all terminology (LSA 45). Definitions are not 
neutral, Burke says, even though the definition-makers would have you think they are. He 
states that “to define, or determine a thing, is to mark its boundaries,” a task he says is 
“beset by inevitable paradox” (GOM 24). 
In Chapter III, I proceed to outline the paradoxical attempts at definition that have 
been made for biotechnology and pharmaceuticals. As one might expect for an emerging 
industry, definitions for biotechnology are widely varied, depending upon the source and 
the timeline in which they were developed. There is even a question as to whether 
biotechnology is an industry at all, as opposed to an application, a trade, an endeavor, or a 
subset or enabler of other scientific disciplines. This ambiguity is reflected in the 
government classification systems of SICS and NAICS, which are discussed. 
Unlike the term biotechnology, the term pharmaceuticals is rarely defined in 
general publications, presumably since the industry is now mature. This doesn’t mean, 
however, that everyone necessarily sees pharmaceuticals the same way. As one industry 
professional writes: 
 
The well-known Indian fable of six blind men and the elephant reminds one of the 
way various groups tend to view the industry. In this fable six blind men are asked 
to describe an elephant to a maharaja who has never seen one. Each feels a 
different part of the elephant (i.e., tusk, trunk, ear, body, tail or leg) and provides a 
totally different description of what the elephant looks like. (Spilker 9) 
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Defining pharma by the products it makes, its research methods, or the manner in 
which it manufactures its products, necessarily positions it in contrast with bio. Whether 
that position can be considered more or less favorable is the uncertain issue. When the 
early pharmaceutical companies defined themselves through chemistry, it was a positive 
rhetorical move since chemistry bespoke modernity and scientific process. However, 
definition—with its scientistic is/is not structure—is limiting. When chemistry became 
viewed more skeptically, the pharmaceutical industry could not disengage itself from this 
field through redefinition. It had to rely on more subtle and textured nuance through 
description. 
In Chapters IV and V, I move to the process by which the pharmaceutical and 
biotech industries are described. Burke, of course, would argue that definition and 
description are both suasive, and I agree. However, unlike definition, description seems 
to have more overt acknowledgement of its subjective tendencies. A man may be a 
bipedal primate mammal by definition, but courageous and strong by description. When 
the bodybuilder Charles Atlas promised to make “a new man” out of a 90-pound 
weakling, he fed the description of man as big, strong, and unafraid—traits that have 
ingrained themselves into the collective consciousness and emerged, time after time, in 
popular media. The paradox here is that given enough repetition, such traits begin to feel 
and act definitive. 
The pharmaceutical industry was able to free itself from rigid definition by 
ascribing certain traits and attributes to itself that could be changed over time. By playing 
with language, pharmaceutical companies—and later, biotech companies—could better 
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demonstrate the alignment of their interests with that of the public. In this manner, 
description allowed for deeper transformative potential than was possible through mere 
definition. 
Burke’s dramatistic pentad is a useful tool to demonstrate the permutations of 
how we could talk about any given subject and to compare these hypothetical 
interpretations with the historic rhetorical record. Is penicillin, for example, a “wonder 
drug” or is it an impotent antibiotic that is ineffective in the war against germ terrorism?  
Playing with language pushes and pulls our attitudes, and makes us more or less 
susceptible to ingratiation. 
In biotechnology narratives, the DNA double helix came to represent not only 
scientific innovation, but life itself. Penicillin was one single drug that sprang from mold 
spores; it originated from nature “outside the window.” DNA, on the other hand, was not 
external nature, but was the nature inside each of us. DNA presented the potential to open 
up an entire array of new therapies, using the so-called secrets that lay within our own 
bodies. That which is secret, however, can also be frightening. The alternative narrative 
to the promise of DNA was the threat of DNA and the specter of biology gone amok as a 
result of the sheer hubris of reckless scientists. In the push-pull of biotech dramatism, 
Watson and Crick could be seen as pioneers and advancers of human knowledge or 
irresponsible self-aggrandizers. The work of George Lakoff (alone, and in collaboration 
with Mark Turner and Mark Johnson) is helpful for understanding the helix as a 
metaphor, and its place as a rhetorical tool for the biotechnology industry. 
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In Chapter VI, I explore the efforts taken in North Carolina to establish a 
rhetorical climate that is receptive to biotechnology, using Berthoff to illuminate how 
meaning is constructed within local communities. Winston-Salem in North Carolina’s 
Piedmont Triad region and Research Triangle Park in Raleigh-Durham are examples of 
areas that have expended significant money and effort to attract and develop 
biotechnology companies because they believe the communities’ values are 
consubstantial with that of biotech. In 1982, the North Carolina Biotechnology Center, 
which was sponsored by the state, became the world’s first targeted initiative to bring 
biotechnology to a local community. In the eyes of many in the state, biotechnology 
stands for newness, vitality, and innovation. The themes of biotechnology promise and 
potential underlie much of the language in economic development literature. In Winston-
Salem, the biopharmaceutical company, Targacept, illustrates the transformative potential 
of biotechnology to change a city’s entire economic base—in this case, from tobacco to 
knowledge, science, and health. 
In Chapter VII, I conclude by exploring where the bio-pharma rhetorical matrix is 
headed next. One hundred years after the emergence of the modern pharmaceutical 
industry, pharmaceutical-biotechnology rhetoric is still rhetoric in flux, with many 
different players attempting to sway the tenor of the conversation. The story continues to 
be constructed within a complex and volatile cultural environment of shifting modernism 
and postmodernism that is influenced by the government, economic development 
agencies, the media, the investment community, academia and the public at large. While 
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some tout the new biopharmaceutical industry as the direction for the future, others 
protest such exuberance as errors of enthusiasm. 
Keeping this drama going—keeping in motion the rhetorical helix that winds both 
toward and away from each other—is just how Burke would have it. As Burke expresses 
the phenomenon,  
 
Put identification and division ambiguously together, so that you cannot know for 
certain just where one ends and the other begins, and you have the characteristic 
invitation to rhetoric. (ROM 549) 
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CHAPTER II 
 
“A RAT… IS A BOY”: UNDERSTANDING BURKE’S SCIENTISTIC AND 
DRAMATISTIC APPROACHES THROUGH PETA 
 
 
As outlined in the introduction, the rhetorical helix operates in two ways: first, as 
interplay between definition and description, and second, as an interactive competition 
between the pharmaceutical and biotechnology industries. This chapter considers the first 
sense of the helix by exploring Kenneth Burke’s notion of scientistic and dramatistic 
approaches to the nature of language. At the heart of this discussion is an examination of 
language that presents itself as solid and unchanging, language that presents itself as fluid 
and malleable, and the relationship between the two. It is an important helix, this 
definition/description swirl, because it trave rses between the liberating concepts of 
possibility and change, and the confining concepts of standardization and stasis. 
In his 1998 testimony to the Grand Jury about his relationship with Monica 
Lewinsky, President Bill Clinton infamously rebutted a lawyer’s challenge to his 
testimony by saying, “It depends on what the meaning of the word “is” is. If . . . “is” 
means is and never has been that is not—that is one thing. If it means there is none, that 
was a completely true statement” (“Clinton’s Grand Jury Testimony”). 
Clintonian onomastics aside, is is the foundation of definition, a word that aids 
and abets the philosophy of Modernism with its idea that objective truth exists. Is is 
complicit with the epistemological philosophy of Descartes, whose famous utterance— “I 
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think, therefore I am”—privileged the human individual and his ability to gain 
knowledge through Empiricism and the scientific method. 
Burke hones in on is by equating it with what he calls the scientistic approach to 
language which, he says, “begins with questions of naming or definition” (LSA 44). 
Burke contrasts this with the dramatistic approach, which stresses language as an aspect 
of symbolic action: 
 
The “scientistic” approach builds the edifice of language with primary stress upon 
a proposition such as “It is, or it is not.” The “dramatistic” approach puts the 
primary stress upon such hortatory expressions as “thou shalt, or thou shalt not.” 
(LSA 44) 
 
 
While the scientistic approach supports the notion of logic, the dramatistic 
culminates more in “the kinds of speculation that find their handiest material in stories, 
plays, poems, the rhetoric of oratory and advertising, mythologies, theologies, and 
philosophies after the classic model” (LSA 45). 
Traditional dictionaries and encyclopedia s take a scientistic approach, seeking to 
embed definitions in concrete and set them permanently. We are persuaded to believe that 
a dog is “a highly variable domestic mammal (Canis familiaris) closely related to the 
common wolf (Canis lupis)” (“Dog” 341) because of the authority of Merriam-Webster. 
A dog is like a wolf, Merriam-Webster says; thus, a dog is not like a rat. 
Although Burke equates the scientistic approach with language as definition and 
the dramatistic approach with language as act, he does not see them as mutually exclusive 
since “definition itself is a symbolic act” (LSA 44). For a startling example of the 
intersection of language-as-definition and language-as-act, one need look no further than 
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to Ingrid Newkirk, president and founder of PETA (People for the Ethical Treatment of 
Animals) who, in the mid-1980s, said the following: 
 
A rat is a pig is a dog is a boy. (Barnes 542) 
 
 
Considered separately, they are just eleven simple words—four nouns, three 
verbs, and three indefinite articles. Considered collectively, they have the power to 
define, inspire, incite, attack, and defend. In sum, this small phrase is a perfect example 
of how words act. 
PETA, which calls itself “the largest animal rights organization in the world” 
(“PETA’s Mission Statement”), says that it “operates under the simple principle that 
animals are not ours to eat, wear, experiment on, or use for entertainment” (“PETA’s 
History”). A major area of concern for the group is the use of animals in scientific 
laboratories, which places Newkirk and PETA squarely at odds with many in the biotech 
and pharmaceutical industries. 
Since the 1980s, Newkirk’s original eleven words have surfaced and resurfaced 
on web sites; in books, magazines, letters, and pamphlets; and on television, radio, and 
other media. And unlike conventional theater, the “rat is . . . a boy” drama has enfolded 
multi-dimensionally over the past three decades—with many stages, actors, audiences, 
and scripts. 
For purposes of studying the biotechnology/pharmaceutical rhetorical matrix, the 
PETA controversy is helpful on a number of levels. Not only can it help to elucidate 
Burke’s descriptions of scientistic and dramatistic approaches to language, but it can be 
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used as an example to show how motives can be queried in dramatistic fashion. It is also 
a particularly useful jumping-off point for understanding the rhetoric of definition and its 
relationship to description and ingratiation. 
At its most basic level, a rat is a pig is a dog is a boy is definitional. Just like the 
editors at Merriam-Webster, Newkirk is attempting to establish a logic of categories and 
relationships. Human beings need to sort things out for reasons both practical and 
esoteric. People name things. They group things they think are similar; they compare and 
contrast those things they think are different. These activities are an attempt to understand 
the world and to organize disparate bits of information into a coherent whole. 
However, definitions are never neutral. They are symbolic, political, and 
powerful. To Burke, it doesn’t matter if it is Merriam-Webster that is doing the defining 
or People for the Ethical Treatment of Animals: 
 
Even if any given terminology is a reflection of reality, by its very nature as a 
terminology it must be a selection of reality; and to this extent it must function 
also as a deflection of reality. . . . Any nomenclature necessarily directs the 
attention into some channels rather than others. (LSA 45) 
 
 
Thus, when Newkirk states that “a rat is a pig is a dog is a boy,” her words are not mere 
definition, but definition-turned-philosophy, with attendant legal, moral, and ethical 
considerations. The same can be argued for Merriam-Webster, Aristotelian, Darwinian, 
and other hierarchical definitions as they, too, are neither simple nor straightforward. As 
Bowker and Star write, categorization always “valorizes some point of view and silences 
another”—an activity they call an “ethical choice” and therefore inherently dangerous (5-
6). They describe how such choices are not always obvious: 
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(C)lassification systems are often sites of political and social struggles . . . 
Politically and socially charged agendas are often first presented as purely 
technical and they are difficult even to see. As layers of classification system 
become enfolded into a working infrastructure, the original political intervention 
becomes more and more firmly entrenched. In many cases, this leads to a 
naturalization of the political category, through a process of convergence. It 
becomes taken for granted. (196) 
 
 
Race classification under apartheid is a particularly vicious example of a political 
classification system, as Bowker and Star assert. The same can be said of the Nazi 
treatment of Jews in World War II, or the so-called ethnic cleansing in the former 
Yugoslavia. 
Another attribution of the “rat is . . . a boy” statement to Newkirk was in the 
August 1986 issue of The Washingtonian magazine. In an article entitled, “Who Will 
Live, Who Will Die?” freelance writer Katie McCabe interviewed people on both sides of 
the animal rights issue. McCabe was granted a personal interview with Newkirk, and 
quotes Newkirk as follows: “Animal liberationists do not separate out the human 
animal,” she [Newkirk] begins, “so there is no rational basis for saying that a human 
being has special rights. A rat is a pig is a dog is a boy. They’re all mammals” (115). This 
ethic, Newkirk explains,  
 
shakes the whole grubby system of biomedical research, because if you jeopardize 
an animal one iota in something that doesn’t benefit it, you’re doing something 
immoral. Even painless research is fascism, supremacism, because the act of 
confinement is traumatizing in itself. (115) 
 
 
Thus in this interview, Newkirk set out some of her emerging thoughts about 
animal rights:  (a) humans are not special; (b) humans are mammals, just as rats, pigs, 
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and dogs are mammals; (c) research is fascism; and (d) research is supremacism. As the 
definition-maker, Newkirk is defining what is, and what is not. 
Such a scientistic approach to language conveys an attitude that the definition-
maker has established the truth. As such, it ends a conversation. One needs look at only a 
small cross-section of incidents in the past 20 years to observe this distinct pattern in the 
“rat . . . is a boy” body of rhetoric. When a scientistic-style definition was presented (e.g., 
animal research is fascism), it would then be rejected by the opposing side of the 
philosophical argument (e.g., animal research is not fascism; animal rights activists are 
terrorists). The opposing side would then present an alternate scientistic-style definition, 
as, for example, when Joseph E. Murray said, “Scientists agree that whenever a cure for 
AIDS is found, it will be through animal research” (5). Such a statement would then be 
rejected by the first group, and so on. Each side would be loath to allow a rigid definition 
at odds with their belief system. In this “is so! —is not!” pattern, scientistic-style 
discourse created an impasse each time it was attempted. 
Even if the very obvious is being defined (e.g., “A rat has four legs and a tail”), 
the “truth” may not necessarily be conveyed. What about a three- legged rat—is it no 
longer a rat?  Definition is in the eye of the beholder, and not necessarily in the eye of the 
beheld, a situation that feels undemocratic. If scientistic language is trying to convey 
truth, then truth should belong to everyone. Some dictionaries have recognized this, and 
are attempting to level the playing field. The online encyclopedia Wikipedia, for 
example, allows entries to be modified by anyone, under openly collaborative rules.  
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Burke states that “to define, or determine a thing, is to mark its boundaries” 
(GOM 24). As such, it is an activity that favors the definer, and puts all others at a 
strategic disadvantage. It is no wonder, therefore, that so many people have reacted 
passionately—that is to say, both positively and negatively—to the definitional phrase 
that converges rat with pig with dog with boy. For this reason, it is possible to find 
Newkirk’s same eleven words on web sites that celebrate her and on web sites that 
demonize her. An Internet and media search of “a rat is a pig is a dog is a boy” reveals 
that the phrase has been appropriated by myriad individuals and organizations, many of 
whom have widely conflicting philosophies. 
For example, one self-professed “rookie animal activist” contributed Newkirk’s 
phrase to an online animal rights forum that was seeking inspirational quotes that support 
their mission to “preserve, promote and advance animal life” (Bozanich). Newkirk’s 
phrase stands alongside quotes from Charles Darwin, Abraham Lincoln, Mohandas 
Gandhi, John Stuart Mill, and Leonardo da Vinci, among other notable thinkers. 
On the opposite side of the coin is Furs.com, an online magazine providing facts 
about leather and fur to the industry and consumers at large. On its frequently asked 
questions page, the organization offers Newkirk’s “a rat . . . is a boy” quote—plus those 
of several other activists—as examples of the “often hidden agenda” of the animal rights 
movement. They call animal rights activists “fanatics” and state that the imposition of 
activists’ views on others is “fascism.” It is a definitional tactic, and a reverse mirror 
image to Newkirk’s statements about scientific fascism. 
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The fact that there are people on both sides of this philosophical fence who are 
using the same words speaks to what Burke calls “inevitable paradox” of definitions, and 
the “unresolvable ambiguity” that resides in the vocabulary and the context of any given 
statement (GOM 24). Yet instead of feeling anxious about the uncertainty of language or 
its context, we should embrace its complexity and excitement in what Burke calls “the 
possibilities of linguistic transformation” or dialectics (GOM 402). 
Burke has several definitions for dialectic, which he describes variously as 
“reasoning from opinion; the discovery of truth by the give and take of converse and 
redefinition; the art of disputation; the processes of ‘interaction’ between the verbal and 
the non-verbal; the competition of cooperation or the cooperation of competition; the 
spinning of terms out of terms” and more (GOM 403). All of this is certainly occurring in 
the “rat is a pig is a dog is a boy” social drama, which is fueled by what Burke calls the 
four basic motives that “are likely to figure in all human association”: guilt, redemption, 
hierarchy, and victimage (P&C 274). 
To see these motives more clearly, it is useful to employ the dramatistic approach 
to language. Whereas the scientistic approach is static and affixed to the notion of is 
versus is not, the dramatistic approach is local and shifting, allowing for plurality, flux, 
and change. The dramatistic realm celebrates uncertainty by treating language as a living, 
breathing, always-changing performance. 
Every drama of course has its actors, and the “rat is . . . a boy” drama has an 
enormous cast of characters. There are those who fervently believe in animal rights, a 
philosophy that carries the notion of animal liberty to an extent that far surpasses simple 
 
 
26 
animal welfare. There are the scientists who use animals to determine the safety of drugs 
in development, and there are some extreme animal liberationists who bomb the homes of 
pharmaceutical workers. There are pet owners, puppy mill proprietors, vegetarians, meat 
eaters, hunters, people awaiting transplants, ethicists, and more. Each one has an opinion 
that is based on their particular selection of reality. 
These actors, whom Burke calls agents, are but one element of the dramatistic 
pentad. What the agents do is the act, where they do it is the scene, how they do it is the 
agency, and purpose is why they do it. The animal rights drama plays out in myriad ways, 
in infinite combinations and interpretations of agent-act-scene-agency-purpose. Here is 
one example: 
 
Scene:   Norway, 1994 Winter Olympics 
Agents:   Five beautiful female supermodels 
Act:    Proclaiming that “I’d rather go naked than wear fur” 
Agency:   Posters affixed to the sides of buses throughout the Olympic Village 
Purpose: To protest the killing of animals to make fur coats 
 
 
What makes the dramatistic approach different to that of the scientistic approach 
is that dramatism has the ability to manipulate the terms, and to keep the play in action. If 
any element of the pentad is changed, the drama changes with it. Would a naked-model 
protest be as effective at a summer Olympics, when temperatures are sweltering and 
wearing fur would be out of the question? What if ugly people were substituted on the 
posters?  Some viewing the posters might respond by insisting the unattractive models 
wear more fur! Or what if male supermodels were employed—would that change the 
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tenor of drama? In fact, the whole idea of women baring themselves for this campaign 
struck a sour note with some feminists. 
Some on the animal rights side of the equation complain that Newkirk’s quote has 
been misused. In a series of frequently asked animal rights questions, animal rights 
advocate Donald Graft writes that the notion that “a rat is a pig is a dog is a boy” is 
“absurd” when “taken alone and literally.” He adds that the quote “has been shamelessly 
removed from its original context and misrepresented” by animal rights opponents. Graft 
says that the original context of the quote is: “When it comes to having a central nervous 
system, and the ability to feel pain, hunger, and thirst, a rat is a pig is a dog is a boy.” In 
this context, Graft says, “the quote is neither remarkable nor absurd.” 
What Graft appears to be doing is attempting to re-solidify the scientistic aspects 
of Newkirk’s quote. That is, he is reasserting the it is definition, adding a specific 
qualifier. The problem is, under the scientistic approach, “a definition should have just 
enough clauses, and no more” with the aim being “to get as essential a set of clauses as 
possible, and to meditate on each of them” (LSA 3).  The more qualifiers that are added, 
the more potential for language to jump from a rigid scientistic mode to a more open 
dramatistic mode. Such a jump occurred in 2001, when Newkirk restated her original 
quote. Writing in Commentary magazine, she said, 
 
While physiologically we are different from rats (they are used in research 
because they are small and cheap), when it comes to feelings like hunger, pain, 
and thirst, a rat is a dog is a pig is a boy. That is a biological fact, not a matter of 
opinion. (4) 
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Although Newkirk employed the phrase “biological fact” to establish fixity, the 
new definitional qualifier (i.e., the physiological difference between people and rats) 
opened the window to new interpretation. The irony in this statement is that shortly after 
Newkirk admitted a physiological difference between man and rat, the biotech research 
community provided evidence of the similarity between man and mouse. In 2002, Celera 
Genomics compared the mouse genome with human and found that “human and mouse 
genomes are remarkably similar not only in the structure of their chromosomes but also at 
the level of DNA sequence” (Winstead). In terms of genome sequences, then, we could 
say that a mouse is almost a boy. 
The process of definition is scientistic, but the process of interpretation is 
dramatistic. “A rat . . . is a boy” can be an argument for the animal rights position that 
scientists should not consider doing research on a rat (or a mouse) any more than they 
would on their own child. The dramatistic, or shifting play of motivation is to say that 
since a mouse (or a rat) is nearly a boy, then it is an excellent and useful model for 
understanding the fundamentals of human health and disease and should be used in the 
laboratory. 
Thus, when we move from the strictly rigid and scientistic is to the more flexible 
and dramatistic should or could, we open the door to the transformative process. By 
forcing a change in the dramatistic pentad  (e.g., shifting the scene, characters, or action) 
we can see events in a different light. 
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A Rat is (or is not) a Boy; Pharma is (or is not) Biotech 
 
The “rat . . . is a boy” drama provides one small example of the rhetorical tension 
between two politically differentiated groups (animal rightists and animal researchers, for 
instance, or animal rightists and fur wearers). In the case of PETA, scientistic-style 
language appeared necessary for initial self-discovery and self-understanding: we are 
this; we are not that. 
We can learn several things from PETA, the first of which is that newness 
prompts definition. Defining a new concept, new organization, or new industry is 
essentially to mark one’s territory. When PETA was formed in 1980 by Newkirk and 
fellow activist Alex Pacheco, one of the first orders of business was to define the 
organization and its philosophy of animal rights, which, for most Americans, was a 
completely unknown concept. 
Like animal rights, biotechnology too was largely unknown in the 1980s and 
several groups of people were very much concerned with defining this new field. 
Scientists, journalists, entrepreneurs, investors and others all had reasons for wanting to 
distinguish biotech from other scientific endeavors and particularly to distinguish it from 
pharmaceuticals. 
Even pharmaceuticals were “new” at one time and, as such, in need of definition. 
Although it can be argued that elements of the pharmaceutical industry existed for 
thousands of years, the modern industry did not come into existence until the late 1800s 
and early 1900s. The concept of pharmaceuticals as a homogeneous collective (as 
opposed to stand-alone apothecary shops) was a new idea that emerged from a 
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commonality of needs and interests at the turn of the twentieth century. The new 
pharmaceutical industry thus began to define not only itself but the space it occupied.  
Their self-definitional language acted in much the same way as a physical wall. 
When biotechnology—a new concept—began to emerge, its very existence destabilized 
the pharmaceutical industry because elements of biotech intersected, but did not 
completely overlap, the self-defined is and is not territory of pharmaceuticals. 
Second, the debate on animal rights exemplifies how any given group considers 
itself and others through the use of language. Is Newkirk a terrorist? A humanitarian? A 
kook? Are research scientists fascists? Heroes?  Hypocrites?  
We could call Newkirk, as agent, a freedom fighter for animals who would be 
cruelly subjected to pharmaceutical testing. Alternatively, we could call her an obstructer 
to the creation of important, life-saving drugs. Perhaps we could say that Newkirk is a 
challenger to traditional and outmoded methods of drug testing—or, alternatively, a 
challenger to legally prescribed, dependable and time-proven methods of drug testing. In 
other words, querying just one aspect of the dramatistic pentad (i.e., agent) reveals the 
complexity in language. 
Just as Benedict Anderson wrote of nation-building in terms of imagined 
communities, so too does the imagination prevail in the building of industries and 
organizations. The language that a group uses to self-define not only paints the 
characteristics of us but also them. If we, as animal rights advocates, are liberators, then 
they, as animal researchers, are jailers. Or if we, as animal researchers, are pioneers for 
new medicines, then they, as animal rights advocates are impediments to the progress of 
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human health. In a similar vein, if an industry such as pharmaceuticals sees itself as a 
producer of tangible produc ts, then those who deal merely in ideas (as some have accused 
the biotech industry) will not be us, but them. 
Yet another lesson is to be found in the inadequacy of definitional language in the 
face of change. As new groups emerge, they find their collective voice and then attempt 
to solidify their version of reality through self-definition. But as is clear from the is—is 
not impasse, rigid definitional language is not adequate to respond to ever-emerging new 
circumstances. The animal rights debate, for example, is but one of hundreds of legal and 
ethical issues faced by drug researchers and manufacturers. Drug pricing, pharmaceutical 
advertising and promotion, and relationships between doctors and pharmaceutical 
manufacturers are just some of the issues in the traditional pharmaceutical arena. In the 
biotech arena, the list gets even longer, with questions about human cloning, eugenics, 
stem cell research, gene patenting, and so on. All of these issues, with their various 
opponents and proponents, acts of protest and defense, and multiple locations and 
chronologies, serve to perpetuate the rhetorical helix. 
A final area for consideration is understanding the pattern of “language that acts” 
and action itself, and the underlying motivation for both. Dramatistic inquiry is useful not 
only for contemporary understanding of motivation (e.g., Why is PETA publishing this 
particular advertisement in this particular venue this particular week?) but also for 
gaining a perspective of motives over time. 
As an example, in 2003 PETA launched an ad campaign entitled, “The Holocaust 
on Your Plate,” which equated the murder of six million Jews during World War II to the 
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killing of animals in factory farms and slaughterhouses via a series of side-by-side 
photographs. One ad juxtaposed a photo of Jewish children behind bars in a concentration 
camp with a photo of pigs behind the bars of a cage. Another showed fully nude, 
emaciated Jewish men juxtaposed with an emaciated cow. 
Immediately after the ads started appearing, a flurry of letters, ads, and web 
postings then started to appear, vigorously protesting the use of Holocaust imagery for 
PETA’s animal rights purposes. In a press release, the Anti-Defamation League (ADL) 
protested the project for trivializing a human tragedy. Abraham H. Foxman, ADL 
National Director and a Holocaust survivor, called the campaign “outrageous” and 
“offensive,” and wrote: 
 
Abusive treatment of animals should be opposed, but cannot and must not be 
compared to the Holocaust. The uniqueness of human life is the moral 
underpinning for those who resisted the hatred of Nazis and others ready to 
commit genocide even today” (“ADL Denounces PETA”). 
 
 
Then, on May 5, 2005, Ingrid Newkirk sent an email letter to the Jewish 
community (“Apology for a Tasteless Comparison”) in which she said she realized that 
the campaign had caused pain. She wrote, “This was never our intention, and we are 
deeply sorry.” (For full letter, see Appendix A). 
Why did Newkirk issue the apology?  Did the scene (thousands of people 
offended to various degrees) influence the agent? Did the act (drawing attention to animal 
rights) not justify the agency (use of Holocaust imagery)? Could it be that one type of 
agency (visual rhetoric) was more powerful—and more dangerous—than another (verbal 
rhetoric)? Since PETA had engaged in visual rhetoric for years, broadcasting undercover 
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video of animals being bruised and bloodied, was the Holocaust metaphor, ultimately 
more horrific than the plight of penned-up, eaten or experimented-on animals? And if so, 
does the privileging of human over animal in this particular instance mean that PETA’s 
philosophy is bending toward a middle ground? 
The point is, by examining the facets of the dramatistic pentad, it is possible to 
generate several different motives for Newkirk’s words (or act) of apology. This is 
significant because it shifts power from the agents on the inside (in this case, Newkirk 
and PETA) to those on the outside who are observing the action. Through their 
interpretation of the pentadic elements, the observers could ascribe motives to PETA that 
are sympathetic (e.g., “Look at Newkirk’s words—PETA must care about people as 
much as animals”), skeptical (e.g., “Why did Newkirk wait two years to issue the 
apology? It must be that the publicity was dying down”), or hostile (e.g., “Newkirk’s 
rhetoric is a non-apology; it’s a half-hearted mea culpa that doesn’t begin to make up for 
the egregiousness of PETA’s attack”). In this manner, it is possible to assign motives in 
ways that can bring others closer (at least in the interpreter’s view) or push them further 
away. 
Dramatism helps us understand the past and why people may have said or done 
what they did. It also helps us understand what is transpiring in the present. As far as the 
future is concerned, Burke sees two possible culminations of the action: either dramatistic 
conflict, which begets victimage and ends in tragedy, or a Platonic dialectic, which 
“states the problem in the accents of an ideal solution” (LSA 54-55). One can see 
potential for either of these in the “rat . . . is a boy” drama. 
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In the victimage and tragedy scenario, many have pointed an accusatory finger at 
PETA not only for scripting words that act to incite fear and violence, but also for being 
complicit with actual violence. PETA would counter that the tragedy in question is a 
system that allows animals to be made into victims. 
The problem with the “ideal solution” scenario is that ideal is in the eye of the 
beholder. Most biomedical research organizations and laboratories have adopted the 
solution consisting of the three R’s as pioneered by Russell and Burch in 1959 and 
consisting of the reduction of the number of animals used, refinement of procedures to 
minimize pain, and replacement of animals with non-animal models when these are 
available. Some animal rights activists believe that this is not acceptable, and the only 
“ideal” solution is to completely ban the use of animals in scientific testing. In 1989, 
Newkirk was quoted as saying, “Even if animal research resulted in a cure for AIDS, 
we’d be against it” (Barnes 542). In 1992, animal activist Dr. Michael W. Fox wrote how 
his personal perspective changed from once accepting animal research to denouncing it: 
 
As a former animal researcher myself, I am no stranger to the altruistic 
rationalizations of the vivisector. One is that “the suffering of the few for the 
benefit of the many is justifiable.” I now call this biological fascism. The only 
animal model for human disease is man himself. Vivisection is a disease in itself 
that no amount of animal research and suffering and killing will ever cure. (93) 
 
 
In 2002, Roberta Kalechofsky, a feminist and animal rights activist, used even 
stronger language to denounce the use of animals in research: 
 
As for animal research, I believe it is satanic. I realize that sounds melodramatic, 
but I don’t use that word lightly. Some things like concentration camps and 
modern warfare are satanic. Laboratories are places that are as fiendish as 
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slaughterhouses. What makes the problem worse in the case of animal research is 
that the people involved are presumably intellectuals—intellectuals without moral 
concern or moral awareness. (Kistler 161) 
 
 
In spring 2007, a group calling itself SAEN (Stop Animal Exploitation Now) 
called for a national week of protests and media events to halt testing and research on 
animals. The group writes, “In our brief history SAEN has made a concrete difference for 
the animals, and we will continue to fight for their freedom until all the laboratory cages 
are empty.” 
Modern political scenarios have always viewed an impasse—the inability to reach 
compromise—as a failure. If language is symbolic action, then rigidly definitional 
language is the curtain that falls to the stage and signals the end of the play. Self-
definitional language appears particularly unambiguous and, thus, impenetrable: “I am 
what I am, and that is that” and by extension, “you are either with us or against us.” 
There is no possibility of transformation. 
By contrast, the language of the biotechnology and pharmaceutical industries has 
been anything but static. Each industry has posited definitions and descriptions that, over 
time, have shifted subtly as the result of ongoing interaction and questioning. In fact, 
such interaction within this rhetorical helix has led to the point at which at least one new 
term—biopharmaceutical—gives the effect of melding the two separate entities into one. 
There is logic in this since both industries have foundations built on the modern scientific 
method and share a mission to develop new drugs for humans and animals. 
But even as some language seeks to push biotechnology and pharmaceuticals 
together, other language seeks to pull them apart. Distinguishing factors between the two 
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groups have included size (small biotechs versus big pharma), relative age, method of 
drug development (biology-based versus chemistry-based) and production capabilities, 
and characterization of the employee base (innovative and risk-taking versus traditional 
and risk-averse). 
What is of interest in the next few chapters is to understand how definition has 
shaped description (self- and otherwise) of the biotechnology and pharmaceutical 
industries and has fed into the public’s perception of the two entities. 
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CHAPTER III 
 
DEFINITIONAL LANGUAGE OF THE BIOTECHNOLOGY 
AND PHARMACEUTICAL INDUSTRIES 
 
 
The very title of this chapter is an example of what Burke would call a terministic 
screen—that is, a language filter that “necessarily directs the attention into some channels 
rather than others” (LSA 45) or guides people toward “certain perspectives while 
eliminating others” (Blakesley 200). When Newkirk stated that “a rat is a pig is a dog is a 
boy,” she was positioning all four beings as equal by definition. In a similar vein, the title 
of this chapter positions both biotechnology and pharmaceutical entities as industries, 
thus giving each of them a status worthy of comparison to one another. 
In one respect, this rhetorical move is meant to solve the age-old problem of 
comparing apples to oranges. For starters, biotechnology is a noun, whereas 
pharmaceutical is largely an adjective. Shifting the two terms to biotech and pharma, as 
seen in the first two chapters, gives both noun status, but is colloquial and perhaps 
inappropriate as a starting point for a chapter on definition. Changing the terms to 
biotechnology, a noun, and pharmaceuticals, also a noun, is problematic since technology 
connotes processes, methods or knowledge, while pharmaceuticals connotes medicinal 
drugs. 
These difficulties are not trivial. Limitations of language can restrict our thoughts 
and direct us down rigid and perhaps misleading rhetorical paths. 
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The linguistic challenges noted above were certainly faced by those who 
attempted to define the emerging field (or area or concept or industry) of biotechnology 
and position it in context with the older field (or area or concept or industry) of 
pharmaceuticals. 
Chapter II explored, in general, how a rhetorical helix of definition and 
description operates by using examples from PETA. The goal of this chapter is to unfold, 
using a dramatistic lens, many of the existing definitions for biotech and pharma in order 
to better understand the motivations of the definition-makers—as well as the 
consequences of their definitions. 
For example, 
 
• Agents: Who is defining the biotechnology and pharmaceutical industries? 
• Agency: How are they doing so? 
• Scene: How do definitions in one era differ from another (e.g., the 1980s 
versus the early 21st century)? 
• Act: What does it mean to call biotechnology an industry – or not call it an 
industry? 
• Purpose: If terms or definitions are being manipulated, then why? 
 
 
In true Burkean fashion, the objective here is not to find the “answers,” but to 
explore an intriguing rhetorical relationship between two similar-yet-different entities. In 
so doing, we can discover more about ourselves—the concepts we are attracted to and 
therefore embrace, the values we express through our language, and the power we derive 
through rhetorical transformation. 
Again, if we envision a helix as a twisted ladder, then the two rungs that appear to 
twist around each other can be thought of as definition and description. Definition is a 
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critical element of the rhetoric helix because the way something is described feeds into 
society’s perception of it. For biotechnology and pharmaceuticals, definitions serve to 
differentiate business and the science of one industry from that of the other. “Official” 
definitions are deemed to be those emanating from a recognized authority (e.g., 
government reports), while “unofficial” definitions are those found in popular journals 
and websites. Since unofficial definitions are more readily available to the general public, 
they may have the greater ability to influence attitude. In any case, definition sets the 
stage for the establishment of ingratiation with the public at large. 
In this chapter, I will begin by focusing on one aspect of definition: classification, 
or the means by which biotechnology and pharmaceuticals are assorted. In the1930s, the 
U.S. government developed the SIC (standard industrial classification system) to group 
businesses. In the 1990s, this system was revised using the North American Classification 
System (NAICS). Both sets of classifications—SIC and NAICS—would attempt to create 
a scientistic bedrock in which to embed the relative positions of biotechnology and 
pharmaceuticals, among other businesses. In so doing, SIC and NAICS established 
precedents that would later resonate throughout biotechnology and pharmaceutical 
descriptions. 
Classifying Pharmaceuticals and Biotechnology as Industries 
 
In Categoriae, Aristotle delineates ten broad categories that can be used to 
distinguish one thing from another. Socrates and Plato are examples of different 
substances; pale and square represent different qualities; and two cubits and three cubits 
are different quantities. According to Aristotle, things can also be differentiated in terms 
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of relationship (e.g., larger vs. smaller), place, time, position, physical accoutrements, the 
actions one takes, and the effects of the actions one receives. 
Aristotle’s work is an attempt to understand the world and to organize disparate 
bits of information into a coherent whole. Similar endeavors emerged thousands of years 
before Aristotle’s sophisticated environment of 350 B.C. Athens, and continue today. 
Prehistoric people could distinguish between plants that harm and plants that heal. 
Modern man can distinguish between plants that exhibit central nervous system 
cholinergic receptor binding activity and those that do not. 
In the U. S., examples of classification and hierarchy can be found to an 
exhaustive degree not only in the structure of the country’s governmental department and 
agencies (the Louisiana State University library has compiled an excellent hierarchical 
directory) but also their output. 
According to the U. S. Department of Labor Bureau of Labor Statistics, an 
industry “consists of a group of establishments primarily engaged in producing or 
handling the same product or group of products or in rendering the same services” 
(“North American Industry Classification System”). 
The Federal government classifies industries for purposes of economic analysis. 
Grouping similar companies into industries can facilitate data retrieval and manipulation. 
For Standard & Poor’s, developer of financial market indices such as the S&P 500, an 
industry is “a group of firms that share some type of economic relatedness,” including 
“similar production methods, similar products, similar services rendered, similar 
inputs/raw materials, similar customers and similar stock performance” (Reingold 3-4 ). 
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Jay Reingold, Vice President of Library Services at Standard and Poor’s says that 
government classification systems are useful for understanding how the economy is 
structured, which industries are growing or declining, where jobs are being created, size 
of the market, and investment risk (5). 
In the 1930s, an era when the American economy was driven primarily by 
manufacturing, the U. S. Government developed the SIC system. Under this system, the 
classification path to pharmaceuticals was via manufacturing and chemicals, as shown in 
this OSHA listing, entitled “SIC Major Group 28”: 
 
Division D: Manufacturing 
Major Group 28: Chemicals and Allied Products 
Industry Group 283: Drugs 
2833: Medicinal Chemicals and Botanical Products 
2834: Pharmaceutical Preparations 
2835: In Vitro and In Vivo Diagnostic Substances 
2836: Biological Products, Except Diagnostic Substances  
 
 
It should be noted that the SIC Industry Group 283 classification is based on 
products. By contrast, the technology required to manufacture those products was 
classified as “laboratory research,” under SIC Industry group 873, per the OSHA listing, 
entitled “SIC Major Group 87,” as follows: 
 
Division I: Services 
Major Group 87: Engineering, Accounting, Research, Management, and 
Related Services 
   Industry Group 873: Research, Development, and Testing Services 
    8731: Commercial Physical and Biological Research 
    8733: Noncommercial Research Organizations  
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Through the 1990s there were numerous revisions to the SIC system that reflected 
the emerging high-technology framework of U. S. industry, including provisions for 
information technology and high-tech health care. The term biotechnology was not 
included in any updated version of the SIC system, although biological products were 
included under the major group of chemicals. 
The SIC structure revealed several dichotomies: chemical versus biological, 
products versus research, and commercial versus noncommercial. As with any 
classification structure, there were problems. Certain industries were not accounted for, 
codes were not always used correctly, and there was difficulty classifying information 
from large companies that are involved in many different industries (Boettcher 6-7). 
The government felt it needed a new, more logical and more detailed standard to 
address the enormous number of new industries in the U. S. economy. Thus, in 1997, the 
Office of Management and Budget (OMB) established an Economic Classification Policy 
Committee (ECPC) to develop, along with the governments of Canada and Mexico, a 
new classification system of industries and definitions to be known as the North 
American Classification System or NAICS (pronounced “nakes”). 
Through a six-digit coding system, NAICS classifies all economic activity into 
twenty industry sectors, as shown in Appendix B. These 20 sectors are subdivided into 
100 subsectors (three-digit), 317 industry groups (four-digit), 725 NAICS industries 
(five-digit) and 1,179 U.S. industries (six-digit). Five sectors (11 through 33) primarily 
produce goods, while 15 provide services. 
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Under the new NAICS system, the term drugs was assigned to subsector 422: 
Wholesale Trade, Nondurable Goods. As shown in Appendix C, the term pharmaceutical 
became linked with the term medicine, and was assigned to industry group 3254: 
Pharmaceutical and Medicine Manufacturing. Meanwhile, the new term, Scientific 
Research and Development, was assigned to industry group 5417, with no distinction 
made between commercial and noncommercial enterprises, as had previously been the 
case with the SIC system. And, just as with SIC, the 1997 U.S. NAICS Codes and Titles 
did not contain the term biotechnology. 
In constructing the NAICS classification system, the ECPC had an opportunity to 
break away from the rigid hierarchy of the SIC system. The committee debated from the 
start whether their approach should be hierarchical top-down; hierarchical bottom-up; or 
non-hierarchical, allowing a flexible data structure that could be “aggregated or 
disaggregated at will” (“Issues Paper No. 2” 11). Ultimately, NAICS retained the same 
hierarchical top-down structure of its predecessor. 
And even though, as the ECPC acknowledged, much of the process was 
“qualitative and judgmental in nature,” the driving force in the development of NAICS 
was a data-driven approach for which the final decision for identifying economic activity 
structure was to rest upon “engineering evidence and institutional knowledge” (Gollop 1). 
Essentially, the government committee chose to reject a more interpretive system—that 
is, one privileging dramatistic openness—in favor of a rigidly defined and traditional 
system that is more in line with a scientistic approach. This choice is reflected in the 
NAICS mission, which is as follows: 
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(1) to facilitate the collection, tabulation, presentation, and analysis of data 
relating to establishments, and (2) to promote uniformity and comparability in the 
presentation and analysis of statistical data describing the economy. (“NAICS—
1987 SIC Replacement, 1997 Final Rule”) 
 
 
Thus the ECPC, through the NAICS classification system, constructed its “reality” of 
higher and lower levels of economic activity. As a government authorized lens, NAICS 
serves as a terministic screen to focus the public on wha t it considers the legitimized 
order of business. In this case, the terministic screen also acts metaphorically, sifting 
categories into tinier and tinier lower echelon subcategories. Per this reality, 
pharmaceuticals is an entity, whereas biotechnology is not. 
As the government itself freely admits, there are inherent difficulties in creating 
classification systems, primarily in “the principles for forming industry aggregations,” as 
it described in the first of several issues papers (“Issues Paper No. 1” 2). 
NAICS was intended to be “flexible,” with updates incorporated every five years, 
per the original announcement issued via presidential press release (“Administration 
Introduces”). It is of interest to note that the first NAICS update, issued in 2002, still did 
not incorporate the term biotechnology. 
In anticipation of the 2007 revision of NAICS, the ECPC engaged in what it 
called “an extensive process of development and discussions . . . with maximum possible 
public input” (“NAICS, Updates for 2007”). 
The absence of biotechnology from the newly created NAICS system disturbed a 
number of business professionals. Thomas A. Glaze, Chief Executive Officer of 
Metabolex, a California biotechnology company, was one of those upset by the omission. 
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He was one of 22 individuals who wrote to the government following a December 27, 
2002 Federal Register Notice requesting the creation of new biotechnology industries. As 
Glaze expressed it, “In science and many other fields it turns out that ‘if you can’t 
measure it, it doesn’t exist.’ Well, biotechnology does exist and it is meaningful and we 
need to measure it” (“NAICS Public Comments” Docket No. 07-0023). 
Patrick R. Gruber, Vice President and Chief Technology Officer of Cargill Dow, 
suggested that four categories—medical biotechnology, food, agriculture biotechnology 
and industrial biotechnology—be added “as a minimum” to NAICS. He wrote: 
 
The current NAICS system does not adequately capture biotechnology industry 
activity. Industrial biotechnology will be at least as large as medical 
biotechnology in the future. Some estimates (McKinsey) indicate a market 
potential of $470 billion per year. (Docket No. 07-0014) 
 
 
Prof. Dr. Manfred Ringpfeil, writing on behalf of the German company Bipract, 
also lobbied for inclusion of biotechnology, suggesting that the ECPC contact BIO, the 
Biotechnology Industry Organization, to provide advice on which categories of biotech 
should be applied to NAICS (Docket No. 07-0015). 
NAICS serves as an excellent example of the public and private dynamics 
involved in classification. From the government’s standpoint, changes to classification 
data can be costly and disruptive. For these reasons, the ECPC says it tries to limit 
revisions to “essential” changes: that is, those that “account for errors and omissions” or 
“clarify the content of existing industries.” However, the Commission says it opens the 
door to “new and emerging industries identified through public comments that are 
supported by the guiding principles of NAICS” (“NAICS, Updates for 2007”). 
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In the case of the new biotechnology requests, the ECPC wrote that it “clarified” 
these as 
 
proposals to create industries for establishments that use biotechnology inputs, 
use biotechnology processes, or produce biotechnology outputs. The practical 
impact of these proposals would be to group a number of establishments that are 
currently classified in the Agriculture, Forestry, Fishing, and Hunting; 
Manufacturing; and Professional, Scientific and Technical Services sectors of 
NAICS. (“NAICS, Updates for 2007”) 
 
 
The ECPC noted that while it “recognized the importance of biotechnology as an 
emerging technology that should be accounted for in NAICS,” it recommended against 
the proposals it received in response to the Federal Register notice. The primary reason 
given was that creating the new biotechnology industries would create duplication of 
production processes that were already classified throughout NAICS. As an example, the 
ECPC wrote that “growing genetically-modified crops is in farming, production of 
biotech enzymes is in the chemicals subsector of NAICS, and manufacturing foods 
classified in food manufacturing” (“NAICS: ECPC Decisions”). 
 
Is It Is or Is It Is Not? 
 
In the government’s NAICS structure we discover an excellent example of the 
scientistic approach to the nature of language, with its stress on definition and concern of 
it is or it is not. Growing genetically modified crops should not be classified under 
biotechnology, the government says, because this activity is already classified under 
farming. Thus, growing crops is farming; growing crops is not its own industry. The 
scientistic approach poses as logic: if a switch is off, it cannot be on. 
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Although the ECPC voted against including biotechnology as a separate category 
in the 2007 revision, the committee did strike a compromise of sorts by recommending 
the creation of a new 6-digit national industry for Biotechnology Research and 
Development, justifying their decision by writing the following: 
 
The new biotechnology research and development industry is in conformance 
with the principles of NAICS because: 1) the new industry will group similar 
establishments using biotechnology processes in experimental research and 
development; 2) the new industry addresses a new and emerging activity resulting 
in the production of advanced technologies, and 3) the new industry is expected to 
be comparable with a biotechnology research and development industry proposed 
in the ongoing revision of the International Standard Industrial Classification of 
All Economic Activities of the United Nations. (“NAICS, Updates for 2007”) 
 
 
From a rhetorical perspective, NAICS communicates several ideas. First, the 6-
digit status of Biotechnology R&D positions it lower in the hierarchy than the 4-digit 
industry group, where Pharmaceutical and Medical Manufacturing is situated. Since the 
pharmaceutical industry was categorized long before biotechnology existed, it had 
territorial advantage. When biotechnology emerged, the government’s task was to retrofit 
this new entity into an already-established system. With the exception of the newly 
created R&D category, the government elected to consider all other biotech processes as 
support functions rather than meriting their own economic classifications. Biotechnology 
facilitates the creation of products, but does not create its own products per se. In other 
words, per NAICS, biotechnology helps other industries; it isn’t an industry in itself.  
What does it mean that the U. S. Government does not position biotechnology as 
an “industry”? One could attribute any number of motives. Perhaps it’s easier to go with 
an already-established structure than reinvent the wheel. Perhaps newness is treated more 
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skeptically than maturity. Or perhaps the question of tangibility—that is, the lack of 
visibility of biotech products—is a factor. 
Whatever the motivation, the importance of being an “industry” cannot be 
understated. Industries have enough critical mass to wield political and economic power 
and influence key decisions. As a group, an industry can lobby for political decisions 
favorable to its member groups. Industries are tracked by analysts as areas of investment. 
Being an industry confers a privileged and validated status. As the U. S. Census Bureau 
(the sponsor of the ECPC) describes it, “Economic census data are studied and 
recombined into a vast array of patterns to yield essential information for government, 
business, industry, and the general public” (Hovland and Gauthier 4). The Bureau also 
writes that government economic data—collected per the new NAICS classification 
system—are important for “composite measures such as the Gross Domestic Product 
(GDP), input-output measures, production and price indexes, and for other statistical 
series that measure short-term changes in economic conditions” (Hovland and Gauthier 
4). Federal agencies use this data to make policy decisions, as do state and local 
governments. 
Yet, as important as the NAICS classification system is, it is only one source of 
influence. Supporters of biotechnology-as-industry can (and do) establish rhetorical 
agency through several alternate means, both scientistic and dramatistic. The 
Biotechnology Industry Organization (BIO) collects its own data and makes it widely 
available to business and government. The financial services organization Ernst & Young 
has tracked biotechnology for over 20 years, thus legitimizing biotech “industry” data 
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through an ongoing historical record. On the dramatistic side, biotech-as-industry is 
established, to use Burke’s terminology, through “the rhetoric of oratory and advertising, 
mythologies, theologies, and philosophies after the classic model” (LSA 45).  
The Power of Definition 
 
One of the most powerful ways to position biotechnology as an industry is to 
define it as such. But definition is a tricky thing, as Burke implies. He writes: 
 
. . . a definition so sums things up that all the properties attributed to the thing can 
be as though “derived” from the definition. In actual development, the definition 
may be the last thing a writer hits upon. Or it may be formulated somewhere 
along the line. (LSA 3) 
 
 
In the spirit of this chicken-and-egg conundrum, let us consider BIO—the 
Biotechnology Industry Organization, which is the largest of its type. BIO says it was 
formed in 1993 out of the merger of two small biotechnology trade organizations. On the 
history page of its website, the organization says :  
 
BIO united the organizations’ 503 companies and 18 employees under one 
umbrella with a representative governing board that reserved one-third of its seats 
for emerging companies. The goal was to achieve a workable balance of power 
within the organization between the handful of large multibillion-dollar firms that 
launched the first wave of biotechnology products and the hundreds of startup and 
mid-size firms that were at the research and development stage. (“History of 
BIO”) 
 
 
Did the formation of BIO position biotechnology as an industry (versus a trade) or 
did BIO simply provide a single focus for what was already clearly an industry? Either 
way, in describing its history, BIO defines itself as an industry organization, with its 
mission as follows: 
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• Advocate the industry’s positions to elected officials and regulators. 
• Inform national and international media about the industry’s progress, 
contributions to quality of life, goals and positions.  
• Provide business development services to member companies, such as 
investor and partnering meetings. 
 
 
In fulfilling this mission, BIO uses NAICS data to track industry trends. It also 
develops much of its own data, as do additional biotechnology associations and councils, 
including the American Biological Safety Association, Council for Biotechnology 
Information, Council for Responsible Genetics, CropLife America, the National 
Agricultural Biotechnology Council, as well as various international and state 
biotechnology associations. Private reference organizations, such as MedBioWorld, also 
track biotechnology industry data, as do investment and banking organizations. In 2006, 
Ernst & Young and Burrill & Company both published twentieth anniversary editions of 
their annual biotechnology industry reports. Ernst & Young, Burrill and many others state 
that the modern biotechnology industry is now about 30 years old, having come into 
being with the founding of Genentech in 1976. As one might expect for an emerging 
industry, definitions for biotechnology are widely varied, depending upon the source and 
the timeline in which they were developed. 
In 1986, Frank E. Young wrote that it is “not a naïve question” to ask what 
biotechnology is. Young, who was commissioner of the U. S. Food and Drug 
Administration at the time, wrote that the “FDA’s working definition of biotechnology is 
the application of biological systems and organisms to technical and industrial processes” 
—a definition he admitted was “necessarily broad” (10). 
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Two decades later, the struggle to define biotechnology continued. At the 2005 
convention of BIO (the world’s largest annual biotechnology industry conference), 
Philadelphia Inquirer reporter Porus Cooper asked several attendees to provide their 
definition. The responses he received ranged from “God, I don’t know . . . It’s hard to 
define” (this from the director of the stem-cell laboratory at King’s College in London) to 
a vague “Biotechnology is future medicine.” One contract researcher said that 
biotechnology was once defined as “‘anything that Amgen and Genentech did’ and the 
big pharmaceutical companies didn’t.” As Cooper observed, “the answer depended on 
whom you asked” (C06). 
W. Steven Burke, Senior Vice President of Corporate Affairs for the North 
Carolina Biotechnology Center, said that when he joined the organization in the mid-80s, 
one of his first orders of business was to gather definitions of biotechnology—an effort 
that yielded 47 distinct examples. 
Biotechnology as Useful, Supportive, Enabling 
 
In its Editors’ and Reporters’ Guide to Biotechnology, BIO says that if you “break 
biotechnology into its root words” one finds 
 
bio—the use of biological processes; and  
technology—to solve problems or make useful products. (1) 
 
 
BIO discounts the first part of the definition—use of biological processes—as 
“hardly a noteworthy event” since humankind has “used the biological processes of 
microorganisms for 6,000 years to make useful food products, such as bread and cheese, 
and to preserve dairy products” (1).  
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Rather, it is the concepts of technology and usefulness that are prominent in 
BIO’s language. On its website-based guide to biotechnology, BIO says a more 
“appropriate” definition of modern-day biotechnology is “the use of cellular and 
biomolecular processes to solve problems or make useful products,” and writes:  
 
We can get a better handle on the meaning of the word biotechnology by simply 
changing the singular noun to its plural form, biotechnologies.  
 
Biotechnology is a collection of technologies that capitalize on the attributes of 
cells, such as their manufacturing capabilities, and put biological molecules, such 
as DNA and proteins, to work for us. (“Biotechnology: A Collection of 
Technologies”) 
 
  
Whereas BIO stresses biotechnology as creating useful products, the U. S. 
Department of Commerce, in 1997, clearly differentiated products from technology: 
 
(B)iotechnology is not defined by its products but by the technologies used to 
make those products. Biotechnology refers to a set of enabling technologies used 
by a broad array of companies in their research, development, and manufacturing 
activities. To date, these technologies have been used primarily by the 
pharmaceutical industry, but they are being used increasingly by a variety of other 
industries, such as agriculture, mining, and waste treatment. (Paugh and Lafrance 
21) 
 
 
Similarly, writers for the Arizona Department of Commerce called biotechnology 
an “enabler of other industries and activities,” with applications including the following: 
 
• Pharmaceutical Applications: medicine and drug delivery applications 
• Medical Applications: human and veterinary therapeutics and diagnostics 
• Agricultural Applications: making plants and crops pest resistant, providing 
improved seed quality, modulating growth and ripening times, enhancing 
nutrient content of feeds, providing simple and inexpensive diagnostics for 
use in field-testing for contaminants and toxic material. 
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• Industrial Applications: industrial enzymes, waste management. (Nathan and 
Turvey 4) 
 
 
Wikipedia, an unofficial but popular website for research, asserts that 
biotechnology can be defined as “the manipulation of organisms to do practical things 
and to provide useful products.” This is echoed by the Columbia Encyclopedia online, 
which states, in part, that biotechnology is a “technological solution to a problem.” 
In his remarks to the Congressional Black Caucus in 2000, USAID Administrator 
J. Brady Anderson asked how the people of the world can better feed its people. The 
answer, he said, lies in the “potential of biotechnology,” which he then proceeded to 
define: 
 
What is biotechnology? I could give you dictionary definition, but for laymen like 
me, it is easier to understand biotechnology by talking about what it can do. We 
can, for instance, use biotechnology to develop new crop varieties that tolerate 
drought, are resistant to insects and weeds, and able to capture nitrogen—an 
essential fertilizer—from the air. Biotechnology can also make food more 
nutritious by increasing the amount of Vitamin A, iron, and other nutrients in the 
edible portion of the plant. 
 
 
The Columbia Encyclopedia also notes that “biotechnology is a general category 
that has applications in pharmacology, medicine, agriculture, and many other fields.” 
This statement points to the concept that biotechnology plays a support role for the 
pharmaceutical industry, at least in terms of its technological applications. 
The Labor Market Information Division of California’s Employment 
Development Department says that biotechnology research offers a promise of 
applications for a number of areas, including “environmental management, biomedical 
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devices, instrumentation, agricultural products, food processing, human and veterinary 
medicines, and pharmaceutical manufacturing” (Peters and Slotterbeck 1). 
Biotechnology as Biology-based 
 
As BIO suggests, the term biotechnology emphasizes the industry’s connection to 
biological processes. Biotech Primer, an educational company, states that “in 1919, Karl 
Ereky created the term ‘biotechnology’ to describe the interaction of biology with human 
technology” (1) and that even in modern usage, biotechnology is still seen as “an industry 
based on biology—the study of living things” (4). The publication states, “Biotechnology 
revolutionized drug design and development by using specific scientific knowledge about 
living organisms, including genetic information that guides development and function” 
(4). 
Access Excellence, an online resource program for teachers managed by The 
National Health Museum in Washington, D. C., cites biotech author Pamela Peters who 
writes:  
 
In its purest form, the term “biotechnology” refers to the use of living organisms 
or their products to modify human health and the human environment. Prehistoric 
biotechnologists did this as they used yeast cells to raise bread dough and to 
ferment alcoholic beverages, and bacterial cells to make cheeses and yogurts . . . 
 
 
Glick and Pasternak associate molecular biotechnology with “the ability of 
researchers to transfer specific units of genetic information from one organism to 
another” (1). This, they say, “relies on the techniques of genetic engineering 
(recombinant DNA technology)” whose objective “is often to produce a useful product or 
a commercial process” (1). 
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Kimball Nill, Technical Issues Director for the American Soybean Association 
and formerly with Monsanto’s biotech research division, developed what he calls, in his 
preface, a “biovocabulary” of biotech buzzwords and concepts to aid those with “little or 
no formal training in the bio and chemical sciences.” He defines biotechnology as “the 
means or way of manipulating life forms (organisms) to provide desirable products for 
man's use” (34) and takes issue with Glick and Pasternak’s emphasis on rDNA. He 
writes: 
 
A common misconception is that biotechnology refers only to recombinant DNA 
(rDNA) work. However, recombinant DNA is only one of the many techniques 
used to derive products from organisms, plants, and parts of both for the 
biotechnology industry. A list of areas covered by the term biotechnology would 
more properly include: recombinant DNA, plant tissue culture, rDNA or gene 
splicing, enzyme systems, plant breeding, meristem culture, mammalian cell 
culture, immunology, molecular biology, fermentation, and others. (34) 
 
 
Nill puts it well in his preface to the book when he writes that 
 
the field of biotechnology is rapidly expanding and evolving, and that new terms 
are entering the mainstream nomenclature at a rapid pace. In fact, the exact 
meaning of some of these terms is still under dispute, while the meaning of others 
will undoubtedly be expanded or narrowed as the technology develops. (34) 
 
 
From Definition to Description 
 
Definitions can vary depending on historical timeframe, the affiliation of the 
definition-maker, and other subtle factors related to intent. Oftentimes, what poses as 
definition (it is, or it is not) can shift to include elements of description. An excellent 
example of this can be found in the annual reports of the North Carolina Biotechnology 
Center. In its first-ever annual report (1984-1985), the organization posits an introduction 
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to biotechnology that is half definition and half speculation. The Center writes, 
“Biotechnology is a frontier of science that will lead to new products and processes 
effecting (sic) up to 70 percent of the GNP in 30 years” (i). 
The word frontier is a powerful symbol of a new horizon, an area open to vast 
commercial exploitation. And in choosing to use the word will, the NC Biotech Center 
creates a definitive statement in which the possibility of failure is not present. Later in the 
report, the NC Biotech Center back peddles on the certainty of success, writing, “As 
indicated in the Introduction of this report, biotechnology is expected to lead to new 
products and processes affecting 70 percent of the GNP within the next 30 years” (7). 
The discrepancy could be attributed to an editing oversight. However, a look at 
some of the annual reports that follow shows a deep-seated optimism that consistently 
moves scientistic definition into the realm of the dramatistic. Consider, for example, the 
definition offered in the Center’s 1990 report, under the heading, “Biotechnology: New 
Tools for Life”: 
 
Biotechnology is a broad collection of new techniques for influencing the living 
cells of microbes, plants, animals and people. It is based on our growing 
understanding of deoxyribonucleic acid, or DNA, the substance of genes and the 
universal blueprint for living organisms. Major techniques of biotechnology 
include genetic engineering, cell and tissue culture, and monoclonal antibody 
technology. The careful use of these and other techniques enables scientists to 
improve the health, traits, products and applications of living organisms. 
Biotechnology is giving us new medicines and diagnostics, more nutritious foods, 
hardier crop plants, more productive livestock, new specialty products for 
industry, and a cleaner environment. (2) 
 
 
In one paragraph, the language moves from the scientistic verbs of is, is based on, 
and include to the dramatistic adjectives of hardier, more productive, and cleaner. This 
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convergence has the effect of making biotechnology itself seem hardier, more productive, 
and cleaner. 
In 1992, the Center had modified its definition of biotechnology. In Table 1, I 
have noted the differences in direct comparison with the 1990 report and suggest 
rhetorical reasons for why the language may have changed.  
 
Table 1 
 
Comparison of the 1990 and 1992 Annual Reports of the North Carolina  
 
Biotechnology Center 
 
1990 Annual Report 1992 Annual Report Comment 
 
“Biotechnology: New 
Tools for Life” 
“Biotechnology: Working 
with Nature to Improve Our 
Quality of Life” 
The 1990 title suggested 
the Frankenstein concept 
of 
Man controlling Nature; 
the revision suggests Man 
working in harmony with 
Nature. 
Biotechnology is a broad 
collection of new 
techniques  
 
Biotechnology is a 
collection of new scientific 
techniques 
 
However, even as the 
concept of Man and Nature 
is strengthened, the authors 
do not want to lose the 
concept of biotechnology 
as science. 
for influencing the living 
cells of microbes, plants, 
animals and people. It is 
based on our growing 
understanding of 
deoxyribonucleic acid, or 
DNA, the substance of 
genes and the universal 
blueprint for living 
organisms.  
 
that use living cells, or their 
parts, to make products or 
solve problems. 
“Influencing” the cells 
sounds ominous, while 
“using” cells to solve 
problems sounds helpful. 
The reference to DNA may 
have been dropped 
because, by 1992, the 
connection between cells 
and DNA may have 
seemed 
superfluous. 
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Major techniques of 
biotechnology include 
genetic engineering, cell 
and tissue culture, and 
monoclonal antibody 
technology.  
 
Major techniques include 
genetic engineering, cell 
and tissue culture, 
bioprocessing, and 
monoclonal antibody 
production. 
The introduction of 
bioprocessing 
(defined by NC Biotech as 
“A technique in which 
microorganisms, living 
cells, or their components 
are used to produce a 
desired end product”) 
reinforces the 
theme of commercial 
applicability. 
The careful use of these 
and other techniques 
enables 
scientists to improve the 
health, traits, products and 
applications of living 
organisms. 
 
These and many other tools 
of molecular biology allow 
scientists  to improve the 
health, traits, products 
and applications of living 
organisms for human 
benefit. 
Saying that scientists must 
carefully use the 
techniques begs the 
question of what happens 
if they don’t; therefore the 
phrase is deleted. The 
phrase for human benefit 
reinforces the positive 
contribution of 
biotechnology. 
 
 
By the 1995 annual report (Table 2), the definition remained essentially the same, 
with a few minor exceptions. Of particular note is the last sentence, as shown in Table 2, 
which had changed substantially from 1992 to 1995. 
 
Table 2 
 
Comparison of the 1992 and 1995 Annual Reports of the North Carolina Biotechnology Center 
 
1992 Annual Report 1995 Annual Report Comment 
 
These applications are creating 
new jobs, enhancing traditional 
industries and generating long-
term economic benefits for 
North Carolina (1). 
These uses of biotechnology are 
creating new jobs, enhancing 
traditional industries and 
generating long-term economic 
and societal benefits for North 
Carolina (1). 
The word uses  reinforces the 
concept of 
biotechnology as friendly and 
helpful. The addition of 
the word societal emphasizes 
the fact that everyone benefits 
from biotechnology, not just 
business enterprises of the State. 
 
 
 
 
59 
By 1997 and 1998, the NC Biotech Center offered a new approach to the 
definition of biotechnology by invoking the concept of biotechnology as an ancient 
science. In a section of the 1998 report that defines biotechnology, the authors write the 
following: 
   
Working with the bounties of nature to improve the quality of human life is an 
idea mankind has pursued since the dawn of civilization. Ten thousand years ago, 
our forefathers’ quest for a reliable supply of food and fiber led them to begin 
selectively breeding plants and animals for superior offspring, and to use 
microbes such as bacteria and fungi to make cheese, wine, bread and other foods. 
 
In the 20th century we learned to use viruses and bacteria to make vaccines and 
antibiotics, microbial enzymes to make detergent and food additives, and bacteria 
to treat sewage and other waste. Also in this century, we gave the ancient science 
a name: biotechnology. (2) 
 
 
The meaning of these two paragraphs seems unmistakable. The first message is 
that although the term biotechnology is new, what biotechnology does is not new. 
Second, biotechnology is made to be analogous with common, everyday products such as 
cleansers, clothing and food. The third point is that biotechnology works with nature, not 
against it. The “definition” of biotechnology in this annual report seems driven by a 
motivation to make biotech seem helpful, yet benign—an important foundation for the 
process of ingratiation, and an effective response to descriptions of biotechnology that 
depict it as frightening, untested, unstable, and nature-adulterating. 
Defining Pharmaceuticals and the Pharmaceutical Industry 
 
Unlike biotechnology, the term pharmaceuticals is rarely defined in general 
publications since the industry is mature and writers presume most people know what 
pharmaceuticals are. 
 
 
60 
In Multinational Pharmaceutical Companies Principles and Practices, Bert Spilker 
attempts a definition of the pharmaceutical industry based on membership and activity, 
but immediately criticizes it, writing: 
 
It is possible to define the pharmaceutical industry as the collection of companies 
that discover, develop, manufacture, and market medicines for human use, but 
this definition is insufficient for several purposes. Although there is a core group 
of companies that are research based and fulfill all four of these criteria, many 
others only meet one, two, or three of the four criteria. (7) 
 
 
Spilker goes on to say that contract research organizations, consultants, research 
firms, and other service organizations can also “be considered part of a national 
pharmaceutical industry” (7). Thus, under Spilker’s expanded definition, biotechnology 
companies could also be considered part of the pharmaceutical industry. 
Within reference materials, many sources define the pharmaceutical industry by 
the products it makes. For example, the Oxford English Dictionary provides a definition 
for pharmaceutical as an adjective as “of or relating to the manufacture, use, or sale of 
medicinal drugs” and as a noun as a “pharmaceutical preparation; a medicinal drug.” 
Encyclopaedia Britannica defines the pharmaceutical industry as a “complex of 
processes, operations, and organizations engaged in development and manufacture of 
drugs and medications,” and pharmaceutical as a “substance used in the diagnosis, 
treatment, or prevention of disease and for restoring, correcting, or modifying organic 
functions.” 
The Britannica Concise Encyclopedia defines the industry not only by its 
products, but by its successes, stating that the “pharmaceutical industry has greatly aided 
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medical progress” with “the occurrence and severity of such diseases as typhoid fever, 
poliomyelitis, and syphilis . . . greatly reduced.” This encyclopedia also notes that, 
“While many drugs, such as quinine and morphine, are extracted from plant substances, 
others are discovered and synthesized by techniques including combinatorial chemistry 
and recombinant DNA technology.” Thus with this definition, the encyclopedia negates 
the idea that the pharmaceutical and biotechnology industries are distinguished from one 
another by the latter’s exclusive use of rDNA technology. 
Some sources emphasize the manner in which pharmaceutical drugs are produced, 
making the distinction that pharmaceuticals are chemical-based. The Oxford 
Encyclopedia of Economic History, for example, says that pharmaceuticals are “products 
of the chemical industry, intended for use as prescription drugs or as over-the-counter 
(OTC) medications.” 
In its history of the pharmaceutical industry, the American Chemical Society 
(ACS) emphasizes the chemical background of pharmaceutical companies such as Bayer, 
which in 1913 was “Germany’s third largest chemical company” (“Bayer”). The ACS 
writes that “Bayer’s reputation as a major pharmaceutical company is primarily a result 
of its exhaustive program of chemical analysis” and that “by 1900, Bayer chemists 
routinely tested all new chemicals for medicinal effects.” The organization notes that 
Bayer’s big breakthrough as a commercially viable pharmaceutical company came in 
1899, when it marketed acetylsalicylic acid under the trade name Aspirin. 
The Environmental Commissioner of Ontario, in its 2004-2005 annual report, sets 
forth a definition of pharmaceuticals as follows:  
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Pharmaceuticals are chemical substances used in medical diagnostics and to 
achieve therapeutic and other desired physiological responses (e.g., synthetic 
hormones in oral contraceptives). They are bioactive (having effects on living 
organisms), and in some cases, toxic by design (e.g., in cancer treatment). 
Pharmaceuticals comprise a large number of diverse but mostly organic molecules 
that range in size. They can be grouped according to their general uses—for 
example, antibiotics, anti-epileptics, anti- inflammatories, cancer treatment drugs 
and oral contraceptives. Pharmaceuticals are typically formulated to be highly 
soluble and are not completely broken down by the body. Over 23,000 drugs, 
comprised of over 3,300 different ingredients, are registered for human use in 
Canada. (182) 
 
 
In this case, the definition highlights the essence of pharmaceuticals as chemicals; as 
abundant; and as substances that can enter (and thus contaminate) the environment.  
Pharmaceutical Self-definition 
 
While biotechnology is redefining itself to appear more mature, the 
pharmaceutical industry is redefining itself to appear newer and more innovative. To a 
great extent, it is doing this by incorporating attributes of biotechnology into its self-
descriptions and by affiliating itself with biotechnology. 
Consider, for example, the definition of biotechnology provided by the 
pharmaceutical industry organization, PhRMA, in its 2005 industry profile. The 
organization writes: 
 
Biotechnology is a collection of technologies that capitalize on the attributes of 
cells, such as their manufacturing capabilities, and put biological molecules, such 
as DNA and proteins, to work for medicine development and other uses. (8) 
 
 
After explaining that the pharmaceutical industry has “developed and adopted” a number 
of new biotechnologies such as bioprocessing, monoclonal antibody technology, 
molecular cloning, and recombinant DNA technology, the organization writes: 
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The convergence of traditional pharmaceutical chemistry and biotechnology has 
led the pharmaceutical and biotechnology industries, once thought of as being 
distinct and independent, to become more similar than dis similar. (8) 
 
 
In fact, the organization notes that “Biotechnology + Pharmaceutical = 
Biopharmaceutical” (7), thus emphasizing a new term that seeks to merge the two 
industries. 
Additionally, the very first line of the introduction to Pharma’s 2006 
pharmaceutical industry profile, notes that “(t)he biopharmaceutical research industry is 
unlike many others. It invents products that people need to avoid illness, maintain their 
health and save their lives” (v). Although the title of the report classifies it as 
pharmaceutical, the internal text immediately binds pharma with biotechnology. Further, 
it positions the newly merged entity as unique, inventive, and therapeutic. 
This self-definition/description has shifted significantly since the emergence of 
the pharmaceutical industry at the end of the nineteenth and start of the twentieth century. 
At that time, the industry defined itself in three major ways, as will be outlined below. 
The first was as advocates of standardization (that is, pursuers of quality, safety, and 
efficacy; believers in self-regulation; establishers of pharmaceutical societies and 
standardized pharmacopoeia; and opponents of government interference). The second 
was as chemists and the third was as rags-to-riches capitalists. With the arrival of the 
1940s—and the commercialization of penicillin—the pharmaceutical industry gave one 
more definition to itself: producer of blockbuster products. 
By most historical accounts, the modern pharmaceutical industry emerged 
concurrently with the introduction and acceptance of germ theory and rise of industrial 
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manufacturing. In order to transition to a modern and professional status, nascent 
pharmaceutical companies had to overcome centuries of popular beliefs about the nature 
of disease and the treatment of illness. Amundsen and Ferngren describe the belief 
systems of ancient times whereby “(w)ell-being depended on living in a state of harmony 
with all aspects of the environment, which was animated by vague numinous or spiritual 
presences and able to be manipulated through a complex variety of magico-religious 
mechanisms” (485). 
The concept of wellbeing as a “state of harmony with deified nature” was to 
continue through the Egyptian and Mesopotamian cultures at the beginning of the third 
millennium B.C., and did not appreciably change—with the exception of the ancient 
Hebrews—until the beginning of “desacralized” medicine in ancient Greece, around 500 
B.C. At this time, “illnesses appear to have been categorized as either mysterious (and 
hence, of divine origin) or common (and, therefore, natural)” (Amundsen and Ferngren 
487). Emerging at this time were medical craftsmen who “practiced empirical medicine 
but with little or no reliance on the magico-religious procedures of their ancient Near 
Eastern counterparts” thus paving the way for rational medicine (487). 
However, the shift of belief systems neither easy nor clear cut. In Making 
Medicine Scientific, Terrie Romano writes of “the untidy nature of the era’s shift from an 
intellectual system rooted in religion to one based on science, bridging worlds often 
thought antithetical, such as the metaphysical idealist and the materialist scientific” (3). 
These two disparate philosophies were particularly evident during the Middle 
Ages with the emergency of alchemy, “a grandiose philosophical system which . . . 
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sought to bring the microcosm of man into relation with the macrocosm of the universe” 
(Read 14). As John Read describes it: 
 
(the) corpus of alchemy was of a dual nature. On the one hand, it was essentially 
practical and allied closely with the arts, crafts, and medicine; on the other, it was 
an indistinct aggregation of mysticism and cryptic expression. These two main 
aspects of alchemy persisted throughout the Middle Ages. (13) 
 
 
The status of the alchemist, too, was also marked by schism. The profession had 
enough credibility that “(r)ogues assumed the title of alchemist solely to increase their 
professional status in the eyes of their patrons” (Read 74). At the same time, the 
preponderance of such false chemists created an atmosphere of deep suspicion in the 
public. Ben Jonson captured the jaundiced view the public took toward alchemists in his 
highly popular 1610 play, The Alchemist, in which the title character is portrayed as a 
“chemical cozener” (191) who represents “(c)heaters, bawds (and) conjurors” (190).  
From the Middle Ages onward, the thrust to separate science from religion took 
greater force, beginning with the Protestant Reformation and continuing through 
seventeenth century Enlightenment and nineteenth-century Darwinism. It was during 
these transitional centuries that modern drug making, as an industry, began to emerge.  
Geoffrey Tweedale of Manchester Metropolitan University traces the history of 
the modern pharmaceutical industry to the “activities of the  apothecaries, who mixed and 
compounded drugs for the physicians and general populace in the fifteenth and sixteenth 
centuries” (33). He writes: 
 
This lineage can be traced through to the activities of those apothecaries who 
became chemists and druggists in the seventeenth and eighteenth centuries. Some 
 
 
66 
of the latter, when they decided to concentrate on the dispensing and 
manufacturing of drugs (instead of following careers in medical practice), created 
anew profession of pharmacy . . . These chemists and druggists provided the 
springboard for later advances in drug manufacture and the businesses they 
operated became the forerunners of some of today’s pharmaceutical giants. (33) 
 
   
Following the scientistic is/is not paradigm, it was clear what the new drug 
makers were not. They were not magicians, mystics or hoaxers. Instead, they were 
members of a new group of professionals who would come to define their industry in 
several specific ways. The emerging pharmaceutical companies saw themselves as 
advocates for quality medicine through the standardization of manufacturing; chemists, 
rather than alchemists, and therefore modernists; and rags-to-riches capitalists. These 
descriptors served the industry well in its early years. However, in later decades, and 
particularly with the emergence of biotechnology, these descriptors would come to be 
challenged in dramatistic fashion. 
Advocates of Standardization 
 
From the mid-nineteenth century through the start of the early twentieth century, 
the new pharmaceutical professionals sought to distinguish themselves from their 
predecessors through the standardized methods they would employ to manufacture their 
products. Up until this time, drug manufacturing was highly decentralized, both in 
Europe and the United States. In fact, for the first 200 years of United States history, drug 
manufacturing was little more than a cottage industry, with medications “either 
compounded from a limited number of drugs or imported from the continent as finished 
products, intermediates, or patent medicines” (Worthen 55).  
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In what we would now consider to be a conflict of interest, doctors at that time 
often doubled as pharmacists, compounding and dispensing the prescriptions they 
themselves wrote. According to historian Gregory Higby, this was an arrangement that 
was of great benefit to the physician’s personal financial success since “medicines were 
always dispensed for cash or for goods” (“A Brief Look” 2). 
Of greater concern was the quality of drugs that were being manufactured. 
According to Higby: 
 
America had become the dumping ground for the poor quality drugs of Europe. 
While it had been common since colonial days for exporters to send shoddy goods 
overseas, the situation worsened in the 1840s. The drug market within Europe 
tightened up through regulation. Moreover, the emergence of alkaloidal chemistry 
made it possible to extract quinine or other alkaloids from medicinal plants and 
then send the partially (or fully) exhausted bark or root off to America. 
(“Introduction” x-xi) 
 
 
A lack of government regulation meant that many of the drugs being produced 
had the potential to be toxic, addictive or both. Opium, for example, was a popular 
ingredient for a “vast range of medicines, patent medicines and quack ‘remedies’ in both 
Europe and American throughout the nineteenth century” (Booth 51). 
In her history of Merck, Fran Hawthorne notes that “there were . . . hundreds of 
so-called patent medicines in the United States mysteriously claiming to cure everything 
from baldness to cancer to babies’ teething pain” (20). She adds that 
 
even the legitimate pharmacists’ drugs weren’t necessarily safe. Because they 
were unregulated, they could be adulterated or diluted, or the wrong ingredients 
could be substituted—which was, in fact, what happened to American soldiers in 
the Mexican War of 1846 to 1848. Congress passed a Drug Importation Act the 
year the war ended that was supposed to ensure that drugs would be inspected for 
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purity and quality at the port of entry to the United States, but it didn’t do much 
good because it didn’t set any standards and it didn’t block the practice of 
appointing unqualified but politically connected customs officials. Between 1879 
and 1906, a hundred more bills on food and drug purity would be introduced in 
Congress; all of them died. (20-21) 
 
 
Early government regulation clearly did not benefit the nascent pharmaceutical 
industry. In fact, tension between the industry and government regulators would become 
a pattern for the next century and a half. Those in the newly emerging industry were 
much more comfortable regulating themselves. While Higby writes that “most 
pharmacists of the early 1800s did not view themselves as “professional men” —they 
were shopkeepers or specialized merchants” (“A Brief Look” 2), by the mid-1800s, this 
situation had changed. The medical profession increasingly focused their attention on the 
clinic and diagnosis, getting more comfortable with leaving compounding to pharmacists. 
Consequently, the number of pharmacy practitioners increased substantially. These new 
breeds of drug makers were ready to shed their image as snake-oil salesmen and develop 
a modern, professional image. 
One way to accomplish this goal was to create professional organizations that 
would set standards not only for the medicines being compounded, but also for the 
behavior and ethics of all members. 
The Pharmaceutical Society of Great Britain was started in 1841. Ten years later, 
in the United States, a convention of pharmacists assembled in New York City, laying the 
groundwork for the establishment of the American Pharmaceutical Association in 1852. 
Their objectives, according to Higby, were several- fold: 
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• Create a national association with a constitution and code of ethics; 
• Support schools of pharmacy; 
• Improve the selection and training of pharmacy apprentices; 
• Investigate secret medicines and quackery; 
• Urge enactment of laws for the inspection of imported drugs; 
• Adopt a National Pharmacopeia as a guide in preparing medicines; 
• Curb indiscriminate sale of poisons; 
• Separate pharmacy from the practice of medicine; 
• Encourage presentation of original papers on pharmacy and science 
(“Introduction” xi) 
 
 
The establishment of the U.S. Pharmacopeia, a national guide that provides 
guidelines for the preparation and use of medicines, led to a major shift in pharmaceutical 
manufacturing away from the pharmacist with individual mortar and pestle, and toward 
large-scale manufacturers and ready-made drugs. As Higby writes, “It was nearly 
impossible for the pharmacist on the corner to make up coated pills and complex 
mixtures with the elegance of the large companies (“Introduction” 3). The same was true 
in England, with the first British Pharmacopoeia published in 1864. 
In a 1980 speech celebrating the centennial of Burroughs Wellcome, company 
president Fred A. Coe, Jr. noted that the corporate mission—“to discover, develop, 
produce and market high quality pharmaceutical products to treat disease and reduce 
suffering”—had not changed over the past 100 years (Coe 7). In pursuit of this goal, 
founder Henry Wellcome purchased the most modern and efficient machinery to support 
the company’s manufacturing efforts. The capital investment was successful because “the 
young company quickly developed a lead in the manufacturing field, excelling in the 
technology of compressing medicine into tablets” (Coe 9). In fact, Henry Wellcome was 
responsible for coining the word tabloid as a term for compressed medicines. As a point 
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of linguistic curiosity, tabloid would later be co-opted by the tabloid newspapers that 
“compressed and condensed news onto small pages” (Coe 9). 
Trademarking was one way of ensuring a company’s reputation for quality 
products. It was a step Burroughs Wellcome took to protect its tabloids from would-be 
counterfeiters. In a 1908 version of its Excerpta Therapeutica, a company-published 
index of diseases and treatment, the company notes that 
 
The trade marks ‘Tabloid’ and ‘Soloid’, invented by B.W. & Co, are B.W. & Co. 
hall marks. They mark the work of Burroughs Wellcome & Co. They mean 
“Issued by Burroughs Wellcome & Co.” They stand for 24 carat products. 
(Burroughs Wellcome 9) 
 
 
In the therapeutic notes section of the Excerpta, the company makes it clear that 
good manufacturing practice and high-quality products go hand in hand: 
 
‘Tabloid’ brand products, the excellence and the advantage of which are now so 
universally recognized, contain only the finest drugs, so that therapeutic activity is 
secured; they are accurate in dosage, are readily carried, and keep well in any 
climate. They are made under the supervision of specially trained and qualified 
chemists and pharmacists of many years’ experience. (Burroughs Wellcome 156)  
 
 [ . . . ] 
 
The admitted superiority of ‘Tabloid’ Brand products is maintained only by 
unremitting care and attention to minute details. They have been often imitated, 
but in no case has their combined perfection of ingredients, manufacture, dosage, 
and therapeutic activity been approached.  
 
In these imitations and counterfeit preparations, there lies an obvious danger to 
the physician’s reputation and to the patient’s health. The word ‘Tabloid’ is a 
brand which designates products issued by Burroughs Wellcome & Co., and to 
ensure the supply of genuine preparations, this brand should always be specified 
when ordering. Medical men are requested to report any cases of substitution. 
(Burroughs Wellcome 157) 
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Like Burroughs Wellcome, then-chemical company Merck was also concerned 
about piracy. In 1890, “Merck labels were being illegally placed on other companies’ 
chemicals” (Hawthorne 21), thus threatening the company’s good name and prompting 
the founder’s grandson to travel to the United States from Germany to oversee the 
business. This move ultimately spurred the transition of Merck from a German-based 
supplier of fine chemicals to a multinational producer of pharmaceutical products. 
Chemists, Not Alchemists 
 
Merck is just one of several large pharmaceutical companies whose roots can be 
traced to chemical manufacturing. As Hawthorne explains, “Pharmacists, in the United 
States as well as Germany, made their own medicinal compounds with ingredients 
bought from fine-chemical companies, many of them German” (20). It was simply logical 
that these suppliers of pharmaceutical chemicals would ultimately try their hand at 
making the drugs themselves. 
Pfizer, the largest pharmaceutical company in the world today, started as a fine-
chemicals business in New York in 1849. Pfizer originally produced tartaric acid and 
cream of tartar, which were useful as a laxative and diuretic, respectively. During the 
Civil War, Pfizer says it expanded its production of drugs, producing “iodine, morphine, 
chloroform, camphor, and mercurials, which in addition to medicinal applications, were 
used in the emerging field of photography” (“Exploring Our History, 1862”) In 1880, 
Pfizer began manufacturing citric acid, which “had a variety of applications, including 
papermaking, dissolving iron oxides, and as a flavoring for foods and in soft drinks” 
(“Exploring Our History, 1849-1899”). 
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The French pharmaceutical company Aventis originated in 1858 as a supplier of 
chemical for the leather and textile dye industries. After “140 years of complicated 
history with companies being bought and sold off, nationalization and privatization, and 
several Nobel Prizes being awarded to chemists connected to the company,” Aventis was 
officially created in 1999 “as the result of the merger of two chemical companies, Rhone-
Poulenc and Hoechst AG” (Turner 45). 
In its history of the pharmaceutical industry, the American Chemical Society 
emphasizes the chemical background of pharmaceutical companies such as Bayer, which 
in 1913 was “Germany’s third largest chemical company.” The ACS writes that “Bayer’s 
reputation as a major pharmaceutical company is primarily a result of its exhaustive 
program of chemical analysis” and that “by 1900, Bayer chemists routinely tested all new 
chemicals for medicinal effects” (“Bayer”). Bayer’s big breakthrough as a commercially 
viable pharmaceutical company came in 1899, when it marketed acetylsalicylic acid 
under the trade name Aspirin. 
The connection of the growing pharmaceutical industry to the chemical industry 
was significant for two reasons. First, the new medicines that were rationally designed 
through chemical science could be made distinct from ancient herbal remedies and 
mystical cures. Second, chemistry established a modern approach to drug making through 
the application of scientific methods of design and analysis. In his history of drug 
discovery, Walter Sneader writes that the rapid development of synthetic organic 
chemistry in the mid-1800s meant that drug makers no longer needed “to rely on nature 
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to provide new drugs” (4) since a “limitless range of new drugs” could now be 
synthesized (5).  
Rags-to-Riches Capitalists 
 
The rags-to-riches tale is a significant and defining narrative for many of the early 
pharmaceutical companies, and sets the foundation for a deep-seated and continuing 
commitment to capitalism in this industry. 
Bristol-Myers Squibb (BMS), the eighth largest pharmaceutical company 
worldwide, was created in 1989 with the merger of Bristol-Myers with Squibb. The BMS 
web site provides a history of the Bristol-Myers side from its founding in 1887 by 
William McLaren Bristol and John Ripley Myers, with startup funds of only $5,000. The 
story on the web site not only describes the rags-to-riches narrative, but also merges in 
the advocate of quality and standardization sub-narrative, as follows: 
 
The partners worked hard to expand the business, but at first it was an uphill 
struggle. From the start, however, they had two rules: insist on high quality and 
maintain the firm’s good financial standing at all costs. (“BMS Brief History”) 
 
 
The web site describes how sales blossomed after the turn of the century with two 
important products: a laxative mineral salt and Ipana toothpaste. The demand for these 
two products, according to the company, “transformed Bristol-Myers from a regional into 
a national company and then an international one,” with gross profits of over $1 million 
by 1924 (“BMS Brief History”). The rags-to-riches story continued, with the company 
going public in 1929 with a listing on the New York Stock Exchange. 
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The history of the Squibb side also reflects the advocate of quality sub-narrative, 
stating that the prototype of the Squibb logo “represented product uniformity, purity, 
efficacy and reliability based on research.”  
Pfizer, too, tells a similar story on its web site. In the section entitled, “1849: 
Arriving in America,” the company writes: 
 
With $2,500 borrowed from Charles Pfizer's father, cousins Charles Pfizer and 
Charles Erhart, young entrepreneurs from Germany, purchased a modest brick 
building on Bartlett and Tompkins streets in the Williamsburg section of 
Brooklyn. Their goal was to make chemicals not then produced in the United 
States. 
 
Their first product, santonin, was used to treat intestinal worms, a common 
affliction in mid-19th century America, but its taste was so bitter, few people 
would swallow it. Combining their skills, Pfizer, a chemist, and Erhart, a 
confectioner, blended santonin with almond-toffee flavoring and shaped it into a 
candy cone. An immediate success, the “new” santonin was soon in great demand 
—and Charles Pfizer& Company was launched. 
 
Within a decade, raw materials from around the world were pouring into the 
young company and more than a dozen chemicals were pouring out. As their 
business prospered, the cousins bought 72 acres surrounding their building, and, 
in 1857, established an office on Beekman Street, in the heart of what was then 
Manhattan's drug and chemical district. (“Pfizer: Exploring Our History 1849-
1899”) 
 
 
The pharmaceutical self-definition of rags-to-riches capitalists was also 
interwoven with messages of hard work and optimism. In a 1966 speech to the 
Newcomen Society, E. Claiborne Robins tells the story of the A. H. Robins 
pharmaceutical company. His grandfather, an “old gentleman (who) worked long hours 
and a seven-day week” founded a “small apothecary and manufacturing chemist’s shop” 
in 1878 in Richmond, Virginia (9). A photo of this shop, included in the Newcomen 
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reprint of the speech, shows a store front with the words Robin’s Chemicals inscribed in 
the window (10b). 
The old gentleman’s son, Claiborne Robins, followed in his father’s footsteps and 
eventually became a registered pharmacist. Upon his graduation, he was tasked to 
develop the manufacturing side of the business, which eventually was established as the 
A. H. Robins Company. When Claiborne died young (two years after E. Claiborne was 
born), Mrs. Martha Robins, E. Claiborne’s mother, took over the business. A photo 
caption from the Newcomen reprint states: 
 
Mrs. Martha Robins, who guided the destinies of the A.H. Robins Company from 
1912 to 1936, was one of the pioneer business-women of Richmond. Her 
determination to keep the Company alive until E. Claiborne could graduate from 
college and pharmacy school was a motivating force in her life, and she gave up 
everything to accomplish it. Mrs. Robins took over the business upon the death of 
her husband. (10a) 
 
 
E. Claiborne Robins notes that he was “well aware of what my mother sacrificed 
to give me an education,” and how she  “moved into a man’s world” by “(m)ixing 
liquids, counting tablets, filling and capping bottles, pasting on labels, (and) keeping the 
books”(10). 
The loan of $2,000 from a local bank was a turning point for the company, along 
with the goodwill of suppliers who “carried us in those days on ‘a wing and a prayer’” 
(12). Robins’ message then turns to one of patriotism, when he states that 
 
this could only happen in America—the story of progress under the free-
enterprise system which is indeed the story of A.H. Robins Company. Under what 
other auspices could a young man parlay an invested capital of less than three 
thousand dollars—borrowed money, at that—into a firm doing business in fifty 
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states and about fifty-five foreign countries, with gross sales of more than sixty-
five million in 1965? (13) 
 
 
Robins notes that in the United States, “under the free-enterprise system, we have 
set the pace for the world in new drug discoveries, while in Communist countries under a 
non- incentive system, not a single worthwhile drug has been produced” (15). He 
expounds on what he considers “threats” to the free-enterprise system, including “the 
cancer of central government control” (15). He states that “(c)ontrol is good only when it 
is helpful to the end product; excessive government control can only be a form of 
strangulation” (16). This is significant because it is a theme that prevails in the 
pharmaceutical industry even today. 
Public Response to the Early Pharmaceutical Industry 
 
Thus by the end of the nineteenth and start of the twentieth century, the 
pharmaceutical industry defined itself in three major ways: as advocates of 
standardization; as chemists and as rags-to-riches capitalists. They had distanced 
themselves from herbalist healers, mystics, and snake oil salesmen. They had 
demonstrated cohesiveness and homogeneity in their industry. They were thoroughly 
modern in outlook, evidenced visually by the new steel and glass buildings they 
constructed. The new laboratories housed well-educated scientists, who worked by 
standard rules and scientific methodology, and a well-trained technical staff that 
manufactured products using validated systems. The chemists were kings; Man was in 
control; and quality, safety, and efficacy were the new watchwords. 
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However, public receptivity to the industry as a whole did not flourish. Writing in 
1959, historian Tom Mahoney said that “Until the1930’s, accomplishments of the 
American drug industry were few” and that “[a]s late as 1939 no ethical drug 
manufacturer in America had a sales volume as large as a department store like Macy’s in 
New York or Hudson’s in Detroit” (4). 
Industry prestige, in fact, was very slow in arriving, and respect for drug 
companies individually was no better. Mahoney notes that in 1927, the American Society 
for Pharmacology and Experimental Therapeutics ruled that “(e)ntrance into the 
permanent employ of a drug firm shall constitute forfeiture of membership” (4). 
An example in literature of the early skepticism toward the pharmaceutical 
industry can be found in Arrowsmith, Sinclair Lewis’ novel of 1925 in which Martin 
Arrowsmith, a young and idealistic physician, makes a career decision to become a 
highly paid member of the “McGurk” pharmaceutical research institute, located in a 
thirty-story high glass and limestone building in New York city (289). At first, he is 
intrigued by the opportunity to focus on important research, but ultimately Arrowsmith is 
horrified by implications of working for a profit-generating organization. He rebels 
against twittering cocktail parties, the idea of publishing first and plugging up the holes 
later, and public relations in general. When Dr. Rippleton Holabird, a business-oriented 
director at McGurk, gushes about the honors that lie ahead for Arrowsmith (“Acclaim by 
scientific societies, any professorship you might happen to want, prizes, the biggest men 
begging to consult you, a ripping place in society!”) (338), Arrowsmith is appalled: 
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He perceived the horror of the shrieking bawdy thing called Success, with its 
demand that he give up quiet work and parade forth to be pawed by every blind 
devotee and mud-spattered by every blind enemy. 
 
He fled to Gottlieb as to the wise and tender father, and begged to be saved from 
Success and Holabirds and A. DeWitt Tubbses and their hordes of address-
making scientists, degree-hunting authors, pulpit orators, popular surgeons, 
valeted journalists, sentimental merchant princes, literary politicians, titled 
sportsmen, statesmenlike generals, interviewed senators, sententious  bishops. 
(339) 
 
 
The novel clearly set forth the ambivalence of the American public toward 
pharmaceutical research. 
In terms of the rhetorical helix, it was all well and good that the pharmaceutical 
industry defined itself in terms that it considered positive. Clearly, the industry’s 
cherished self-definitions (advocates for standard manufacturing, chemists, rags-to-riches 
capitalists) had largely been framed in terms of how the industry wished to view and 
position itself, and not necessarily in terms of appeal to those outside the industry. 
Significantly, it was not until the pharmaceutical industry constructed the “second 
rung” of its rhetorical helix that public opinion would begin to shift in its favor. This 
second rung would consist of description—a construction of meaning that would be not 
merely understood by others, but embraced by them. Unlike concrete definitions, 
description bathes the subject in an aura of intangibility, where feelings and impressions 
predominate over facts and figures. 
The descriptive side of pharma’s rhetorical helix did not truly flourish until the 
industry began making products that contributed substantially to the betterment of 
mankind. The teeter-tottering of public opinion would tip distinctly in favor of the 
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pharmaceutical industry in the 1940s with the advent of a “miracle drug” known as 
penicillin. This was a product that would not only define the pharmaceutical industry as a 
producer of life-saving drugs, but would, for decades to come, color most descriptions of 
the industry in bright rosy hues. The development of penicillin allowed the 
pharmaceutical industry to weave rich and vivid descriptions of itself that spoke to the 
industry’s compassion, humanity and genuine concern for others, and would pave the 
way for public ingratiation. 
 
 
80 
 
CHAPTER IV 
 
AFTER DEFINITION, DESCRIPTION: USING BURKE’S DRAMATISTIC LENS 
TO VIEW THE PHARMACEUTICAL INDUSTRY 
 
 
As described in the previous chapter, at the turn of the twentieth century, 
emerging pharmaceutical companies defined themselves as advocates of standardization, 
chemists, and rags-to-riches capitalists. Since the rhetorics of definition and description 
operate as a helix to engender ingratiation, it was not sufficient for drug companies to 
define what they were, via definition; they also needed to determine how they were, via 
description. It is description, rather than definition, that establishes an aura around a 
person or thing described. In the rhetorical helix, definition and description are integrally 
linked, with the latter an essential step toward ingratiation. A positive aura is built on the 
self-styled rhetoric of reputation. 
Thus, emerging pharmaceutical companies needed to become their own audience 
(ROM 563), in Burkean terms, in order to identify the sympathetic qualities, 
representative anecdotes, and heroic metaphors that would represent them and thereby 
refute any disparaging commentary on their industry. This then set the stage for the 
process of identification, whereby members of the general public would come to believe 
that their interests (e.g., good health, recovery from illness) were “consubstantial” (ROM 
545) with that of the pharmaceutical industry. 
Whereas what pharmaceutical companies were had been defined in is or is not 
scientistic fashion, how they were became described in shalt or shalt not dramatistic 
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fashion. Burke calls this, satirically, “directing the intention” as it applies to how an 
individual chooses to conduct his affairs (LSA 45). Yet, by setting out an ethical 
intention, which largely is directed to oneself, one also directs the attention of others to 
the establishment of those ethics (as well as, it should be noted, their subsequent 
achievement or failure). 
Burke also notes that many of the observations that we make about any given 
reality are largely related to “the spinning out of possibilities implicit in our particular 
choice of terms” (LSA 46). For example, he says, the injunction crede, ut intelligas 
(“believe that you may understand”) is “at once pious and methodological” and serves “to 
define the relation between faith and reason” (LSA 47). 
It is revealing that the word credo (“belief”) was chosen by the pharmaceutical 
company Johnson & Johnson (J&J) to represent its internal code of ethics. J&J’s credo 
was written in 1943 by company founder Robert Wood Johnson. In it Johnson outlined a 
hierarchy of responsibilities: first to those who use the products; next to employees who 
work in plants and offices; third to management; fourth to communities; and last to 
stockholders. It is an excellent example of “shalt” style rhetoric in which an ethical 
environment of what should be is privileged. 
The company provides a copy of the 1948 version on its website, as follows: 
 
 Our Credo 
 
We believe that our first responsibility is to the doctors, nurses, hospitals, 
mothers, and all others who use our products. Our products must always be of the 
highest quality. We must constantly strive to reduce the cost of these products. 
Our orders must be promptly and accurately filled. Our dealers must make a fair 
profit. 
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Our second responsibility is to those who work with us—the men and women in 
our plants and offices. They must have a sense of security in their jobs. Wages 
must be fair and adequate, management just, hours reasonable, and working 
conditions clean and orderly. Employees should have an organized system for 
suggestions and complaints. Supervisors and department heads must be qualified 
and fair minded. There must be opportunity for advancement—for those qualified 
and each person must be considered an individual standing on his own dignity and 
merit. 
 
Our third responsibility is to our management. Our executives must be persons of 
talent, education, experience and ability. They must be persons of common sense 
and full understanding. 
 
Our fourth responsibility is to the communities in which we live. We must be a 
good citizen—support good works and charity, and bear our fair share of taxes. 
We must maintain in good order the property we are privileged to use. We must 
participate in promotion of civic improvement, health, education and good 
government, and acquaint the community with our activities. 
 
Our fifth and last responsibility is to our stockholders. Business must make a 
sound profit. Reserves must be created, research must be carried on, adventurous 
programs developed, and mistakes paid for. Adverse times must be provided for, 
adequate taxes paid, new machines purchased, new plants built, new products 
launched, and new sales plans developed. We must experiment with new ideas. 
When these things have been done the stockholder should receive a fair return. 
We are determined with the help of god’s grace, to fulfill these obligations to the 
best of our ability. (“Credo”) 
 
 
In this case, the company positions its credo alongside its name to establish the 
reality that J&J has not merely composed a morally based belief system, but that J&J 
itself is to be believed. J&J determines how it shall or shall not be, codifies these 
decisions through its credo, and steers the company to this guidance. The public then 
absorbs this rhetoric through news articles, broadcasts of the day and so forth. 
The terms of the credo reflect J&J’s culture, and the company updates the credo 
as needed to adjust with the times. The most recent version of the credo incorporates new 
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shalt rhetoric that places emphasis on care for the environment and maintaining balance 
between work and family. 
Over the years, and especially during the company’s Tylenol crisis of 1982 when 
several people died after ingesting the product, the term J&J’s Credo has served as a 
terministic screen to reinforce the description of J&J as a highly ethical company that 
makes decisions consistent with a morally upright belief system. 
J&J’s credo balances statements that are directed toward an internal audience with 
those that are focused externally (e.g., on patients and the community), which makes the 
credo a particularly effective example of descriptive rhetoric. While Burke writes that 
“(i)n traditional Rhetoric, the relation to an external audience is stressed” (ROM 562), he 
also says: 
 
a modern “post-Christian” rhetoric must also concern itself with the thought that, 
under the heading of appeal to audiences, would also be included any ideas or 
images privately addressed to the individual self for moralistic or incantatory 
purposes. For you become your own audience, in some respects a very lax one, in 
some respects very exacting, when you become involved in psychologically 
stylistic subterfuges for presenting your own case to yourself in sympathetic 
terms. . . . The individual person, striving to form himself in accordance with the 
communicative norms that match the cooperative ways of his society, is by the 
same token concerned with the rhetoric of identification. To act upon himself 
persuasively, he must variously resort to images and ideas that are formative. 
(ROM 562-563) 
 
 
Thus for J&J, and indeed for all pharmaceutical companies, it is difficult to 
present an effective and sympathetic case to the outside world unless the argument is first 
presented and accepted by those inside the company. 
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Company mission statements represent opportunities for pharmaceutical 
companies to “test drive” messages with employees prior to sharing them with an 
external audience. The values that a corporation chooses for itself—the shalt and shalt not 
directives—are captured in a number of publications that are shared with others. In 2004, 
for example, Bayer published a newly revamped mission statement in a pamphlet called 
Science for a Better Life. In it, Chairman of the Board Werner Wenning explains that the 
new mission statement 
 
(d)efines our future perspectives, our goals and our values, and guides our 
strategy at a time of sweeping change. It out lines to our stockholders, our 
customers, the public and especially our employees how we think and behave as a 
company. In seeking to arouse everyone’s enthusiasm to contribute to Bayer’s 
success, we aim to impart one thing above all else: the fascination that is Bayer. 
(Bayer AG Communications 2) 
 
 
The pamphlet merges language that is scientistic and definitive with language that is 
dramatistic and descriptive, such as, “Bayer is an inventor company infused with a 
pioneering spirit” (6). Bayer underscores its text with messages of innovation, new 
technology, and idealism, as follows: 
 
This mission statement underscores our willingness as an inventor company to 
help shape the future and our determination to come up with innovations that 
benefit humankind. Of special importance in this respect are: 
- new products emerging from our active substance research,  
- the consumer health business,  
- the growth markets of Asia,  
- new areas such as biotechnology and nanotechnology. (3) 
 
 
Companies reinvent themselves as well through their values statements which, 
like mission statements, define what a company is through descriptions of how it 
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behaves. On its website, Pfizer lists its company values of “integrity, respect for people, 
customer focus, community, innovation, teamwork, performance, leadership and quality.” 
To this are added definitive statements such as “We recognize that people are the 
cornerstone of Pfizer’s success” and “Since 1849, the Pfizer name has been synonymous 
with the trust and reliability inherent in the word Quality” (“About Pfizer”). 
Occasionally, the role of internal audience can be assumed by an individual 
leader. For example, Roy Vagelos, the former chief executive officer and chairman of 
Merck, tells his own story in The Moral Corporation, conflating the moral and 
philosophical lessons of his life with that of his pharmaceutical company employer. He 
has a dialogue with himself upon joining Merck, identifying the sympathetic qualities of 
past companies, and adding his own personal flavor. He describes himself and what he 
stands for, and, by extension, does the same with Merck. 
Vagelos writes that when he joined Merck, he “knew very little about the 
pharmaceutical business and virtually nothing about the American business sys tem” but 
he was convinced that  
 
if the company improved the quality of its research and [its] strategy for drug 
discovery, it would have a much better chance of someday developing new 
therapies that would really make a difference. That was the hook for me – 
believing I could have a positive impact on the company’s ability to reach that 
laudable goal. (Vagelos and Galambos 25) 
 
 
In this manner, Vagelos is presenting Merck’s case to himself, merging scientistic 
definition with dramatistic descrip tion. In essence he is saying, ‘Yes, we define ourselves 
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as capitalists; but we shall be capitalists with a strong work ethic and a commitment to 
doing good.’ 
Vagelos also references his own personal rags-to- riches story of capitalism. He 
tells of his Greek-born mother and father, writing: 
 
My life has in many ways been the classic American drama: Poor immigrants  
come to the United  States and work very hard; their children receive an excellent 
education and lead a better life. Like most such myths, the story has some truth to 
it, as it certainly does in my case. (Vagelos and Galambos 4) 
 
   
Vagelos’ reference to myth invokes the idea of play, and of the give and take that 
exists in language. If we describe ourselves as ethical and heroic, and others describe us 
as such, eventually description has the potential to meld with definition. Language creates 
the reality. For example, during his lifetime, Albert Einstein delivered highly intellectual 
lectures and published works of brilliance; today, the name Albert Einstein is 
synonymous with genius. 
At the turn of the twentieth century, being a chemist meant being modern, 
scientific, and rational. It was how pharmaceutical companies defined themselves, and it 
provided a foundation for the descriptive language they shared with the public. But by the 
turn of the twenty-first century, being a chemist was perceived as equivalent to tampering 
with nature. In 1962 the environmental writer Rachel Carson confronted the chemical 
industry with her landmark publication, Silent Spring, and the description of chemicals 
shifted from helpful to hurtful. 
As was evident throughout the Newkirk “a rat . . . is a boy” example, the idea of 
definition and the idea of what ought and ought not to be wrap around each other 
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incessantly. This is particularly evident in literature. In the novel, The Last Prophet, for 
example, two characters are describing the nature and essence of pharmaceuticals and the 
pharmaceutical industry, in conjunction with “chemtrails” —a relatively new term to 
describe suspicious chemicals allegedly released in the vapor trails of over flying aircraft. 
Their conversation is as follows: 
 
“OK, well, you know how most all of TV is owned by just a few companies?” 
“Yeah.” 
“Well those companies make their money mostly through selling commercials 
right?” 
“OK.” 
“Have you noticed most of the commercials are for pharmaceuticals now-a-
days?” 
“Oh, well yes, I guess that’s true.” 
“OK well, there you go.” 
John confused, “what are you talking about?” 
Tim tries a different angle, “Alright, what are chemtrails made of?” 
“Ah, chemicals, Barium…” 
“Right chemicals, and what are pharmaceuticals made of?” 
John gives him a patronizing, “chemicals?” 
“Exactly, see, there ya go.” 
John rolls his eyes. 
“You’ve got your poison, and you’ve got your antidote and they’re both made out 
of chemicals.” 
“Oh!”, John didn’t expect that. It reminded him of something he recently heard. 
John recaps, “so the pharmaceutical companies are putting chemtrails in the air 
which cause disease, so they sell drugs which help the disease and they control 
the TV stations because of all the money they spend on commercials which sell 
their drugs.” (Carter 91) 
 
 
Through his characters, Carter defines pharmaceuticals as chemicals and as both 
the antidote and the poison itself. Carter says his book is “a work of fiction and in no way 
is meant to characterize real persons or events,” but he then adds, “However, the message 
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is real” (i). In so writing, Carter is very much in the vein of Rachel Carson by using a 
dramatistic and literary approach to deliver a scientistic message. 
Thus in both works of literature and reference materials, we find opposing 
scientistic-style definitions (or viewpoints) spiraling in a rhetorical helix toward each 
other, encountering the other, and being made unstable by some change to the dramatistic 
pentad (e.g., the people involved, the time frame, the surrounding circumstances). The 
definitions then spiral out again, changed—significantly, modestly or barely 
perceptibly—as a result of the encounter. 
At the turn of the twentieth century, pharmaceutical companies defined 
themselves through the precise and standardized ways they manufactured their products. 
But by the turn of the twenty-first century, the industry was under fire for cutting corners 
and being sloppy in their drug development process. MedAdNews, one of the premier 
publications of the pharmaceutical industry, recently carried an editorial entitled, “Word 
to the Wise” that warns the industry that words are critical to public perception. The 
author writes that complicated pharmaceutical industry jargon, which usually is peppered 
throughout company press releases and other public documents, is an impediment to true 
understanding. She writes that, as a consequence, 
  
Pharmaceutical industry image continues to be a problem. There is a lot of talk 
about how the general public thinks the industry is out to empty its pockets, that 
companies are hiding critical information about side effects, that DTC [direct to 
consumer advertising] hypes drugs at the expense of patient health. (Truelove 3) 
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Obviously the “right” words and the “right” descriptions lead to public ingratiation, 
whereas the wrong words lead to alienation. Less obvious is how to determine what will 
strike a responsive chord in the public. 
The Myth of Pharmaceutical Traits 
 
In a lecture on semantics and discourse, Philipp Koehn writes that it is possible to 
detect stereotypes through the use of Google. By typing in a nationality, along with the 
phrase are known to be and a wild card asterisk, it is possible to gain a perspective of 
how that nationality is perceived. He provides the following examples: 
 
• Enter: Scots are known to be * => fruga l, friendly, generous, thrifty, . . . 
• Enter: Englishmen are known to be * => prudish, great sports- lovers, people 
with manners, courteous, cold, . . . 
• Enter: Germans are known to be * =>pathetic, hard-nosed, arrogant, very 
punctual, fanatical, hard-working, . . . 
 
 
To write that a Scotsman is thrifty is to go beyond the realm of definition into, as 
Burke would put it, “the rhetoric of oratory and advertising, mythologies, theologies and 
philosophies after the classic model” (LSA 45). For example, The Thrifty Scotsman is the 
company name and symbol for a used furniture store in Littleton, Colorado. The thrifty 
Scot is fodder for scores of jokes about penny pinchers. While descriptions such as thrifty 
do not define Scottish citizens per se, many descriptions emerge from some basis in 
reality. As the Scottish Council Foundation, a non-profit research organization, writes: 
 
Rightly or wrongly, the Scots are regarded as a nation that understands money. 
The concept of the “thrifty Scot” may be little more than a caricature, but 
Scotland is home to much of Britain’s domestic and international financial 
services industry. (Vizard 7) 
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The thrifty Scot is seen as an endearing mythology—if it were not, such a 
characterization would never even be mentioned in an official investment brochure. As 
Koehn points out, the Scots have other stereotypical traits, too. These are largely positive 
in the public eye. 
In his biography of Alexander Fleming, a key figure in pharmaceutical history, 
Gwyn MacFarlane writes that Fleming “acquired the true Scottish characteristics and, 
like most expatriate Scots, he retained them tenaciously throughout his life” (3). 
The ascribing of praiseworthy Scottish traits to Fleming—not just by MacFarlane, 
but by many others—gave Fleming a heroic status that would be consistent with his use 
as an early pharmaceutical industry icon. The description, too, of Fleming’s mythological 
discovery of penicillin lent credence to the positioning of the pharmaceutical industry as 
purveyors of miracle drugs. Similarly, in 1908 the immunologist Dr. Paul Ehrlich 
described what he saw as “magic bullets”—chemical compounds that would seek out and 
kill disease-causing microorganisms while having no harmful effects on the patient 
himself. 
Writing in 1945, Dr. Boris Sokoloff characterized Ehrlich’s approach as “the 
proud conviction of German science” whereby “man’s intellect overcomes every natural 
obstacle on the road to success” (123). He contrasted this with penicillin, which followed 
“the road of research designated by those natural forces that dominate and control the 
human organism” (123). Thus, penicillin was linked with nature, not chemicals. Even 
more powerful, from a rhetorical perspective, were the descriptions of miracle drugs and 
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magic bullets, which would endure in the public consciousness for much of the twentieth 
century. 
The author of a 1945 history of penicillin entitled Yellow Magic: The Story of 
Penicillin says that he was convinced that many people would take issue with the title of 
his book. He writes: 
 
Medical men bridle at the word magic when it is used in connection with their 
science. They are similarly provoked by the word miracle. Miracles, they contend, 
happen only in biblical literature, not in modern hospitals. And they say that there 
is no magic involved when some new drug snatches back a life that was within 
moments of extinction. 
 
Despite the modern medical man’s dislike and distrust of the word magic, I still 
believe that its use is justified. But the reader can decide this for himself. (Ratcliff 
3) 
 
 
From a definitional standpoint, the pharmaceutical industry had worked hard to separate 
itself from the idea of miracles and magic. Yet, from a descriptive and dramatistic 
standpoint, these concepts were somehow comforting and understandable to the public at 
large. 
One reason for studying the role of description, particularly in the Fleming story, 
is to gain insight into the part it plays in the rhetorical helix. Although definition is 
suasive to a degree, its scientistic structure allows limited maneuverability of language. 
Ingratiation, on the other hand, presupposes that an emotional connection has been made 
and that the interests and motives of one party are deemed to be the same as another 
party. Description is the process in the middle. Description can allow us to feel closer to a 
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subject, and move us toward ingratiation, or distant from a subject, prompting perhaps 
another attempt at description or definition. 
By examining the descriptive rhetoric surrounding the pharmaceutical industry, it 
is possible to probe how rhetoric serves to act. That is, by using Burke’s dramatistic 
pentad, we can re-view the myths of Fleming and penicillin and expand the multiple 
narratives that are possible. 
The first task is to explore what the general population has embraced about the 
penicillin narrative and then to draw comparisons with other narratives originating from 
the pharmaceutical industry itself. Ultimately, the goal is to find the descriptive 
terminology that is so ingrained, so long- lived, that it seems nearly definitional.  
Pharmaceuticals: Hero or Villain? 
 
In today’s world, one doesn’t need to look far to find a description of big 
pharma—that is, the world’s major pharmaceutical companies—as an irresponsible 
industry that “jack(s) up the price of drugs,” “refuses to do any research with natural 
methods or prevention” and “fudge(s) the data used in scientific papers” (Kinsinger C3). 
Although pharmaceutical insiders would likely beg to differ, the fact remains that many 
elements of these characterizations have now become entrenched in the public’s 
perception. 
Yet historically, in the mid-twentieth century, the pharmaceutical industry had 
achieved eminent status, with penicillin serving as its quintessential success story. 
Collectively, the industry began to establish its heroic metaphors and representative 
anecdotes, and the star of this language “act” was clearly penicillin. From an internal 
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communications perspective, not only did penicillin reinforce pharma’s connection with 
chemistry, it also validated the industry’s ability to successfully manufacture a 
complicated product and sell it to millions. 
External rhetorical texture came from images of trailblazing and heroism. 
Penicillin was powerful and effective, and served as an example of pharmaceutical 
prowess. As a blockbuster product (that is, a drug with a substantial number of sales), 
penicillin was a forerunner for other blockbus ter drugs, such as Prevacid and Prozac, 
which also achieved major commercial success. However, as opposed to blockbusters 
such as Viagra, which could be considered merely life-enhancing, penicillin was life-
saving, particularly during the Second World War. And although aspirin was and is a 
highly successful pharmaceutical whose origins can be traced to nature (in its case, the 
willow bark), aspirin did not perform the same heroic feats as penicillin. Furthermore, 
since aspirin was a product of German research, it became tainted as a result of World 
War I. In fact, the trademark Aspirin was seized shortly after the war by the Allies. 
As a potent symbol of the pharmaceutical industry, however, penicillin was aptly 
suited for U. S. and British public relations and would provide powerful ammunition for 
many, many years against any detractors of the industry. 
Penicillin also had a fascinating narrative associated with its discovery—a 
narrative that continued to be told decades after the fact. For example, in 1999, when 
Time magazine published its list of the “most important scientists and thinkers” of the 
twentieth century as part of its “Most Important People of the Century” series, it included 
the discovery of penicillin. The Time magazine article by Dr. David Ho relates the story 
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of how, in 1928, spores from a Penicillium notatum mold had accidentally drifted into 
Dr. Alexander Fleming’s laboratory and settled onto a culture dish that had been smeared 
with Staphylococcus bacteria. In what Ho describes as a “Eureka” moment, Fleming 
noticed that the bacteria did not grow in the areas contaminated by the mold and thus, the 
mold must have somehow inhibited bacterial growth. Ho, who describes Fleming’s 
discovery as “the stuff of which scientific myths are made,” writes the following: 
 
It was a discovery that would change the course of history. The active ingredient 
in that mold, which Fleming named penicillin, turned out to be an infection-
fighting agent of enormous potency. When it was finally recognized for what it 
was—the most efficacious life-saving drug in the world—penicillin would alter 
forever the treatment of bacterial infections. By the middle of the century, 
Fleming’s discovery had spawned a huge pharmaceutical industry, churning out 
synthetic penicillins that would conquer some of mankind’s most ancient 
scourges, including syphilis, gangrene and tuberculosis. (117) 
 
 
This story of Fleming’s discovery, with little variation, has been told and retold 
countless times. As a familiar and popular tale, the Fleming story serves as a tool to 
understand people’s thinking about pharmaceuticals. It is Fleming’s discovery that 
serves, in Burkean terms, as the “representative anecdote” (GOM 60) that succinctly 
sums up a more complex story. 
It’s also a basis—a line in the sand—from which we can observe departures. 
Through the Fleming story, we can assess which parts of the narrative resonate with the 
public and which parts are glossed over. 
The prototypical narrative casts Fleming as the “young Scottish research scientist” 
(Ho) who is both brilliant and charmingly messy. As the folklore goes, Fleming disliked 
the chore of washing the laboratory dishes, and so allowed them to pile up instead of 
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washing them after an experiment. Fleming worked in what the Fleming Museum calls a 
“small, musty, dusty laboratory” at St. Mary’s Hospital in London—a place where mold 
spores apparently could flourish. 
It is interesting to note that Ho describes Fleming as a “young Scottish research 
scientist,” although Fleming was 47 years old at the time of the incident. As will be 
discussed later, the use of youth, or newness, in pharmaceutical (and later, biotech) 
descriptions is a recurring and strategic rhetorical move to engender ingratiation. 
Fleming’s status as “the first” is of major importance to the myth. His premier 
status in being the first to discover penicillin allows him to be lionized as a “Trailblazer” 
(Hantula), “Pioneer” (Kaye), and “Groundbreaker” (Parker), while his intelligence and 
scientific acumen positions him in anthologies entitled “Giants of Science” (Birch) and 
“Great Minds of Science” (Tocci). In the literature, penicillin is variously described as a 
“wonder drug,” a “miracle drug,” and a “magic bullet.” In his hyperbolic version above, 
Ho says that penicillin—“the most efficacious life-saving drug in the world”—would 
“change the course of history.” Just as Neil Armstrong was the first on the moon and 
Columbus was “first” to discover America, it is Fleming who is the first to discover 
penicillin. 
What Ho also does is gloss over what happens between the time the mold was 
discovered on the culture dish and the spawning of a huge pharmaceutical enterprise, by 
using the passive phrase, “when it was finally recognized for what it was.” There is no 
mention of the fact that there were others involved in making penicillin into a medicine 
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or the great number of steps that had to transpire in order to transform the mold into a 
useful medicine. Thus, Ho distills a complicated process into a simple one. 
Ho’s approach is similar to that found in other popular narratives such as 
children’s books, anthologies, popular magazines, websites, and sermons—anywhere a 
complicated story is made simple. If, as Burke suggests, language is a selection of reality, 
then the popular narrative is its ultimate end product. It is a story stripped down to its 
most basic layer. 
An important part of the popular narrative concerns Fleming’s altruism. 
RampantScotland, a web site devoted to “everything about Scotland” describes Fleming’s 
motivation for bacterial research as stemming from seeing the “failure of current 
antiseptics to treat infected wounds” during his own stint during World War I. The site 
contends, “Fleming did not patent penicillin, hoping that this would help to develop the 
product as a cheap and effective drug” (“Famous Scots”). 
Not only was Fleming altruistic, he was also modest and self-effacing, according 
to several biographers. Tocci describes how the cash award from the Nobel Prize “would 
be most of the money that Fleming ever made from his work with penicillin” (102). And 
when penicillin drug manufacturers once offered Fleming a check for $100,000 (worth $1 
million in 21st century terms), Tocci writes, “Fleming protested, saying that he could not 
possibly keep the money for himself. So he asked that the money be used for research by 
his department at St. Mary’s Hospital” 103). Fleming biographer Andre Maurois, writing 
in 1959, talked about the scientist’s positive qualities that many attribute to the Scots, 
such as “a capacity for hard and sustained work, a combative spirit which refuses to 
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admit defeat, a steadfastness and loyalty which creates respect and affection, and a true 
humility which protects against pretentiousness and pride” (9). 
Goldsworthy and McFarlane offer another perspective of the story of penicillin, 
calling it a myth that “meets the specifications of the archetypal ‘quest story,’ as 
described by the Russian anthropologist Vladimir Propp.” They write: 
 
The basic quest story seems to be a template in every human culture. It involves 
heroes who undergo trials or answer riddles, usually with the help of magical or 
divine intervention (in this case, mould spores drifting through windows). It has 
been argued that the quest story's structure (along with other story structures) is 
“hardwired” into the human brain, and that such structures evolved, like poetry 
and music, in human brains as mnemonic aids to help preliterate people store and 
remember vast quantities of words. (176) 
 
 
Barthes, on the other hand, would argue that myth is simply “a type of social 
usage,” and “system of communication” (109). Fleming’s story, in other words, was (and 
is) useful for society, and this usefulness not only propelled his tale “from a closed, silent 
existence to an oral state” (109) but kept it there fo r years. Although Barthes asserts that 
there are no eternal myths, there are certainly very ancient ones (110). In popular fairy 
tales, the brave young knight slays the dragon and is rewarded with princehood. In the 
Alexander Fleming version, the kind Scottish researcher saves countless lives and is 
rewarded with a knighthood (in 1944) and the Nobel Prize (in 1945). And upon his death 
in 1955, Fleming “was given the kind of funeral reserved for national heroes, his ashes 
interred near those of Nelson and Wellington in the crypt of St Paul’ s Cathedral” 
(Gilchrist 31). 
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In summary, what seems to be deeply ingrained in the psyche of the public is the 
story of Fleming as a brilliant, ethical man, and inadvertent hero. As a website at the 
Massachusetts Institute of Technology puts it, “No scientific story illustrates the power of 
luck coupled with ingenuity quite like the tale of the discovery of penicillin” 
(“Inventor”). 
In accepting and promulgating the “standard” version of the story, we (that is, the 
collective we) reject other potential narratives—of which there are many. What is 
involved—what is the human motivation—when we say Alexander Fleming discovered 
penicillin by chance? How is this to be accounted for? Clearly, there are aspects of the 
standard version that are sympathetic to the pharmaceutical industry. Saving lives with a 
unique medical compound (penicillin) is one. Having industry associates with virtuous 
personal characteristics (Fleming) is another. At the same time, there are aspects of the 
story that appear less harmonious with industry objectives. If, for example, we embrace 
the concept of accidental discovery, what does that say about modern research methods 
that stress a systematic and deliberate scientific approach? Also, what happens when the 
star of this heroic scenario (penicillin) begins to lose its potency through misuse or in the 
face of antibiotic resistant bacteria? The latter example in particular shows how 
definitions and descriptions (e.g., “this is heroic”/“this is not”) can easily become 
destabilized. 
Through dramatism, it is possible to reveal the many variations of the penicillin 
story, with the overarching objective of understanding popular reaction to the 
pharmaceutical industry at large. Below, six variations of the penicillin story are 
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presented, using Burke’s pentad of terms. In each variation, the change of one term, scene 
(that is, a different historical time period) drives a completely new potential narrative. 
Through these variations, it is possible to observe the push and pull of descriptive 
rhetoric and gain an understanding of how all of us have come to think and talk about the 
pharmaceutical industry. 
Pentad 1: The Early Twentieth Century 
 
If the simple, popular narrative of the discovery of penicillin is put into Burke’s 
pentad format, we have the following: 
 
Act:    The discovery of penicillin 
Scene:   The early 20th century 
Agent:   Alexander Fleming as hero 
Agency:   Fortuitous drifting of mold spores on the right spot at the right time  
Purpose:   Seeking to solve the mystery of the body’s fight with infection 
 
 
In this pentad, the event takes place in the generic 20th century, a catch-all timeframe that 
synthesizes the year 1928 into a 100-year period. It is a timeframe that is chronicled in 
magazines and anthologies under headings such as “the most important discoveries of the 
twentieth century.” Alexander Fleming’s discovery of antibiotics was included as one of 
“ten magnificent achievements” in the field of medicine (Friedman and Friedland 228). 
In 2007, when the British Medical Journal invited its readership of physicians to list the 
greatest medical breakthrough since 1840, the discovery of antibiotics came in at number 
two, with roughly fifteen percent of the vote. (Good sanitation was first, at roughly 
sixteen percent.) (Ferriman 111). Robert Bud, principal curator of the National Museum 
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of Science and Industry in London, described penicillin as the “iconic antibiotic” whose 
“introduction into clinical practice was widely celebrated” (“Antibiotics”). 
In embracing this scenario, we are saying that we like the concept of the agent as 
one doctor, acting alone, who has a noble purpose and admirable Scottish traits. We also 
respond positively to an act that is the first of its kind and represents a trailblazing 
discovery. This scenario also privileges fortune, destiny and God—all concepts that are 
somehow greater than man. 
In this scenario, the agency is also strongly related to nature and biology, since it 
is air that carries the natural mold substance to the Petri dish. An underlying theme could 
be that Nature provides the answers to man’s critical problems. 
As mentioned earlier, this is the scenario that can be found in popular literature, 
such as anthologies and children’s books, and in popular journalism.  
Pentad 2: 1928 
 
The first years of the 20th century were fraught with suffering and death. World 
War I (1914-1918) leveled heavy casualties in Western Europe. While many were the 
direct result of artillery fire or chemical weapons, such as mustard gas, many other 
soldiers died from trench foot, a fungal infection that often led to gangrene and 
amputation. 
The two years following World War I were even worse, when the Spanish Flu 
pandemic killed between 20 and 40 million people – roughly one-fifth of the world’s 
population. An estimated 675,000 Americans of influenza during the pandemic, ten times 
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as many as in the world war, and of the U.S. soldiers who died in Europe, eighty percent, 
or 43,000, fell to the influenza virus and pneumonia and not to the enemy (Crosby 206).  
By the time 1928 rolled around—the year that Fleming observed the penicillin 
mold—both the war and the pandemic had been over for a decade. With no pressing 
urgency to develop an anti- infective, penicillin lay dormant in Fleming’s lab. Thus, 
instead of characterizing Fleming as a brilliant hero, the alternative pentad could label 
him as incompetent and lacking the skills to develop penicillin into a viable medicine; 
lazy and unindustrious; or lacking vision that the horrors of the previous decade could 
happen again. Given such a scenario, the new pentad could look like this: 
 
Act:    Noticing a curious bacterium on a Petri dish, and then doing  
  nothing with it. 
Scene:   1928, ten years after WWI and the Spanish Flu pandemic 
Agent:   Alexander Fleming as incompetent /unindustrious /short-sighted 
Agency:   Penicillin as a mere curiosity  
Purpose: To record a mere curiosity while pursuing the “real” objective of  
  looking for cure for syphilis. 
 
 
One example of this pentad was found in 2006 on the British Broadcasting Company 
website. In its pages on historical figures, the BBC characterized Fleming as incapable 
and an egotist:  
 
After his initial discovery, Fleming did little more than keep a supply of the 
mould and return to his routine work. It was the scientists Howard Florey and 
Ernst Chain who developed penicillin further. Florey and Chain were chiefly 
responsible for the research which led to its success as a drug, although Fleming 
took most of the credit for the discovery and its subsequent development. 
(“Historic Figures”) 
 
 
 
 
102 
In fact, this version didn’t even give credit to Fleming for identifying the substance, but 
gave the credit to “one of Fleming’s colleagues who identified the mould as penicillin.” 
It is to be noted that as of March 1, 2007, this characterization of Fleming was no 
longer posted on the BBC website, but replaced with a new version. The new version still 
credited Florey and Chain with “develop(ing) penicillin further,” but deleted any 
inference that Fleming either sat on his hands in developing penicillin, or hogged the 
credit once it was made available as a drug. 
Obviously, at least at some point in 2006, someone at the BBC website had made 
the decision to allow Fleming to be stripped of his “heroic” status. This action could have 
been taken to elevate the notion of a team rather than individual effort; to disparage a 
Scotsman; to bring forward the achievements of “scientists” rather than country doctors; 
to elevate the status of Florey and Chain, or any other host of theoretical reasons. 
Whatever the rationale, the 2006 version did not stand for long. In the 2007 version, 
Fleming’s heroic status appears to have been restored, and several points were added to 
ameliorate his personal characterization. 
The above is just one example of this particular pentad in action. However, the 
fact that the Fleming anti-hero story appeared, disappeared, and was replaced by the 
traditional Fleming-as-hero story speaks to the impetus to preserve the “traditional” story.  
The BBC has always championed British heroes and it seems probable that 
nationalistic motivation is also somehow in play in this scenario. This is a theme that will 
be discussed further, per the scenario below. 
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Pentad 3: The War Years (1939-1945) 
 
World War II was the deadliest conflict in history. Battlefield casualties came 
either immediately, as the result of bombs or bullets, or slowly and painfully, from 
infection and gangrene. The U. S. and British governments were under tremendous 
pressure to address the issue of infection and tremendous resources were directed to 
“save our boys.” Penicillin needed to be manufactured on a large scale, and it needed to 
be done quickly. 
This is the basic story of penicillin and World War II. Beyond this, the story 
expands in a number of ways. In the new pentad featuring WWII as the scene, the lone 
Scottish doctor and his Petri dish are no longer in the forefront of the story. Instead, 
Fleming is relegated to an historical and somewhat sentimental position, replaced by 
major pharmaceutical companies, governments, and others as the dominant drivers of the 
story. 
 
Act:    The development and commercialization of penicillin 
Scene:   The years of World War II 
Agent:   Pharmaceutical companies; governments 
Agency:   Fermentation and chemical synthesis as new “weapons” to fight  
  infection 
Purpose: To “save our boys” from infection and gangrene; to win the war 
 
 
In what can be considered a neo version of the Revolutionary War, U. S. and 
British governments fought for control of the story of penicillin and for the credit of its 
discovery. In his account of the American pharmaceutical industry, Tom Mahoney quotes 
Dr. Henry Welch, director of the Food and Drug Administration’s antibiotic division. 
Welch says, “The American chemical and pharmaceutical industries have never been 
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given ample credit for the tremendous efforts they put forth in the development of 
penicillin” and “It is the ingenuity, drive, and ‘know-how’ of the American chemical and 
pharmaceutical industries that have made possible this tremendous advance” (Mahoney 
12). 
Historical researchers John Mailer and Barbara Mason describe the tug of war 
between the agents as follows: 
 
Authors have written any number of books and articles on [the story of penicillin], 
and while most begin with Sir Alexander Fleming’s discovery in 1928 and end 
with Sir Howard Florey’s introduction of penicillin into clinical medicine in 1941 
or John C. Sheehan’s inorganic synthesis in 1957, broad differences of opinion 
exist between and among the principal scientists, governments, laboratories, and 
drug industries in Britain and the United States as to the details of this story. Over 
and above the microbiological and chemical achievements in penicillin’s 
discovery are to be found aspects of competition between two nations and their 
scientists; political and wartime intrigue; competition for academic and financial 
reward; the formidable challenge of producing penicillin in quantities to support 
the military in World War II; the complexities of cooperation among 
governmental, industrial, and academic entities; and human, legal, and national 
differences over patent rights and royalties in postwar years. (39) 
 
 
As writers for the periodical Illinois History Teacher, Miller and Mason concern 
themselves with the role Illinois played in the development of penicillin. They describe 
how German bombing raids imperiled Britain’s manufacturing capabilities, thus 
necessitating production in the United States and specifically at the government-
sponsored Northern Regional Research Laboratory in Peoria, Illinois, “the middle of the 
greatest corn-growing farmland in the world” (Miller and Mason 42). Of Illinois, the 
authors write: 
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The corn-milling industry of 1941 was already well experienced with the 
fermentation process required to produce penicillin. But since the original 
penicillin molds from England produced uneven results in the manufacturing 
process, American scientists needed a more reliable source. They found the mold 
they needed, which was “discovered on ripe cantaloupes by Mary Hunt from 
Peoria.” (42) 
 
 
Later in the article, Miller and Mason set up a polarity between the government 
scientists at Peoria and the pharmaceutical industry, with the former advocating 
“scientific disclosure of information” and the latter insisting on “the protection of 
proprietary rights” (42). This gives the government an open and generous role, and the 
pharmaceutical industry (defined principally as Merck, Pfizer, Squibb and Abbott) a 
more avaricious stance. 
Miller and Mason privilege the activity of the state of Illinois, and also elevate the 
status of American crops in producing a more potent medicine. Mary Hunt, a lab worker, 
is given special mention, demonstrating that ordinary folks can play as much of a role in 
medical history as Nobel laureates. Although they assign the role of hero to the United 
States government, the authors cannot completely discount the contributions made by the 
pharmaceutical companies. They write: 
 
Thanks to the work of scientists and their staff, together with the Illinois farms 
and numerous drug companies, the drug saved the lives of hundreds of thousands 
of war victims during World War II and has continued to shorten illness and save 
lives every day since. (43) 
 
 
Pharmaceutical companies, of course, also vie for control of the WWII penicillin 
story. Ads contemporary to the time depict pharmaceutical companies as the “masters” of 
the complex problem of penicillin manufacturing. A typical example is the ad shown in 
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Figure 1, from Schenley Laboratories, which is no longer in operation as an antibiotic 
manufacturer. 
  
 
 
Figure 1. Schenley Laboratories Advertisement for Penicillin, 1944. 
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The ad, published in Life magazine on August 14, 1944, reads as follows: 
 
 
When the thunderous battles of this war have subsided to pages of silent print in a 
history book, the greatest news event of World War II may well be the discovery 
and development—not of some vicious secret weapon that destroys—but of a 
weapon that saves lives. That weapon, of course, is penicillin. 
 
Every day, penicillin is performing some unbelievable act of healing on some far 
battlefront. Thousands of men will return home who otherwise would not have 
had a chance. Better still, more and more of this precious drug is now available 
for civilian use . . . to save the lives of patients of every age. 
 
A year ago, production of penicillin was difficult, costly. Today, due to specially-
devised methods of mass-production, in use by Schenley Laboratories, Inc. 
and the 20 other firms designated by the government to make penicillin, it is 
available in ever- increasing quantity, at progressively lower cost.  
 
Listen to “THE DOCTOR FIGHTS” starring RAYMOND MASSEY, Tuesday 
evenings, C.B.S. See your paper for times and stations. 
SCHENLEY LABORATORIES, INC. 
Producers of PENICILLIN-Schenley 
 
 
The ad’s sidebar was entitled, “From Ordinary Mold—the greatest healing agent of this 
war!” It reads: 
 
On the gaudy, green-and-yellow mold above, called Penicillium notatum in the 
laboratory, grows the miraculous substance first discovered by Professor 
Alexander Fleming in 1928. Named penicillin by its discoverer, it is the most 
potent weapon ever developed against many of the deadliest infections known to 
man. Because research on molds was already a part of Schenley enterprise, 
Schenley Laboratories were well able to master the problem of large-scale-
production of penicillin, when the great need for it arose. 
 
 
The ad’s language references Alexander Fleming (a name that in 1944 still carried 
weight and authority) and describes penicillin as a “miraculous” substance. At the same 
time, the company also identifies a problem more contemporary to 1944—that is, large-
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scale production—and describes how Schenley was able to “master” that problem, thus 
elevating itself and its peer companies to heroic status. 
Even today, the “race” to produce penicillin still figures in pharmaceutical 
company lore. In its 2005 citizenship report, Pfizer notes how in 1944 the company used 
deep-tank fermentation to successfully mass-produce penicillin and become “the world’s 
largest producer of the ‘miracle drug’” (33). The company distinguishes itself historically 
from its peers by stating that it is the only company to use fermentation technology of all 
those producing penicillin, and that “(m)ost of the penicillin used by Allied forces on D-
Day is made by Pfizer” (33). 
The notion of accepting a challenge figures prominently in the WWII penicillin 
story. Abbott Laboratories noted that in 1941, Britain sought help in initiating large-scale 
production and “Abbott accept[ed] the challenge.” In doing so, Abbott became “one of 
the five pioneers in the United States” (“Abbott History”). 
Pfizer also says in 1941 it “respond[ed] to an appeal by the U. S. Government to 
expedite the manufacture of penicillin” and “emerged victorious” in the race for 
production (“Pfizer: Exploring Our History 1900-1950”). 
Bristol-Myers Squibb also touts the fact that “(s)ix decades ago, discoveries by 
Bristol-Myers Squibb helped make the mass production of penicillin possible. Today, we 
are still the largest manufacturer of penicillin in the world, and the maker of some of the 
world's most prescribed antibiotics” (“Bristol Myers Squibb: Working Together”). 
For its part, Merck tells the story of how, in 1942, the head of its research labs, 
Dr. Randolph Major, was able to secure a few grams of the precious penicillin 
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commodity in order to save the life of a “young wife and mother.” The feature story, 
describes how the company was concerned about ensuring the supply of penicillin for the 
war effort, but also in saving the life of Anne Miller, a nurse, wife and mother in New 
Haven, Connecticut. The website states that Mrs. Miller’s temperature chart, which 
“looked more like the great market crash of 1929” is preserved in the Smithsonian 
Institution, thus validating the heroic status of the drug, the era, and the company 
(“Milestones in Merck History”). 
And in his discussion of Merck as a “moral corporation,” Roy Vagelos makes a 
point of mentioning Merck’s “long record of superb accomplishments,” including 
“important contributions to the development of penicillin and streptomycin, the first 
effective treatment for tuberculosis” (Vagelos and Galambos 23). 
Clearly, playing a part in the successful outcome of WWII is a recurring motif in 
the literature of several major pharmaceutical companies. Furthermore, competition for 
WWII glory, even in the early twenty-first century, remains active. A fall 2003 
publication by Bristol-Myers Squibb quotes Murray Kaplan, a former employee of the 
company, as saying that “Bristol Laboratories was probably the first to crystallize 
penicillin in the U.S., but the company, being small and secretive at the time, did not get 
the credit it should have” (“Penicillin and the Age of Miracles” 2). 
The article describes how scientists at Bristol conducted experiments with 
fermentation and chemical synthesis to improve penicillin. At the same time, the article 
makes a point of saying that Kaplan’s “stroke of luck” in 1944 “brought another 
tremendous breakthrough.” The article states: 
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The bottle-grown penicillin harvested at the Taylor Street laboratory yielded a 
yellow-gold extract that scientists had not yet learned to refine into pure 
crystalline form, which would make true mass production possible. Murray 
Kaplan, the 21st employee hired by Bristol Laboratories, was among those 
working day and night on this problem. Then one day, someone accidentally 
knocked a test tube of penicillin out of Mr. Kaplan’s hand. 
 
“My first reaction was, there goes six months of work all over my desk. I got a 
cloth, wiped up the desk and put the cloth aside. I looked at the cloth a little while 
later, and I saw that penicillin crystals were clinging to it. I knew then that we had 
our form.” (2) 
 
 
The Kaplan story is interesting because the “accidental” nature of his discovery harkens 
back to the Fleming story and reinforces the appeal of fortune over the scientific process. 
Even when the scene of the pentad is changed to World War II and 1940s-era chemistry, 
writers cannot help but summon, once again, the allusion to a power that is greater than 
man. This largely Christian meta-narrative positions man as imperfect but capable, 
through careful observation of nature, of discovering the secrets of God’s plan, as 
described in the book of Genesis. Since nature is the agent in these “accident” narratives, 
one possible implication consistent with a Christian lens is divine intervention (God as 
agent in the form of Nature) rather than accidents, since accidents per this theology do 
not happen in a world that unfolds according to God’s plan. 
Pentad 4: 1945 
 
In December 1945, when the Nobel Foundation was awarding its annual prizes, 
the last battle of World War II was over by six months. Although, as per the pentad 
above, pharmaceutical companies like Merck, Abbott, Pfizer, and Bristol-Myers Squibb 
had competed (and still do compete) for public acknowledgment of their contributions to 
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the development of penicillin, it was ultimately three individuals who were recognized by 
the Foundation: Alexander Fleming, Ernst Chain, and Howard Florey. 
Chain was a university-trained chemist and a refugee from Nazi Germany. In 
1933 he fled to England and obtained a position in chemical pathology at Oxford 
University. Florey was Australian, also a chemist, and also a professor at Oxford. Chain 
and Florey collaborated in 1938 to begin work on penicillin. 
At the Nobel presentations, it was noted that it was unusual that only four years 
had elapsed between a scientific discovery (i.e., isolating the active substance in 
penicillin) and Nobel Prize recognition. In terms of motivation, one could argue that the 
Nobel Committee truly sought to bestow honor on the deserving individuals or, less 
charitably, that theirs was a strategic initiative to be a part of the publicly well-known and 
well-regarded story of penicillin. It can also be argued that Nobel Prize ceremonies are 
simply dressed-up political statements, in the same vein as other award ceremonies.  
Since World War II had yielded the atomic bomb, the ramifications of man’s 
genius was somewhat suspect. Awarding a Nobel Prize for the contribution of penicillin 
to mankind was a convenient way to make reparations for human-initiated harm. In 
presenting the awards at the Nobel ceremony, Professor G. Liljestrand, a member of the 
Staff of Professors of the Royal Caroline Institute, said: 
 
In a time when annihilation and destruction through the inventions of man have 
been greater than ever before in history, the introduction of penicillin is a brilliant 
demonstration that human genius is just as well able to save life and combat 
disease. (Nobel Foundation) 
 
 
Thus the pentad for this scenario would play as follows: 
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Act:   Awarding the Nobel Prize in Medicine to Sir Alexander Fleming,  
  Ernst Boris Chain and Sir Howard Walter Florey 
Scene:   December 10, 1945, six months after the last battle of WWII 
Agents:   The Nobel Foundation 
Agency:   Presentation of Award at the Nobel banquet in Stockholm, Sweden    
Purpose:   Per the will of Alfred Nobel, the Nobel Prize is given to the  
  “person who shall have made the most important discovery within  
  the domain of physiology or medicine”; to be a part of the historic  
  story of penicillin; to make amends for WWII evils 
 
In their acceptance speeches, all three recipients were vying to tell a different part 
of the story. Chain discussed being part of a persecuted race and how he was grateful to 
Providence that he could work on a project to alleviate suffering. Florey’s message was 
that scientists “must be free to pursue scientific enquiries without political interference,” 
and Fleming was motivated to tell his story of how the discovery was an accident. Thus 
two of the three recipients stressed that which is greater than man. 
Also important was the notion that the three Nobel recipients were acting for the 
good of man, rather than for their own private gain. At the awards ceremony, Professor 
A. H. T. Theorell, Director of the Department of Biochemistry at the Nobel Institute of 
Medicine, related one of Grimm’s fairy-tales in which a student received a wonderful 
plaster (bandage) from a “mighty spirit.” One side of the bandage had the power to heal, 
while the other side could turn iron into silver, thus making the student-turned-physician 
both celebrated and wealthy. At the Nobel banquet, Theorell said, “You have dug up a 
wonderful plaster, too, that has healed countless sores . . . but there is a difference 
between you and the student—you have not used that side of the plaster which made 
silver” (Nobel Foundation “Banquet Speech”). 
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Although Florey and Chain also received the Nobel Prize in 1945, it is safe to say 
that their names are less well known, by far, than that of Fleming. Whereas, for example, 
the New York Public Library has nine titles on Alexander Fleming, it has only two on 
Howard Florey and merely one on Ernst Chain. The ratios are similar in periodicals as 
well. 
Macfarlane said that it was with “a lingering sense of injustice” that he wrote a 
book about Howard Florey, and that the sense of injustice was compounded when the 
Florey book was rejected by various publishers (x). Macfarlane writes: 
 
[N]one of the commercial publishers whom I approached showed any interest 
either in the subject or the author except one, who suggested kindly that I should 
write a biography of Fleming instead. ‘At least,” he said, ‘everyone has heard of 
him.’ (x) 
 
 
If Florey’s story is not well known, then Ernst Chain’s story is even less so. 
Ronald Clark writes that Chain “has remained the relatively unknown scientist in the 
enterprise, even though he became a leading figure in the development of antibiotics” (1). 
Clark states that Chain, a German-born Jew, was an irritating and prickly man who 
supported “causes that were not always popular” (149). 
For his part, Macfarlane says that although Fleming’s ascension to world hero is 
“unjustified by the facts of scientific history” (ix), it is not necessarily Fleming’s doing. 
He is quick to point out that the “honest, likeable and truly honest” Fleming (x) was not 
likely the source of the Fleming-as-hero version of events, but was rather a factor of a 
“somewhat mysterious exercise in public relations” (ix) in which newspaper accounts of 
the day attributed Florey and Chain’s work to Fleming. It may be, of course, that the 
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Fleming version is simply easier to tell than the Florey/Chain version. David Wilson 
writes that the standard myth leaves out a number of important ideas, one of which is that 
the word penicillin should actually be penicillins. He writes: 
 
Go back to the very first word of the standard myth—penicillin. It is used in the 
singular, as it will be throughout this book. Yet this is incorrect, the word should 
be in the plural—penicillins. There are many different types of penicillin in nature 
and literally thousands more penicillins have been produced by scientists in their 
laboratories. (5) 
 
 
Such complexity, however, is hard to capture in the popular press.  
 
From the 1945 scenario, we can assume that in the public psyche the following 
notions are privileged: individuals, rather than corporations or individuals working on 
behalf of corporations; “that which is greater than man”; and selflessness in the pursuit of 
the common good. 
Pentad 5: 2007 
 
As we skip to the present day, we find that the traditional penicillin story (i.e., that 
penicillin is a miracle drug and Alexander Fleming is a hero) is still rampant. Evidence 
for this can be found in the modern media, recently published books and many websites. 
The popular penicillin narrative shows up regularly in retrospective news stories, 
as it did in the “Best of Leaders & Success” section of Investor’s Business Daily 
(Alexander A03). The headline for this story captures all of the essential elements to the 
myth: “His Messy Desk Sparked the Discovery of Penicillin; An Eye for Observation: 
Researcher Alexander Fleming’s Keen Concentration Helped Deliver a Knockout Punch 
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to Bacteria.” Even the concept of “knockout punch” positions Fleming as a victorious 
protector of mankind. 
Alexander recounts the story of Fleming’s messy work area and reminds readers 
of Fleming’s Scottish heritage. She also privileges Fleming’s personal attributes of 
creativity and astuteness, with a keen sense of observation for the natural world: 
 
As a young boy, Fleming trained his senses so he could detect the smallest 
changes in the world around him. Wandering around his family’s 800-acre sheep 
farm in Scotland as a child, Fleming memorized every crag and stream. He made 
it a point to notice the slightest shifts in the color of the leaves and the grass 
beneath his feet. Looking at his experiments, Fleming’s eyes were tuned to focus 
on the tiniest areas. In his spare time, Fleming used different colors of bacteria to 
create brilliant “paintings” in petri dishes. This might’ve seemed like sheer play, 
but in doing so Fleming trained himself to see the exact hues of different bacterial 
strains and thus opened his creative mind. (A03) 
 
 
Alexander also chronicles Fleming’s persistence: 
 
 
Convinced his discovery would change the course of medicine, he presented his 
findings in London at the February 1929 Medical Research Club meeting. His 
colleagues weren’t impressed. They ignored his findings, claiming that penicillin 
was useless because there was no way to preserve and mass produce it. Fleming 
didn’t back down. He published his research in the British Journal of 
Experimental Pathology and passed papers and proof of the medicine to his peers. 
He gave out samples of his mold to anyone who showed an interest. (A03) 
 
 
Alexander also privileges Fleming’s role in the commercial development of 
penicillin, making no mention of the role of government or major pharmaceutical 
companies.  
A major part of the narrative is the idea that Fleming is somehow merely a tool or 
conduit of God. Fleming has been widely quoted as saying, “I can only suppose that God 
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wanted penicillin, so He created Alexander Fleming” (Anderson 64). Those who choose 
to replay this quote are reinforcing the notion of Providence, and that Fleming was 
merely there to observe what God had provided. Typical of this is a sermon presented to 
St. Simon’s Anglican Church in North Vancouver in which the minister conflates 
Fleming and Jesus: 
 
Countless millions have been saved physically through Fleming’s sacrificial work 
on penicillin. Countless millions have been saved spiritually through Jesus’ 
sacrificial work on the cross. When is the last time that we thanked God for such 
amazing acts of generosity? (Hird) 
 
 
The classic discovery of penicillin story provides evidence that the public views 
the following positively: 
 
• The concept of a modest individual as single discoverer 
• Medicine that comes from nature 
• A heroic product, a wonder drug 
• Medicine that is effective and serves a noble purpose 
• Altruism 
• Reward for a good deed (but not just any reward – recognition, rather than 
profit) 
• The idea of God (or fortune or destiny) helping to unveil the drug 
 
 
If the above is true, then what the public does not respond to is the following: 
 
  
• Institutional discovery (either large corporations or the government) 
• Chemistry-based medicine 
• Medicine that serves no noble purpose 
• Profit as a driving motivation 
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Pentad 6: The Generic 21st Century 
 
Penicillin is now 80 years old, and the old reliable story is now threatened—not 
by government, or big business, or chemists, but by the fact that penicillin itself may no 
longer be the wonder drug it once was. 
 
Act:   The resistance of bacteria to antibiotics such as penicillin 
 Scene:   Early 21st century, more than 70 years after penicillin was first  
   made commercially available 
Agents:   Health-care professionals; individuals 
Agency:   Misuse of antibiotics; ignorance 
Purpose:   Major threat to public health 
 
 
Many media outlets have raised the alarm that antibiotics may no longer be 
effective. The South China Morning Post said that the “spectre of a plague of superbugs 
that do not respond to treatment . . . is not the futuristic scenario it may seem to 
generations who grew up in a world made safer by the wonder drug penicillin” (“Change 
of Attitude” 14). The paper listed the factors it believed contribute to the resistance 
problem, which included the issuance of prescriptions for healthy patients, overly short 
courses of treatment, illegal sales, and general misuse, including self-medication. 
According to the paper, the World Health Organization said that unless these practices 
are changed, “the rise of drug-resistant diseases threatens to turn the clock back to the 
dark days before penicillin” (14). 
On their website, the Centers for Disease Control called antibiotic resistance “one 
of the world’s most pressing public health problems.” It wrote that resistance “can cause 
significant danger and suffering for people who have common infections that once were 
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easily treatable with antibiotics” (“Get Smart”). The site warns that when antibiotics no 
longer work, the consequences can be life-threatening. 
The fault for this, the CDC goes on to say, rests with regular folks who pressure 
their doctors to prescribe penicillin “just in case”—not realizing that antibiotics are only 
effective against bacterial infections and not viruses. The CDC also points the finger at 
those who neglect to finish their prescribed course of medicine. By killing off some, not 
all of the bacteria, these careless individuals make the bacteria that are left in the body 
even stronger, turning them into “superbugs.” 
The finger-pointing is not just directed toward the uneducated man. The 
government points to the use of antibiotics in chicken feed, a common pharmaceutical 
practice for years (e.g., Bayer Corporation). Others place the blame with the government, 
saying it needs to step up education and control of the industry. 
No matter who is at fault, if penicillin is rendered ineffective, the pharmaceutical 
industry will have lost its major star. The industry’s magic drug will have been taken 
away and the reputation of Fleming, which has been so carefully carved and preserved 
for the past half century, may be irreparably damaged. It is an ironic situation because 
Fleming himself foresaw potential problems with resistance. 
Sorting Out the Narratives 
 
The six alternatives outlined above expand on the standard myth of Fleming and 
the discovery of penicillin as the representative narrative for the pharmaceutical industry. 
The alternative narratives demonstrate the stories that could have flourished, but did not. 
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Clearly, much of the Fleming story and the description surrounding it has served to 
ingratiate the pharmaceutical industry with the public at large. 
The many stories of penicillin have been useful to pharmaceutical companies in 
the past and Fleming’s name and story are still invoked by them today. Photos of Fleming 
and his hand-written notes can be found, for example, on the Pfizer website, and the 
company routinely makes reference to Fleming and penicillin in its annual reports. On the 
Pfizer website, the company includes a summary of Fleming’s achievements and a visual 
of an old ad showing WWII service personnel with the caption, “These are alive today     
. . . because of penicillin.” 
Similarly, GlaxoSmithKline, in a section on worldwide business development, 
lists the discovery of penicillin on a page called “Forward Thinking.” The company 
writes: 
 
Forward Thinking enables GlaxoSmithKline to successfully pioneer and deliver 
new and innovative medicines for a world that is waiting. Forward Thinking is 
also the reason that GlaxoSmithKline recognizes the value in seeking 
collaborations with like-minded companies, whose own similar promise to the 
world can only strengthen with the right collaborator. (GlaxoSmithKline 
“Forward Thinking”) 
 
 
Like most pharmaceutical companies, Glaxo has adjusted its definitional and 
descriptive rhetoric over the past several decades to better engender public ingratiation. 
While, in the early part of the twentieth century, the pharmaceutical industry in general 
took pride in its values of standardization, chemistry, and capitalism, the public 
responded to concepts of biology and altruism and the messy story of Fleming’s 
discovery of penicillin. The industry and the public reached a stasis of sensibility in the 
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mid-twentieth century when they saw eye to eye on the pharmaceutical industry as 
representing quality, capitalism with heart, and responsiveness to the public need. 
However, this balance shifted toward the end of the twentieth century when the 
public no longer viewed the pharmaceutical industry as caring, competent, or careful, and 
began to seek more appealing alternatives—including natural-based products and/or 
biotechnology. 
The emergence of biotechnology as a science did not, in itself, disrupt pharma’s 
self-concept since the industry simply considered biotechnology as another tool. From the 
mid-twentieth century onward, pharmaceutical companies continued to describe their 
essential characteristics as doing good for humanity by creating the products that make 
people well. Such a self-description can be found in company speeches, advertisements, 
historical documents, and autobiographies. In its 2002 annual report, for example, Pfizer 
incorporates all of the messages that resonated successfully with the public throughout 
the twentieth century. On a page entitled, “Helping people live longer, happier, healthier 
lives,” Pfizer describes itself as “an original American company.” The company reminds 
the public that it “was there in World War II with a breakthrough in penicillin production 
that save thousands of soldiers’ lives.” The company also points to its caring and 
responsiveness by making the claim that it has always put people first. The company 
writes: 
 
One-hundred fifty-four years ago, in a small brick building on Bartlett Street in 
Brooklyn, New York, an original American company called Pfizer opened its 
doors . . .  
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We’re still there today, and since 1849 our mission has stayed the same: to help 
more people live longer, happier, healthier lives. 
 
  
The report concludes with the registered tagline: “Pfizer. Life is our life’s work” (73). 
 
Pfizer, as well as most big pharma manufacturers in the U.S. in the late-twentieth 
century, continued to build and reinforce an aura of themselves as patriotic humanitarians 
through the terministic screens of life and happiness. Freedom, too, is part of the essential 
message, with freedom from disease and illness conflated with the freedom of operation 
for the pharmaceutical industry. One example can be found in a keynote address that 
Hank A. McKinnell, Jr., Chairman of Pfizer, gave to the World Health Care Congress in 
Washington. McKinnell spoke about his “vision for a new American healthcare system . . 
. that is distinctly grounded in the virtues and qualities that make America—America.” 
Success of this vision, he said, “would lead to a healthcare system that makes the most 
from America’s best virtues—individual freedom, personal responsibility, and 
community caring.” 
Yet while large pharmaceutical manufacturers were sounding the trumpets for a 
new system of healthcare, the public became increasing skeptical about big pharma’s 
ability to deliver the innovation necessary for such a new system, particularly in 
comparison with the newly forming biotechnology industry. 
As discussed earlier, the general public is not attached the concept of 
corporations, the government, or the specifics of science. For the regular man, it is human 
health that is all- important, with innovation the conduit for achieving it. The emergence 
of the biotechnology industry and its intrinsic capabilities for innovation are causing the 
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pharmaceutical industry to recast itself once again. It is possible to argue that 
biotechnology, by being new, has made the pharmaceutical industry seem old by 
comparison. By being fresh and innovative, biotechnology has made pharma seem staid. 
By bringing a fresh imperative to change society, biotechnology has made pharma seem 
complacent. And by being—for the most part—not yet profitable, biotechnology has 
made pharma seem avaricious in its corporate earnings. 
With public ingratiation clearly at stake, the pharmaceutical industry began to 
modify its self-expression. In doing so, it stepped up the activities associated with the 
first sense of the rhetorical helix—that is, recursively modifying its self definition and 
description to generate a positive aura and engender public appeal. At the same time, 
pharma commenced activities associated with the second sense of the rhetorical helix 
whereby it began to engage in interactive competition with the biotechnology industry. 
Thus, faced with public skepticism, big pharma began to shift its “technological 
paradigm . . . from a chemical to a biological basis” (Gambardella 162) and infused its 
self-description with messages of new and vital capabilities for innovation. All this was 
done in reaction to and in competition with the new and self-defined industry called 
biotechnology. 
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CHAPTER V 
 
THE DOUBLE HELIX AS BIOTECHNOLOGY’S 
REPRESENTATIVE ANECDOTE 
 
 
If the development of penicillin is the representative anecdote for the 20th century 
pharmaceutical industry, then the discovery of the double-helical structure of DNA in 
1953 must surely be the same for the biotechnology industry. By illuminating how genes 
are organized within the body and how they serve to build and maintain a living 
organism, the double helix provided a new and critical understanding of molecular 
biology which Genentech calls “the basic science underlying biotechnology.” Genentech, 
founded in 1976, is generally acknowledged as the world’s first biotechnology company. 
Without the double helix, the thinking goes, there would be no biotechnology. As 
Robert Tjian, professor of molecular and cell biology at UC Berkeley and co-founder of 
the biotechnology company Tularik expresses it, “There would be no biotechnology 
sector without the structure of the double helix, but at the same time, the full implications 
of the double helix would not have been realized without the biotech industry” (Sanders). 
Biotechnology and the DNA double helix, in other words, are symbiotic; one cannot exist 
without the other. 
As this chapter will discuss, the double helix is one of science’s most powerful 
metaphors, possessing the capability to evoke both fiery passion and cool logic. As 
Lakoff and Turner write, “metaphor is a matter of thought—all kinds of thought: thought 
about emotion, about society, about human character, about language, and about the 
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nature of life and death” (xi). Lakoff and Turner provide a number of parameters to 
distinguish metaphorical thought. These include conventionalization, whereby a 
metaphor is “automatic, effortless, and generally established as a mode of thought” and 
basicness, whereby it is linked to cultural thought (55-60). Although the image of the 
double helix is relatively new, it has already become so ingrained in our way of thinking 
about science that it has gained footing with many other metaphors of life. The double 
helix, metaphorically speaking, is a key to the mysteries of life; it is a map of humankind; 
it is a blueprint of our selves. As Lakoff writes, “Metaphor is principally a way of 
conceiving one thing in terms of another, and its primary function is understanding” 
(Lakoff and Johnson 36). Whether we see a two-dimensional drawing or a three-
dimensional sculpture, we understand that the double helix represents new and innovative 
science. 
From the start, the emerging biotechnology industry grasped control of the image 
of the double helix and as a result accrued the associated benefit of its positive aura. The 
pharmaceutical industry, by comparison, could invoke the powerful imagery of the 
double helix only through its association with biotechnology. It was not enough for big 
pharma merely to capture the term double helix in its self-definition or description. The 
pharmaceutical industry had to rhetorically wind its way in and out of the biotech 
industry, competing head-to-head with biotech in order to gain proximity to the term. 
Prior to the discovery of DNA’s double helical structure in 1953, the term “double 
helix” was virtually non-existent. A search of The New York Times archive revealed no 
usage until 1953—the year that Watson and Crick made headlines with their discovery of 
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the structure of DNA. The first references after that were primarily definitional, 
explaining how the double helix related to the organization of deoxyribonucleic acid and 
its subunits of adenine, thymine, cytosine, and guanine. For the public, DNA was a 
highly abstract concept, until definition became description through the image of DNA’s 
double helix as a gently twisting ladder. 
When Aristotle devised his “Great Chain of Being” metaphor, he allowed people 
to visualize man’s place in the universe through a chain (or ladder) in which all life is 
positioned hierarchically from lowest to highest. Lakoff and Turner write that “(t)he 
reason that the GREAT CHAIN METAPHOR is so powerful in scope is that it applies to 
our overall knowledge of everything in the Great Chain, from human beings down to 
inanimate physical objects” (172). They write that when we say, “Achilles is a lion” it 
means that we are asked to “understand the steadfastness of Achilles’ courage in terms of 
the rigidity of animal instinct” (195). 
Although Aristotle’s metaphor allowed people to visualize man’s place in the 
universe, it also locked people into fixity of thought: 
 
(I)f every link is occupied, and none are occupied twice, no species can ever move 
from one position to another, since to do so would leave one level empty and put 
two species on another. Thus, in Aristotle’s perfect universe, species couldn’t ever 
change. This idea …was the prevailing perspective at the beginning of the 19th 
century. One of the great cultural changes over that century was the movement 
away from this restriction in thinking toward a more dynamic view of the natural 
world. Without this adjustment in thought, it is probable that Darwin (and 
Wallace) would either never have conceived of evolutionary thought, or would 
have made no impression when they published their ideas. (Fancher) 
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In 1953, the new “ladder of life” was the double helix of DNA. The image of 
ladder held to what Lakoff and Turner would call a basic conceptual metaphor (54) that 
provides a concrete visualization of the nature of life. However, Aristotle’s ladder and the 
DNA ladder vary to one significant extent: whereas the former represents rigidity and 
quintessentiality, the latter represents potential and transformation. The DNA ladder, 
which in a metaphorical sense, can ascend to great heights, is also capable of being 
unstable and shifting, with rails and rungs splitting apart from one another and 
reconnecting with others. In Aristotle’s ladder, man was forever separate from the 
animals. In the DNA ladder, the essence of man shifts in and out, by virtue of genetic 
engineering, recombinant DNA technology, genetic modification, and gene splicing. 
Scientists in Taiwan reported that they added genetic material from jellyfish into pigs in 
order to make them fluorescent and hence easier to study under ultraviolet light 
(Coonan). At other labs, scientists continue to work on the design of transgenic pigs that 
can serve as organ donors for humans. 
When Lakoff and Turner ask, “Can anything be anything?” (199), they could well 
have been speaking about the metaphorical malleability of the double helix to act in ways 
that stimulate the collective imagination. The “new” DNA ladder plays with the 
metaphor, allowing us to question the essence of ladder in rhetoric, much as M. C. Escher 
did with staircases in art. 
As with the history of penicillin, the tale of the DNA double helix encompassed a 
tangle of human emotions as various factions struggled for control of the story. The DNA 
narrative, like penicillin, has both a popular version as well as lesser-known accounts that 
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wrestle for a place in the public consciousness. And, as with penicillin, the rhetoric 
surrounding DNA reveals much about our culture, our values and our deep-seated need 
for the power of transformation. 
From the start, the DNA double helix came to represent science, knowledge and 
even life itself. As a powerful symbol of innovation, DNA easily replaced penicillin in 
the public’s collective imagination. Whereas penicillin was perceived as simply one 
single drug, albeit a potent and life-saving one, DNA was a tabula rasa, a blank slate on 
which mankind would ascribe its most fervent hopes for the future. 
The most simplified version of the DNA double helix story features James D. 
Watson and Frances Crick as the duo that, in popular terms, cracked the code of DNA 
and discovered the secret of life. The importance of DNA to biotechnology and the 
prominence given to Watson and Crick is expressed concisely in the following sentence, 
taken from The Biotech Investor’s Bible : 
 
The biotechnology industry’s watershed moment occurred at Cambridge 
University in 1953 when James Watson and Francis Crick first discerned the 
double-helix structure of DNA (deoxyribonucleic acid). (Wolff 4) 
 
 
Similarly, as business writer Richard W. Oliver expresses it, “Watson and Crick’s 
discovery created an entirely new field: biotechnology” (114). 
Watson and Crick, as the two discoverers of the double helix, is the version of the 
story that everyone knows. As one observer put it, “The names of Watson & Crick are 
one of those things that just seems to stick in everyone’s head no matter how little they 
paid attention in school (kind of like the term onomatopoeia)” (West). The amalgamated 
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Watson-and-Crick name has appeared often in anthologies, in lists of important people 
and in children’s books. Time magazine, for example, places Watson and Crick on its list 
of the 100 most important people of the century, with the merged pair occupying one spot 
(Wright). The World Almanac for Kids 2004, which says on its cover that is “trusted by 
parents” and “loved by kids” compresses the story by saying that in 1953, “Francis Crick 
and James Watson figured out the structure of DNA, opening up a new era in biology” 
(Seabrooke 312). The 2007 science fiction film, The Last Mimsy, features a class of 
elementary school children being taught by their science teacher about Watson, Crick and 
DNA. Children’s author Donna Farland, an elementary science specialist for the Boston 
public schools, uses Watson and Crick to illustrate the concept of collaboration in her 
book, It Takes Two: The Story of the Watson & Crick Team. Her book is meant to 
illustrate that two people working together on a project is better than working alone. 
The reality of course, is that the success that Watson and Crick enjoyed by being 
first to publish (in the journal Nature in 1953) was predicated on the hard work of many 
others including, notably, Rosalind Franklin. Her famous “photograph 51” clearly 
showed the structure of DNA and, depending on one’s perspective, either formed the 
basis for Watson and Crick’s hypothesis or confirmed it. Public relations for the late 
Franklin (who died from cancer in 1958 at age 37) have escalated in recent years, with 
feminist science studies often leading the charge. 
Maurice Wilkins, Franklin’s supervisor, also contributed substantially to 
unveiling the molecular structure of DNA and, like Watson and Crick, received a Nobel 
Prize for his efforts in this field. However, unlike Watson and Crick, his name did not 
 
 
129 
resonate with the public and upon his death in 2004, he was called “the forgotten man of 
DNA” (Radford). Several recent books have attempted to resurrect Wilkins’ name, 
including a memoir by Wilkins in which he refers to himself as “The Third Man of the 
Double Helix.” In the publisher’s notes for Wilkins’ 2005 book, Oxford University Press 
acknowledges Wilkins’ forgotten status by asking, “Quick, who won the Nobel Prize for 
discovering the double helical structure of DNA” and answering, “Most people would 
say Watson and Crick.” The publisher goes a step further by calling Wilkins the “Rodney 
Dangerfield” of biology, presumably for the lack of respect the scientist received for his 
part in the discovery. 
Yet another player in the double helix drama was Linus Pauling, a quantum 
chemist at Caltech. A pacifist and outspoken critic of nuclear proliferation, Pauling was 
nearing a solution to the puzzle of DNA structure when the U. S. government rescinded 
his passport, thus denying him access to critical scientific information. Burkean 
dramatism would question the link between Pauling’s political leanings and his ultimate 
place in science history.  
Since few people have the time or interest to sit and read expanded versions of the 
events in question, the basic and most simple version is usually the one that 
predominates. In this case, the tale of Watson and Crick—just as with the story of 
Alexander Fleming—is appealing in its ability to reduce a complex series of events to 
one “eureka” moment. This is a particularly useful device for journalists, who seek to 
reference past events as a quick bridge to the main thrust of their articles. For example, 
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shown in Table 3 are the opening paragraphs of several typical articles published in 
mainstream newspapers. 
 
Table 3 
 
Mainstream Media References to Crick and Watson 
 
Opening Paragraphs Citation 
Throughout the history of science, lasting fame 
and glory have generally been reserved for the 
men and women with the big ideas: Galileo, Sir 
Issac (sic) Newton, Charles Darwin, Marie Curie, 
Albert Einstein, Francis Crick and James Watson, 
to name a few. 
 
Robert Koch arguably belongs on this list. 
 
LaFee, Scott. ““Cultural Revolution;  
Why the Petri became Science’s Favorite Dish.” 
The San Diego Union-Tribune 
25 Jan. 2007: E-1.  
 
 
The Human Genome Project may go down as 
public health’s silver bullet. 
 
It took more than a decade and $300 million for 
scientists to create a person’s chemical code, the 
sequence of DNA that forms a complete genetic 
blueprint. 
 
Today, a half-century after James Watson and 
Francis Crick discovered the twisted-ladder 
structure of DNA, science is on the verge of 
dramatic advances in medicine. Armed with a 
growing knowledge of human genes, researchers 
hope to one day alter and even conquer some 
hereditary diseases. 
Loft, Kurt. “The Stuff of Life.” Tampa Tribune 21 
June 2004: 6. 
 
Science, of course, is a young man’s game. 
Newton, Einstein and many other greats were in 
their late teens or early 20s when they made their 
huge discoveries. So, from a purely scientific point 
of view, Nobel Prize laureate and University of 
Chicago grad Dr. James Watson was entirely 
correct when he advised 13-year-old U. of C. 
medical student Sho Yano to “concentrate on 
making a big discovery and not getting a 
girlfriend.” 
 
Ahem. With all due respect to Watson, one of the 
major scientists of the 20th century, the discoverer, 
along with Francis Crick, of the DNA double 
helix, we aren’t so sure that his advice is sound, 
either for this particular young prodigy or for 
students in general. 
 
“Lighten up, Doc.” Editorial. Chicago Sun-Times. 
21 Jan. 2004: 63. 
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ANYONE who still doubts the towering influence 
of MTV’s “Real World” on American culture (it is 
to television what Watson and Crick’s work on 
DNA was to molecular biology) has only to 
compare two similar shows this Sunday to concede 
the point. 
 
“Anatomy of a Scene,” on the Sundance Channel, 
is a documentary about making the movie “The 
Secret Lives of Dentists.” 
Stanley, Alessandra. “Where Has Escapism 
Gone?” The New York Times. 18 Jul. 2003: E-1. 
 
Fifty years ago this week, two brash young 
scientists in an obscure lab at the University of 
Cambridge in England unraveled the structure of 
DNA, the elegant living thread that is the genetic 
basis of inheritance and evolution. 
 
The discovery of the double helix by James 
Watson, 25, and Francis Crick, 36, on Feb. 28, 
1953, unveiled what Crick called “the secret of 
life.” 
 
DNA is the molecule that makes and maintains all 
life. It enables life to re-create itself. It contains the 
blueprints and the toolbox for understanding how 
humans work. Even now, researchers are 
exploiting these tools to turn medicine from an 
uncertain science in which they treat the symptoms 
of disease to one in which they attempt to find out 
and fix precisely what is wrong. 
Sternberg, Steve. “Double Helix Unlocked Key to 
Life. USA Today. 24 Feb. 2003: 1D. 
 
Western culture is filled with examples of heroic 
male friendships. Lewis and Clark opened up the 
American West. James Watson and Francis Crick 
unveiled the DNA double helix, the secret of life. 
Crime -fighting duos from the Lone Ranger and 
Tonto to Batman and Robin have kept bad guys at 
bay. And what have women’s friendships 
fostered? Cut to Carrie and her “Sex and the City” 
pals sipping cosmos and dishing about their 
boyfriends, Dolly Parton and the Steel Magnolias 
bawling at the local beauty salon and Rebecca 
Wells ’s Ya-Ya Sisterhood with their motto: 
“Smoke, drink, never think.” 
Kuchment, Anna. “The More Social Sex.” 
Newsweek. 10 May 2004: 88. 
 
 
 
The simple story of Watson and Crick has, without question, embedded itself in 
the public consciousness. But is what appeals in the Watson and Crick story the same as 
appeals in the Fleming story? By examining the standard myth and opening it up to 
dramatistic variations, we can better understand why the Watson-and-Crick story 
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resonates with the public, how the story relates to the biotechnology and pharmaceutical 
industries at large, and how the language used to describe any given scenario is always in 
negotiation, always affected by culture, and always performing. 
In Chapter IV, the alternative narratives for the discovery of penicillin were 
distinguished by a change of historic scene, from the early 20th century to the early 21st 
century. For the DNA double helix story, the object of scrutiny is purpose, followed 
closely by agency. Purpose offers a perspective of why the agent may have performed the 
act, while agency describes how the agent achieved his or her aims. By querying purpose, 
we can ascribe a host of motivations to the one act of discovery and reveal the ambiguity 
in various interpretations of the event. Doing this sets the stage for the wider question of 
public perception of the biotechnology and pharmaceutical industries. 
To address Burke’s theoretical question, “What is involved when we say what 
people are doing and why they are doing it,” it is useful to distinguish between what 
agents themselves say their motivations are, what others attribute as the motivations of 
the agents, and what practitioners of the dramatistic pentad might conjecture. For Watson 
and Crick’s single act of ascertaining the molecular structure of DNA, it is possible to 
devise an entire spectrum of motivation, with each theoretical “purpose” expressing 
specific cultural values. 
Most anthologies, in summarizing Watson and Crick’s efforts, ascribe simple 
motivations to the pair on the order of scientific curiosity (Olby; Stich, Carruthers and 
Siegal), competition (Runco), or the quest for the Nobel Prize (Starko). Undoubtedly, 
much of this comes from The Double Helix, James Watson’s own account of the 
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discovery. In the book, Watson speaks of DNA as “a mystery, up for grabs” (13). He 
discusses his hope to beat the eminent scientist Linus Pauling “at his own game” (37) and 
speaks of himself as “one of the winners” of the race for the double helix (13). 
Watson recounts the day when Crick entered the Eagle pub at Cambridge and 
announced that he and Watson “had found the secret of life” (126). But nowhere in the 
book is any reference made to exactly how that secret could benefit mankind, if at all. In 
fact, altruism does not seem to be Watson’s strong point. He has been described as “the 
Caligula of biology” for his bluntness (Segerstrale 292). Watson himself acknowledges 
that he tolerates no fools, saying that “a goodly number of scientists are not only narrow-
minded and dull, but also just stupid” (18-19). His partner, Crick, fares little better by 
Watson’s account, as he says, “I have never seen Francis Crick in a modest mood” (15). 
These accounts clearly contrast with the older story of penicillin and the so-called modest 
character of Alexander Fleming. 
One cognitive researcher proposes that emotions—curiosity, happiness, hope, 
sadness, and anger—are the underlying factors that drive scientists: 
 
Fear can also be a motivating emotion. Watson and Crick were very worried that 
the eminent chemist Linus Pauling would discover the structure of DNA before 
they did, and they also feared that the London researchers, Rosalind Franklin and 
Maurice Wilkins, would beat them. Watson wrote that when he heard that Pauling 
had proposed a structure, “my stomach sank in apprehension at learning that all 
was lost.” (Thagard 240) 
 
 
Many philosophers have delved into the complex topic of motivation, with some 
saying full recognition of one’s purpose may not be overtly apparent even to the agent 
himself. Smith, for example, discusses the ambiguity inherent in the pursuit of the Nobel 
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Prize, with Alfred Nobel’s altruistic dictate on the one hand (awarding of the prize “to 
those who, during the preceding year, shall have conferred the greatest benefit on 
mankind”) and “instant fame and fortune” on the other (96-97). 
Pollack speaks of the heady realization that comes to a scientist when his or her 
name is permanently associated with an aspect of nature, as in “the Freudian slip and the 
Watson-Crick model of DNA” (80). He writes: 
 
Players in a game that can confer even this sort of immortality—however rarely—
cannot be playing only for conscious stakes. In the medical sciences, the belief in 
winning immortality of this sort can become problematic . . . It is not that science 
and medicine wish to avoid finding cures. It is that they are too strongly 
motivated by an irrational, unconscious need to cure death to be fully motivated 
by the lesser task of preventing and curing disease . . . (80) 
 
  
Rhetorician Leah Ceccarelli also speaks to the life-affirming traits of molecular 
biology. She asks about Watson and Crick, “What was it that motivated them (and others 
responsible for the birth of molecular biology) to break away from more traditional 
approaches in physics and in biology” to focus on “the physical nature of living matter”? 
(62). She provides several answers to her own question; one reason is because the field 
offers “big problems to solve”; another is what she calls a “psychological motivation” of 
guilt (62). She writes that the motivation for physicists “may have been the deep guilt that 
many felt about their participation in the Manhattan project; perhaps some sought a new 
career in the biological sciences because they had a desire to be part of something that 
was life-affirming rather than destructive” (62). 
Corner, who is concerned with capturing the proper voice of a given agent in 
documentary format, speaks to the motivation of science itself. He writes that 
 
 
135 
although there were the usual egoistic motivations in the race for the structure of 
the double helix, awe of the elusive structure itself was a motivation, as is evident, 
if not explicit, in Watson’s account of the discovery. But to colleagues of Watson 
and Crick, their pursuit of the structure seemed at times zealous or obsessive. (87) 
 
 
Since the motivations listed above are varied and somewhat conflicting, we can 
reconcile them in a useful way by stating that all of the attempts to determine purpose 
underscore the rhetorical malleability of biotechnology. In other words, people see in 
biotechnology what they want to see. If one chooses to see biotechnology as noble, then 
it is possible to ascribe this characteristic to the motivations of Watson and Crick. 
Conversely, in choosing to see biotech as dangerous, one could characterize their actions 
as too rushed and too blinded by competition. To a large extent, narrative selection (that 
is, language use) is indicative of the underlying beliefs and values of a people and 
society.  
Of all the possible motivational factors, three themes stand apart:  Watson and 
Crick as pioneers, Watson and Crick as advancers of human knowledge, and Watson and 
Crick as self-aggrandizers. These are the major narrative themes that provide a basic 
foundation for biotechnology rhetoric and from which to begin an exploration of 
biotechnology descriptive language. 
Pentad 1: Watson and Crick as Pioneers  
 
 
Act:   Discovery of the double helical structure of DNA   
Scene:  1953, Cambridge, England  
Agent:  James D. Watson and Francis Crick 
Agency: Publication in the April 25, 1953 edition of the journal Nature  
Purpose:  To be the first; to win the “race” against other scientific  
competitors 
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As discussed in earlier chapters, being first in any endeavor conveys special 
status. In the public mind, Alexander Fleming achieved this special status for his 
discovery of penicillin and as such became immortalized in public anthologies. The fact 
that Fleming’s discovery was characterized as “accidental” (and thus, in the minds of 
many, fate- or God-driven) did nothing to diminish Fleming’s premier status. By contrast, 
the scientific quest to describe the molecular structure of DNA has seldom been 
characterized as an accident, but rather as a well-calculated race as in the title of the 1994 
film, Race for the Double Helix. A plot synopsis of the film says, “Watson and Crick race 
to find the structure of DNA before Linus Pauling, Maurice Wilkins, or Rosalind 
Franklin can find the key to unlocking the secret.” 
Watson himself, in his memoir The Double Helix, refers both to the concept of a 
horse race (“But now the race was over and, as one of the winners, I knew the tale was 
not simple and certainly not as the newspapers reported”) (13) and a game to be won 
(“Within a few days after my arrival, we knew what to do: imitate Linus Pauling and beat 
him at his own game”) (37). Glasner and Rothman write extensively about scientists and 
the concept of winning the race: 
 
It is not really surprising that scientists find themselves in situations that lead to 
races. After all in any field at any given moment there are only a limited number 
of key or important problems or research tasks, often fewer than the available 
talented people and groups seeking to solve them. The ability to function as a 
scientist depends on access to resources, both financial and intellectual. These are 
easier to obtain if one is highly regarded by one’s peers and research awards 
agencies. Being first to make a major discovery provides priority over potential 
rivals both for prestige and intellectual property rights. Winning the race provides 
prestige, which in the scientific community is an important component of social 
power. However, it is not always clear who has won the race . . . (46) 
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The race-to-success metaphor is well-embedded throughout various accounts of 
the Watson and Crick story (e.g., Ede, Marx) as well as other science-based events of 
recent history. In the early 1960s, for example, Americans were enthralled by the space 
race, which was the rivalry between the U. S. and the Soviet Union to put a human being 
into orbit. When the Soviet Union won this victory in 1961, the U.S. reframed the 
competition to be the first on the moon, reflecting a strong nationalist sentiment to 
achieve an American victory. 
During WWII, nationalism was clearly a motivating factor among pharmaceutical 
companies who were intent on keeping penicillin out of the hands of the Germans, which 
they did successfully. Nationalist sentiment may or may not have been at work for the 
Americans Watson and Pauling, and the British Crick, Wilkins, and Franklin. From a     
U. S. standpoint, it can be argued that the American love of competition extends 
throughout its culture, from sports to consumer products (e.g., Avis versus Hertz; IBM 
versus Macintosh). The race for the molecular structure of DNA was no exception. When 
the New York Times reported in a 1953 headline that an “American and Briton Report 
Solving Molecular Pattern of Vital Nucleic Acid,” the newspaper proclaimed that their 
work “should make biochemical history” (17). Interestingly, the article also credited Dr. 
Linus Pauling, whom they identify as an American, as having “done most of the pioneer 
work on the problem” (17). 
From the moment of the announcement, characterization of Watson and Crick’s 
achievement as a race helped set the tone for biotechnology as purposeful, driven and 
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goal-oriented. The race to the double helix would subsequently generate the race for the 
human genome and, later, the race to commercialize biotechnology. 
Like the race for the double helix, the race for the human genome generated huge 
feelings of rivalry among the parties involved, which were the government-funded 
Human Genome Project, first headed by James Watson and later by Francis Collins, and 
its rival, Celera, a private company led by Craig Venter. Since the human genome story is 
much newer than the double helix story, its narrative in many ways is still being 
constructed. In fact, as of as few years ago, the human genome project was so new, that 
computer spellcheckers were correcting the term to read, “The Human Gnome Project” 
(Shreeve 14). 
The purpose of the human genome project is to create a map of all genetic 
material in human beings. Although the human genome project was considered the 
grandest quest, similar projects were undertaken to create maps of genetic material for 
other living entities such as the mouse, fruit fly, and yeast. Mapping is accomplished 
through DNA sequencing, which is the process of determining the exact order of the 
three billion chemical bases that comprise human DNA. The metaphor of map is 
appropriate since it speaks to pioneers trying to find their way in an entirely new terrain. 
To the one who gets to the finish line first come the fruits of victory. It is not accidental 
that Venter called his corporation Celera, which is Latin for “speed.” 
The two groups, public and private, differed substantially on their approach to the 
genome. The strategy of the Human Genome Project was to map first and sequence later, 
which placed the emphasis on making sure that all elements of the genome were correct 
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and in place from the start. As the journal Nature explains it, “The public project’s 
sequencing strategy involved producing a map of the human genome, and then pinning 
sequence to it. This helps to avoid errors in the sequence, especially in repetitive regions” 
(Olson 816). 
The Celera group, on the other hand, felt that speed was of the essence, since they 
were profit-driven and thus responsible to their investors. They took a shotgun 
sequencing approach, which underscored the belief that if it’s close enough, it’s good 
enough. In essence, the shotgun method involved assembling the genome without using a 
map (“What a Long, Strange Trip”). 
From the early 1990s, the two groups vied with one another to be the first to 
publish. In the same week in February 2001, Celera published its draft sequence of the 
human genome in Science, while the Human Genome Project published its sequence in 
Nature. Many have characterized the rivalry in simplistic terms, with HGP on one side 
and Celera on the other. In this characterization, HGP was in support of the public at 
large, with their intentions placed squarely on the goal of making the information from 
the genome available to all. Celera, on the other hand, was clearly profit driven, with the 
intention of grabbing the rights and protecting its patents. Shreeve escalates the concept 
of competition between Collins and Venter by calling their rivalry “the genome war.” At 
the same time, he writes that a simplistic, black-and-white view is not necessarily 
appropriate because every characterization is dependent on individual perception. While 
some saw Venter as egotistical, others perceived him as cautious and graceful. Shreeve 
writes eloquently of the ambiguity of the man and the science: 
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While those recollections contradict each other, they may also both be accurate, 
not just because two people often see the same individual differently, but because 
some individuals can project two images simultaneously. They are self-contained 
contradictions, like holograms whose views toggle back and forth depending on 
the angle of the light striking them. . . . 
 
I am doing this for humankind, Venter seemed to say. Turn the hologram, and I 
am in it for myself. I am Albert Schweitzer. I am Bill Gates. Flip the hologram 
faster—I am Bill Albert Schweitzer Gates. I am a scientist. I am an entrepreneur. I 
am a scientist/entrepreneur. I am the slash between the two. How can you not love 
me? Go ahead, hate me. You think I care? (Shreeve 51) 
 
 
In play during the human genome race was the cult of personality. The popular 
press characterized Collins as a noble and selfless individual who was capturing the 
knowledge of the Creator. His “side” stood for the belief that information from the 
human genome project belonged to the people; it was good for humankind. Venter, on the 
other hand, was considered by many to be arrogant, ego-driven, and determined to be 
first in order to make a name for himself and to make money. 
Ultimately, Celera’s goal of becoming the “the world’s definitive source of 
genomic information” failed when HGP “showed the will and ability to stay just a few 
months off the company’s pace” (Shreeve 368). In 2002, Craig Venter stepped down as 
Celera’s president and the company then began a series of changes to its corporate 
structure and mission. Celera describes this transition on its website, using language that 
positions its genomic database business in the past and puts the understanding of disease 
in the future. On its website, the company writes: 
 
While the Celera database business ultimately became profitable, it was clear by 
2000 that this was not a sustaining business model, as the public effort caught up 
and provided free access to genome sequences.  
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Celera moved on—both scientifically and commercially. Scientifically, we 
recognized that understanding complex conditions like Alzheimer’s and 
cardiovascular disease required a greater understanding of human genetic 
variability . . . (“Celera”) 
 
 
This language straddles the gap between altruism and commercialism. 
Throughout the genome war, Venter was portrayed as a profiteer who sacrificed quality 
science for a so-called quick and dirty approach to getting answers and who sought 
patents on what rightly should belong to mankind—i.e., human genes. Celera was 
accused of grabbing for genes in much the same manner as the California ‘49ers rushed 
for gold. Now, with the above language, Celera shifts the focus toward acknowledging 
the needs of patients who would most profit from genetic-based therapeutics. This is a 
softening strategy, and one that has been employed for many years by pharmaceutical 
companies in their advertising and other public rhetoric. 
Science is allowed to mix with business, in other words, only if the common good 
is place in the forefront. This is something that the Human Genome Project seems to 
recognize. On its website, HGP touts the human genome accomplishment as “one of the 
great feats of exploration in history—an inward voyage of discovery rather than an 
outward exploration of the planet or the cosmos . . .” (“All About”). At the same time, the 
group also takes care to emphasize the good to mankind through genomics. HGP writes, 
 
We are entering a new age of discovery that will transform human health. Our 
eventual knowledge about the workings of the genome has the potential to 
fundamentally change our most basic perceptions of our biological world. It is 
difficult to predict what will be learned and how future knowledge will be 
applied, but there can be little doubt that understanding the genome will 
revolutionize our concept of health and improve the human condition in 
remarkable ways. (“All About”) 
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For the public, ingratiation with a scientific effort is highly dependent on the 
promise (and not necessarily the actuality) of a tangible outcome of the race. As long as 
the promise is there, the reality seemingly can wait. When news of Watson and Crick’s 
achievement was conveyed to the public, reporters and others spoke of the “secret” of 
life, a future-oriented metaphor that spoke to a virtual treasure box of information of 
potential use to mankind. Similarly, the human genome project was a “blueprint” of the 
human being. Follow the steps of the blueprint accurately, the assumption went, and 
perfect humanity could be possible. An alternative metaphor for the human genome 
project has been “cracking the code of life,” whereby the genome is a secret that the 
human genome project unlocks. The perception is that once the secret has been unlocked, 
it will be possible to understand human diseases and disorders and fix the defects. The 
possibility also dangles that scientists can bioengineer life to make sure there are no 
defects in the first place. The reality is, of course, far more mundane with real advances 
in medical therapies lagging well behind the hype. 
The metaphor of a race to the finish line is also well tied into the concept of 
youth. The stereotypical perception has always seemed to acknowledge that the young 
are far more fleet-footed than the old. Youth is associated with swiftness of body and 
mind, and imbued with verve and vitality. The term young is frequently linked with the 
term scientist when the author wishes to make a point about new and innovative 
developments in science. In fact, the term “young scientist” is far more predominant in 
common speech than its opposite. A Google search in early 2007 of the term “young 
scientist” revealed 58,800 hits, whereas “old scientist” had merely 3,450 hits. 
 
 
143 
“Experienced scientist” had 2,380 hits and “mature scientist” had only 449 hits. Such 
deep-seated bias toward science and youth also appear in literature, as in this example 
from Frameshift: 
  
And so Pierre found himself back in an introductory genetics course. By 
coincidence, the same pencil-neck Anglais teaching assistant who had originally 
pointed out the heritability of eye color was teaching this one. Pierre had never 
been one for paying attention in class; his old notebooks contained mostly 
doodled hockey-team crests. But today he really was trying to listen . . .at least 
with one ear. 
 
“It was the biggest puzzle in science during the early 1950s,” said the TA. “What 
form did the DNA molecule take? It was a race against time, with many 
luminaries, including Linus Pauling, working on the problem. They all knew that 
whoever discovered the answer would be remembered forever . . .” 
 
Or perhaps with both ears . . . 
 
“A young biologist—no older than any of you—named James Watson got 
involved with Francis Crick, and the two of them started looking for the answer. 
Building on the work of Maurice Wilkins and X-ray crystallography studies done 
by Rosalind Franklin… 
 
Pierre sat rapt. 
. . . 
 
“It was an amazing breakthrough—and what was even more amazing was that 
James Watson was just twenty-five years old when he and Crick proved that the 
DNA molecule took the form of a double helix . . .” 
 
Morning, after a night spent more awake than asleep, Pierre sat on the edge of his 
bed. 
 
He had turned nineteen in April. (Sawyer 42) 
 
 
In another example, youth and ambition are presented as naturally occurring 
hand- in-hand: 
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Watson had learned of Linus Pauling’s and Robert Corey’s work on the structure 
of crystalline amino acids and small peptide proteins. Pauling was one of the most 
famous organic chemists in the world. Watson feared that Pauling would soon 
model DNA structure, robbing the young and ambitious scientist of fame and 
scientific immortality. Watson saw himself in a scientific race with Pauling to be 
the first to discover the structure of DNA. Pauling did not know that Watson 
existed. (But this is the general model of human competition, the young racing to 
exceed their elders; and scientists are only human.) (Betz 29-30) 
 
 
Pentad 2: Watson and Crick as Advancers of Human Knowledge 
 
Unlike the previous narrative alternative in which the pursuit of science is 
interpreted as a race or a game to be won (with commercial profit, world recognition and 
competitive satisfaction as possible rewards), this second version sees knowledge as an 
end in itself.  
 
Act:  The discovery of the double helical structure of DNA   
Scene:  1953, Cambridge, England  
Agent:  James D. Watson and Francis Crick  
Agency: Research; work in the laboratory 
Purpose:  To contribute to the body of world knowledge; to satisfy  
  intellectual curiosity; to share findings with others 
 
 
Rathman writes that Watson and Crick’s discovery in 1953 was the “ignition 
spark” that led to “advances in gene manipulation, monoclonal antibodies, gene 
sequencing and gene synthesis” and billions of dollars in investment (47).  According to 
Nature magazine, while the human genome project “does not hold a candle to Watson 
and Crick’s 1953 paper,” the human genome does launch the era of post-genomic science 
(Baltimore 814). It is clear that what one scientist does can pave the way for others to 
follow. 
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Evelyn Fox Keller, rhetorician and professor of the history and philosophy of 
science, has written that Watson and Crick, like many other molecular scientists, were 
greatly influenced by the book What Is Life? by Erwin Schrödinger. The book, first 
published in 1944, begins with Descartes’ famous quotation, cogito ergo sum, which 
argues that when one thinks, one exists. This quotation has special meaning for many 
scientists, who simply are not satisfied unless they are challenged with a puzzle that 
stretches their brainpower to the limit. 
For his part, Schrödinger set out by asking what he called a la rge, important and 
much-discussed question: “How can the events in space and time which take place within 
the spatial boundary of a living organism be accounted for by physics and chemistry?” 
(3). Schrödinger reveals his optimism and his faith that mankind can attain an answer to 
this incredibly difficult question when he writes, “The obvious inability of present-day 
physics and chemistry to account for such events is no reason at all for doubting that they 
can be accounted for by those sciences” (4). 
This, then, was the intellectual gauntlet that was thrown down and was picked up 
with enthusiasm by Watson and Crick. In The Double Helix, Watson writes that 
Schrödinger’s book “very elegantly propounded the belief that genes were the key 
components of living cells and that, to understand what life is, we must know how genes 
act” (18). Watson also says that this belief is what prompted Crick to change his career 
path to biology. 
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In his presentation speech at the 1962 Nobel Prize ceremony, Professor A. 
Engström of the Royal Caroline Institute clearly privileged the value of knowledge when 
he addressed the winners by saying: 
 
Dr. Francis Crick, Dr. James Watson, and Dr. Maurice Wilkins. Your discovery 
of the molecular structure of the deoxyribonucleic acid, the substance carrying the 
heredity, is of utmost importance for our understanding of one of the most vital 
biological processes. Practically all the scientific disciplines in the life sciences 
have felt the great impact of your discovery.  
 
 
Biotechnology resonates with the intellectual thrill of seeking and possibly 
obtaining answers to some of the greatest mysteries of nature and human existence. Such 
language can be readily found in recruitment ads, which frequently emphasize the need 
for curious minds to solve scientific problems. The biotechnology company Invitrogen, 
for example, says that its staff is comprised of scientists who “dream big thoughts, have a 
thirst for change, understand how to work with people around the world, and have an 
insatiable curiosity to see what’s next” (“Invitrogen”). 
The Biotechnology Institute, a non-profit organization whose mission is to 
“engage, excite, and educate the public, particularly young people, about the promise and 
challenges of biotechnology” offers interviews with a number of biotechnology scientists 
on its website. Most of those interviewed cited personal curiosity and a desire for 
intellectual freedom. A profile of Bruce T. Lahn, a professor of human genetics at the 
University of Chicago, reveals that his favorite book as a child in China was Ten 
Thousand Questions, and that his natural curiosity continues to surface in his research on 
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the human genome, with new questions such as “why is the Y chromosome so small?” 
and “why is Y a magnet for male fertility genes?” (“Biotech Career Profiles”). 
Seeing the “big picture” is frequently cited as a source of inspiration for biotech 
scientists. A 2002 article in Career World magazine quotes a pathologist from Houston, 
Texas, as saying: 
 
Science is about the relationship between humans and nature. It’s not about 
hawking some product [or] attending boring sales meetings. . . . It’s about 
uncovering real truths of the universe—how matter and energy interact to produce 
what we call life with all its complexity. (Wallis 6) 
 
The same article also lists a host of other altruistic reasons for selecting a career in 
biotech: 
. . . biotechnology will be the branch of science that discovers ways to improve 
the diagnosis and treatment of hereditary diseases. It will provide us with safer 
drugs and more environmentally friendly herbicides and pesticides. 
Biotechnology will help us find cures for spinal cord injuries, come up with 
innovative new ways to solve crimes, help clean up the environment, and give us 
safer, more efficient industrial products. That’s why the amount of money 
invested in the biotech industry increased a whopping 156 percent in one year, 
from 1999 to 2000. (6-7) 
 
Pentad 3: Watson and Crick as Self-Aggrandizers  
 
The alternative narrative above emphasizes the notion of sharing findings with 
others. However, for modern-day scientists, such collegiality usually comes only after 
publication and patent filing. These are well-accepted practices that protect intellectual 
property and corporate investment. Much has been written of Watson and Crick’s race to 
be published as well as the race, years later, between HGP and Celera in codifying the 
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human genome in public journals. This third alternative narrative explores the gap 
between the good-natured competition of Pentad 1 with a more cutthroat competition in 
which self- interest is the driving force. This alternative narrative also explores the hubris 
of Watson and Crick in elevating Man (with a capital “M”) to controller of his destiny 
and man (with a small “m”) as usurper of the proper recognition that by rights should 
have also gone to a female colleague. 
The pair published their results in the prestigious British scientific journal Nature, 
and then soon became scientific superstars. 
 
Act:  The discovery of the double helical structure of DNA   
Scene:  1953, Cambridge, England  
Agent:  James D. Watson and Francis Crick  
Agency: Autobiographies, speeches 
Purpose:  To advance personal interests 
 
 
In The Astonishing Hypothesis, Francis Crick puts forth the proposition that 
“‘You,’ your joys and your sorrows, your memories and your ambitions, your sense of 
personal identity and free will, are in fact no more than the behavior of a vast assembly of 
nerve cells and their associated molecules” (3). He argues that just as the work of Galileo 
and Newton expanded Man’s knowledge of physics, and Darwin and Wallace illuminated 
evolution, the understanding of the molecular nature of genes expands our view of living 
creatures. Crick is a humanist, stating that a majority of neuroscientists see the soul as 
nothing but “myth” (6). Further, he insists that nature is knowable by man, in stating, 
“The history of science is littered with statements that something was inherently 
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impossible to understand (“we shall never know of what the stars are made”). In many 
cases time has shown these predictions to be incorrect” (6). 
Crick also makes his position very clear in his autobiography, What Mad Pursuit: 
A Personal View of Scientific Discovery, when he writes of his early skepticism and 
view of himself as an “agnostic with a strong inclination toward atheism” (10). He writes 
that “it is detailed scientific knowledge which makes certain religious beliefs untenable” 
(11). 
Crick’s bold position set off, predictably, a host of counter-arguments, largely 
from Christian philosophers and other theologians. Mark L. Y. Chan, for example, 
critiques “the reductionist idea that the human person is coextensive with and reducible to 
his or her genetic constitution” (191). He accuses Crick and others of promulgating “a 
naturalistic world-view that sometimes manifests itself in a doctrinaire intolerance of all 
who do not subscribe to a thoroughgoing materialistic view of the person” (192). Haught 
contrasts Crick’s idea of reductionism, which “implies that the only real ‘stuff’ lies at the 
bottom, at the level of mere matter, fully accessible to scientific conquest” with religion, 
which believes that “(t)he more elusive and mysterious things are, the more important 
and real they are” (74). Almy goes so far as to call Crick ridiculing of theology and 
“contemptuous of any possibility of explaining the mind outside of materialistic science” 
(119-120). He writes, “For Crick, those who look for anything more are ignorant and 
sentimental” (120). 
Surprisingly, James Watson also describes Crick’s superior attitude in his memoir 
The Double Helix. He writes, 
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Though he was generally polite and considerate of colleagues who did not realize 
the real meaning of their latest experiments, he would never hide this fact from 
them. Almost immediately he would suggest a rash of new experiments that 
should confirm his interpretation. Moreover, he would not refrain from 
subsequently telling all who would listen how his clever new idea might set 
science ahead. 
  
As a result there existed an unspoken yet real fear of Crick, especially among his 
contemporaries who had yet to establish their reputations. The quick manner in 
which he seized their facts and tried to reduce them to coherent patterns 
frequently made his friends’ stomachs sink with the apprehension that, all too 
often in the near future, he would succeed, and expose to the world the fuzziness 
of minds hidden from direct view by the considerate, well-spoken manners of the 
Cambridge colleges. (16-17) 
 
 
Watson infuses his own egotism when he writes that Crick did not worry about those who 
were skeptical of DNA since “(m)any were cantankerous fools who unfailingly backed 
the wrong horses” (8). 
Watson elevates his and Crick’s status, in part, by disparaging other scientists. He 
calls most botanists and zoologists “a muddled lot” who often “wasted their efforts on 
useless polemics about the origin of life or how we know that a scientific fact is really 
correct” (53). Although he calls Linus Pauling “one of the world’s leading scientists” 
(79), he also critiques Pauling’s scientific articles as “full of rhetorical tricks” (31). 
Worse is Watson’s treatment of Rosalind Franklin, whom he characterizes as a “real 
problem” who “could not keep her emotions under control” (21). Watson writes 
extensively of Franklin’s appearance: 
 
By choice she did not emphasize her feminine qualities. Though her features were 
strong, she was not unattractive and might have been quite stunning had she taken 
even a mild interest in clothes. This she did not. There was never lipstick to 
contrast with her straight black hair, while at the age of thirty-one her dresses 
showed all the imagination of English blue-stocking adolescents. So it was quite 
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easy to imagine her the product of an unsatisfied mother who unduly stressed the 
desirability of professional careers that could save bright girls from marriages to 
dull men . . . Clearly Rosy had to go or be put in her place. (20) 
 
 
Watson even writes that he “wondered how she would look if she took off her 
glasses and did something novel with her hair” (51). Finding no warmth in Franklin, 
Watson later writes, “The thought could not be avoided that the best home for a feminist 
was in another person’s lab” (21). 
Whatever Watson thought about Franklin’s looks or personality was only part of 
the issue. Of greater concern to many was the possibility that Crick and Watson had 
cheated Franklin out of the recognition that was properly due her. As the UCLA physics 
department expresses it, Franklin’s colleague Maurice Wilkins, “without obtaining her 
permission, made available to Watson and Crick her then unpublished X-ray diffraction 
pattern of the B form of DNA, which was crucial evidence for the helical structure” 
(“Franklin”). 
Some felt that Crick and Watson, who did not credit Franklin in their published 
paper on the structure of DNA, cheated Franklin of the Nobel Prize. Others argue that 
since the prize was awarded in 1962, it was Franklin’s death in 1958, at the premature 
age of 37, which cheated her since Nobel Prizes are awarded only to living recipients.  
One of the earliest writers to champion the cause of Franklin was Ann Sayre, who set out 
to correct what she felt were falsities in Watson’s book. The American Society for 
Microbiology, which houses Sayre’s collection of Rosalyn Franklin materials, says that 
“Sayre felt that the portrait of her friend Franklin (who had died in 1958) that emerged 
from Watson’s book was not only unflattering, but wrong” (Zilinskas). 
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Sayre says that starting with the nickname of Rosy, which was never used by any 
friend of Franklin’s, Watson created a mythological “female grotesque we have all been 
taught either to fear or to despise” (19). Whereas Watson writes that “Rosy . . . claimed 
that she had been given DNA for her own problem and would not think of herself as 
Maurice’s assistant” (20), Sayre says that such a characterization makes Franklin seem 
“uppish” and “mutinous” (20). Franklin was, in fact, “quite justified in her reluctance” to 
be so labeled, says Sayre, because Franklin did not work for Maurice Wilkins at all (20). 
“We have been misled” (20) she writes. She adds that Watson’s book teaches us that 
“science is done by ambitious and competitive people” (17). 
When asked about the possible injustice done to Franklin, the scientist Linus 
Pauling defends Crick and, to a lesser degree, Watson, in the following interview 
remarks: 
 
There are probably some scientists who are opportunists, who are eager to make 
their mark in the world and consider that more important than learning about 
nature. Crick isn’t that sort of man at all. He has great interest in scientific 
problems and works away at them essentially independent of whether the 
solutions will benefit him. Crick is a good scientist. In The Double Helix you can 
see Watson is very much interested in fame and fortune. I think he’s interested in 
science, too. (Brian 11) 
 
 
In his theories of creativity, Mark A. Runco  postulates that Watson and Crick 
were not motivated as much “from the desire to beat out other individuals so much as . . . 
the kind of achievement motivation that is tied to success” (356). He writes: 
 
In other words, someone may be motivated to achieve and accomplish something, 
and the only way they can accomplish it is to beat out others who are trying to do 
the same thing. In Watson’s case, the prize was the Nobel award. (356-357) 
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And yet, other sources—as in this quotation by Watson himself—indicate that 
fame in itself is a driving motivator for Watson: 
 
I was 17, almost 3 years into college, and after a summer in the North Woods, I 
came back to the University of Chicago and spotted the tiny book What is Life by 
the theoretical physicist Erwin Schrödinger. In that little gem, Schrödinger said 
the essence of life was the gene. Up until then, I was interested in birds. But then I 
thought, well, if the gene is the essence of life, I want to know more about it. And 
that was fateful because, otherwise, I would have spent my life studying birds and 
no one would have heard of me. (“Succeeding” 1812) 
 
 
Sorting out the Narratives 
 
The differences between the representative narratives for the pharmaceutical and 
biotech industries are numerous. As a representative anecdote for the early 
pharmaceutical industry, the popular story of Alexander Fleming as discover of penicillin 
is uncomplicated and, over the past 85 years, has settled down into a standard myth that is 
rarely challenged. Biotech’s representative narrative, by contrast, is newer and still being 
constructed. Although Francis Crick died in 2004, James Watson is still alive and 
generating new commentary through his own writing and through interviews. It is to be 
noted, however, that the pharmaceutical story is far from finished, as it, like 
biotechnology, continues to be influenced by culture and contemporary events. One 
prime example is the negative publicity surrounding Vioxx (rofecoxib), an anti-
inflammatory drug that was withdrawn in 2004 by Merck & Co. following concerns 
about the drug’s association with an increased risk of heart attack and stroke. Events such 
as these elevate public skepticism of the safety of pharmaceutical drugs in general. 
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Whereas the public rhetoric surrounding Fleming portrays him as a modest man 
with good personal qualities, that surrounding Crick and Watson is more mixed. In 
anthologies, newspapers and other public narratives, Watson and Crick are largely 
described as intellectually curious and desirous of winning a scientific race. However, in 
many accounts Watson, in particular, is seen as egotistical and hungry for fame, qualities 
that are also frequently attributed to Craig Venter, a figure who looms large in later 
biotech history. Interpretations of character are often fraught with ambiguity, and 
particularly vulnerable to reinterpretation following a passage of time. In the rhetorical 
matrix of the pharmaceutical and biotechnology industries it could be possible to re-
characterize the Fleming popular character (as opposed to the actual man) as staid and 
old-fashioned, rather than modest and unassuming. Watson and Crick, by contrast, could 
be interpreted as having the positive characteristics of boldness, initiative, and vitality. 
One only needs to peruse a few chapters of Watson’s account of The Double Helix to 
obtain an idea of the young, brash man who positioned himself front and center of a 
whole new chapter in science history. This, perhaps, underscores the rhetorical message 
of biotechnology as new, young, brash, big, bold, and given to hyperbole. It is a science 
that defies the general public to look away. As Matt Ridley writes, the double helix and 
the genome (which he calls the “towering bookends” of Watson’s biotech career) could 
easily have been discovered by any number of others. He writes: 
 
. . . any one of them could have snatched the prize if they had shared Watson’s 
urgency and vision. But that is what makes Watson’s achievement all the more 
remarkable. It was precisely because the prize was ripe, and so many brilliant 
minds were after it, that his grasping it equal- first was an act of genius. He may 
have shaved only months, perhaps a year, off the timetable of history, but he won 
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the race, something Shakespeare and Beethoven never had to do . . . What a much 
duller—and safer—history DNA would have had without Watson stirring things 
up. From the first friction with Rosalind Franklin to the battle against regulation 
in the 1970s to the confrontations with Craig Venter in the 1990s, it was Watson’s 
ability to live dangerously that made history. (xv) 
 
 
Biotechnology rhetoric that seeks ingratiation with the public does not emphasize 
the very human motivations of jealousy and mean-spiritedness, of course. Instead, the 
attributes that are positioned foremost include a spirit of entrepreneurialism, risk-taking, 
brilliance, youth, flexibility, and ingenuity. These traits are attractive to venture 
capitalists, who are the financial lifeblood of emerging, nonpublic biotechnology 
companies, and who often consider themselves mavericks of sorts. 
In the Fleming anecdote, the popular notion is that nature was revealed through a 
fortunate (and perhaps divinely initiated) accident. The Watson and Crick story, by 
contrast, is all human, with the two often portrayed as hard workers who pursue a 
personal quest to discover life’s secrets. Religion and science have seldom been happy 
bedfellows, and the thought that Man could suddenly be in possession of —or worse, 
manipulate—elements of nature is a theme that frequently emerges to frighten the public 
and thus destabilize the acceptance of biotech. Whereas Fleming’s penicillin was given 
by God, the thought goes; DNA and genetics are the case of man playing God. The 
polemic to this would argue that those who champion biotechnology embrace a healthy 
sense of self and a scientific rationality that assumes achievable answers to cosmic 
questions. Fleming aside, the pharmaceutical world, too, has long been the subject of 
many of the same ethical and theological concerns now facing biotech, although to a far 
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lesser extent since pharmaceuticals are perceived more as the manipulation of chemicals 
than the manipulation of the very biology that constitutes life. 
For their respective efforts, Fleming, Crick, and Watson were all awarded the 
Nobel Prize—the “Holy Grail” for scientists and source of legitimacy for public 
perception of brilliance. In the Fleming story, the public took little note of those who 
came later—for example, Chain and Florey—whose efforts helped turn a bacterium into 
medicine that would be made available to all. Despite efforts by groups such as the 
American Chemical Society, an elevation of their status in the public’s mind simply did 
not take hold. Similarly, Maurice Wilkins’ name and involvement in characterizing the 
double helix are largely unknown. However, efforts to redeem the status of his colleague, 
Rosalind Franklin, continue to gain traction in the early twenty-first century. Franklin is 
becoming a new representative anecdote for women in science, and her name is 
increasingly present in historical anthologies. In a roundabout way, the successful 
inclusion of Franklin in the annals of science argues for a characterization of 
biotechnology as democratic and accessible to all brilliant minds. Successors like Barbara 
McClintock, honored with a Nobel Prize for her work in genetics (and subject of a first-
class U. S. postage stamp issued in 2005), and Linda Buck, who won the Nobel Prize in 
2004 for her work on gene coding for olfactory receptors, also reinforce the notion that 
biotechnology is open to all. The Franklin-as-hero is a modification (some would say 
improvement) of the standard Crick and Watson story, which continues to elevate the 
status of a specific individual (as opposed to corporations), but introduces a sense of 
fairness into the mix. 
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In the penicillin story, the drug itself is the star. Knowing that the general 
population places a high value on safe and effective therapeutics, the pharmaceutical 
industry infuses its public rhetoric with the ingratiating message of helping people 
through prescription medicine. Biotech, on the other hand, largely relies on messages of 
promise and potential since many of its products have not yet transitioned from theory to 
actuality. 
If one rejects the premise that the above alternative narratives are mutually 
exclusive, then a combined list of characteristics could be posited for the biotechnology 
industry, as represented by Watson and Crick: 
 
• The concept of a team of two as prime discoverers 
• Later acceptance of a female scientist as critical to the discovery (thus, 
opportunity and fairness) 
• Boldness 
• Human initiative; pioneering spirit 
• Youth; newness 
• Quickness; ability to think and act fast 
• Ability to live dangerously; courage 
• Drama; hyperbole 
• Sense of self, scientific rationality (or, alternatively, “man playing God”) 
• Love of new ideas, knowledge 
• Science based on human cells, genetic code 
• Potential of biotech science 
• Promise of useful products 
 
 
Of the collective list, the most powerful and transformative biotechnology 
industry attributes are captured in the words promise and potential. As future-focused 
words, they abet a malleable and personalized vision of how science could, should and 
ought to be. Youth and newness, too, are linked to the concept of transformation since the 
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future offers options that are wide open to those who are young (or enterprises that are 
young). Genentech, the company that is universally acknowledged as the first 
biotechnology company, has a culture that feels “more like a college campus than a pillar 
of the FORTUNE 500” and cultivates an attitude of “flout(ing) conventional wisdom and 
tak(ing) a damn-the-torpedoes approach to naysayers” (Morris, Burke, and Neering 80). 
The concept of pioneering and its associated characteristics of boldness and 
courage speak to the future and transformation as well. The very nature of discovery is 
linked to imagination: one can only guess as to what appears on the other side of the 
door. Until the door is opened, any manner of destiny can be imagined. The opening of 
the metaphorical door to the double helix was an action that generated more doors, each 
becoming bigger and wider and holding behind them concepts that were increasingly 
grand (or, depending on perspective, frightening): a map of the human genome, 
personalized medicine, the re-engineering of human beings, immortality.  
Promise and Potential as Powerful and Transformative Biotech Rhetoric 
 
The science historian Robert Bud has commented on the “promiscuity” of the 
word biotechnology (“Biotechnology in the 20th C.” 419). By this, he means that the term 
has been used in many ways by many people, thus exemplifying the ambiguity of the 
word and the concept. He calls biotechnology a “boundary object” between engineering 
and biology that “can be associated with many passage points and translations” (419). He 
writes, “Typically, border objects tend to have shifting meanings, depending on which 
neighbour is dominant” (“Uses of Life” 3). He writes: 
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‘Bio’ suggests natural; it connotes all those living things whose lives, it often 
seems, would be better but for the human species. By contrast ‘technology’ 
evokes human control over nature. The combination of the two has often seemed 
deeply disturbing, even monstrous, as amalgams of people and machines have 
been described. (“Uses of Life” 2-3) 
 
 
 It can be argued that biotechnology is also a boundary object between the 
pharmaceutical industry and life science. If one accepts an ultimate vision of either 
defeating death completely or at least postponing it indefinitely, then penicillin and other 
antibiotics fulfilled this powerful vision for many decades. Life expectancy in 1900, for 
example, was 49 for white women and 47 for white men. By 2000, these numbers jumped 
to 80 and 75, respectively (Stevenson). While some of the reasons for increased life 
expectancy can be attributed to improvements such as better sanitation and nutrition, 
immunizations and antibiotics were also acknowledged to have played an important role. 
 However, by the end of the twentieth century, the infallibility of penicillin and 
other antibiotics was clearly jeopardized by the emergence of antibiotic-resistant 
microbes. With no new miracle drugs on the horizon, the pharmaceutical industry did not 
seem to be in a position to lead the way to a new era of continuous life. However, from a 
rhetorical standpoint, if biotech is a boundary object, then pharmaceuticals had several 
passage points to it. Big pharma could ingest biotech literally, through mergers and 
takeovers, or it could simply appropriate the language of biotech—that is, the language of 
risk-taking and innovation. Both of these scenarios are commonplace, and are what 
Kenneth Burke would term a state of merger that acts to “bridge the gulf” between two 
voices in a dialogue (GOM 402). 
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 In its 2005 industry profile, for example, the pharmaceutical organization PhRMA 
writes that “(t)he convergence of traditional pharmaceutical chemistry and biotechnology 
has led the pharmaceutical and biotechnology industries, once thought of as being distinct 
and independent, to become more similar than dissimilar” (5). 
 A 2002 advertisement by the giant pharmaceutical company Aventis illustrates 
the merger of the traditional pharmaceutical rhetoric with a new message of innovation. 
The ad, subtitled “Our Challenge is Life,” reads, 
 
Whether young or old, people wish to live a long and healthy life. Aventis, a 
world- leading research-oriented pharmaceutical company, makes a decisive 
contribution to the protection of health with innovative pharmaceuticals, 
preventive vaccines and therapeutic proteins. We are using our comprehensive 
experience and competence, as well as new technologies like biotechnology, to 
research and develop new and improved pharmaceuticals. After all, it is our aim 
not only to be able to treat illnesses more effectively but to prevent them. So that 
all of us can enjoy a long and healthy life. (43) 
 
 
 The ad, which depicts a three-generational family (grandfather, mother, father 
and two children) skillfully blends the old and the new in both its visual and textual 
rhetoric. It can be argued that the family represents the pharmaceutical and biotechnology 
industries, with the former bringing wisdom and experience to the narrative, while the 
latter brings the improvements of youth. 
 The absorption of biotechnology by big pharma is not always perceived as a 
strength for the latter, but often as a desperate means to stay afloat. As an example, when 
the biotechnology industry reached its 25th anniversary, the San Francisco Chronicle ran 
an article that described how biotech was “hotter than ever, viewed by many as the 
answer to the problems of old-line drug companies saddled with portfolios of dated 
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products” (Tansey). The author also wrote of Pfizer’s loss of $20 billion in market value 
“when it had to scrap development of an experimental cholesterol drug that it had hoped 
would replace its blockbuster Lipitor, soon to lose its patent.” The author writes: 
  
Pfizer’s disappointment epitomized the predicament of big pharmaceutical 
companies, whose flagging in-house research efforts are forcing them to buy or 
partner with biotech companies to maintain growth rates.  
 
“If you look at big pharma, they’re in deep yogurt,” said Steven Burrill, chief 
executive of the life sciences merchant bank Burrill & Co. in San Francisco. 
(Tansey) 
  
 
 In positioning itself head to head with big pharma, biotechnology often takes an 
equal and opposite tack. Michael S. Rosen, president of Rosen Bioscience Management, 
is a frequent contributor to Midwestbusiness.com, an online technology newsletter. 
Rosen’s articles frequently position one industry against another, with titles such as 
“Biotechnology Flourishes in 2005, while Big Pharma Flounders” and “Eat Your Heart 
out, Big Pharma: Top 10 Biotech Companies Explode.” Biotechnology rhetoric often 
tampers fears about the industry through the appropriation of pharmaceutical language—
that is, expression of nobility of purpose through the advancement of human health and 
declaration of goodwill for humankind. In so doing, biotechnology could position itself as 
the “white knight” and position the pharmaceutical industry as the metaphorical dragon to 
be slain. A cover article in Forbes magazine illustrates this scenario. The magazine says 
that “killer germs” (also referred to as “scary superbugs”) kill 100,000 people a year: 
 
Frighteningly lethal and insidiously efficient, these bacteria replicate and mutate 
prodigiously, turning out variants that elude most of the chemical weapons— 
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antibiotics—that medicine has invented over the past century. (Langreth and 
Herper 62) 
 
 
What’s worse, the article continues, is that “Big Pharma, rather than riding to the 
rescue, has largely abandoned antibiotic research, a low-ticket business, for more 
lucrative pursuits” (64). Thus in one short sentence, Forbes has undermined the 
characteristics of the pharmaceutical industry as altruistic and noble and has crushed the 
Fleming myth of penicillin as wonder drug. The help that is on the way, the magazine 
says, is “not from the drug giants but from a coterie of obscure biotech boutiques” (64). 
The magazine continues the imagery of biotech versus pharmaceuticals when it talks 
about how one scientist was a “defector” from big pharma, leaving it for an antibiotic 
startup (74). It is an example of Burke’s state of division between two voices in a 
dialogue (GOM 402). 
Biotechnology rhetoric frequently can be distinguished from pharmaceuticals 
through bolder use of language and through closer alignment with life sciences. Whereas 
pharmaceuticals could only hope to “cure” mankind of diseases and disorders, the 
argument goes, biotech could seek permanent immunity against these ills through re-
engineering of the body. An article in The Scientist, which calls itself a “magazine of the 
life sciences,” asks the question: “What if humans were designed to last?” The authors 
write: 
 
Evolution has given humans a beautifully orchestrated set of genetic programs to 
carry most of us through to sexual maturity, but we have also been given a brain 
large enough to ponder our demise. Yet, if the molecular, cellular, and genetic 
machinery used to conceive, develop and operate a human were designed rather 
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than the result of evolution, humans would be different and life would look 
different. This is our challenge. (Olshansky, Butler, and Carnes 28) 
 
 
 Thus, even evolution—which has long been the ultimate symbol of 
transformation—comes up short against biotechnology. Whereas evolution is passive, 
biotechnology is active and deliberate. Biotechnology products have the theoretical 
capability to be customized to individual people, in contrast to a “one-size fits all” drug 
such as penicillin. Tay-Sachs disease, for example, is a fatal genetic disorder caused by a 
specific enzyme deficit. It is impossible to introduce the needed enzyme directly into the 
brain, where it is needed, due to its protective barrier. The brain can, however, be 
penetrated by a bacterium that carries a “good” gene, which then reproduces in the body 
and replenishes the proper enzyme. As of this writing, genetic engineering for Tay-Sachs 
remains hypothetical and, like many biotech-related initiatives, subject to intense 
scientific and ethical debate. 
 Bio, as an equivalent term for biotechnology, has now become a code word for all 
that is new and innovative. The term has gained so much perceived value that companies 
that are not even related to biologically based science are using the phrase. EdenPure, a 
company based in Canton, Ohio that manufactures and sells portable heaters, recently 
mailed an information packet to consumers along with a letter marked “Biotech 
Research.” EdenPure’s heaters have nothing to do with biotechnology, but since biotech 
connotes that which is new and innovative, EdenPure can impart these benefits onto its 
products simply by appropriating biotech language.  
 
 
164 
 As a terministic screen, the word bio directs the attention to size (small and 
startup), market space (that which is not pharmaceutical) and attitude (fresh and 
youthful). That biotech is also edgy and “sexy” can be seen in a recent advertisement 
from Harrison and Star, a creative services company. The ad, which is entitled, “Making 
Science Sexy,” shows a female torso whose low-cut blouse is loosely tied with ribbons 
that are configured to look like the double-helix (Harrison and Star 65). 
 Some development organizations have used visual rhetoric to connect local 
culture with biotechnology messages. Invest Australia, a national agency to promote 
investment in Australia, recast the double helix as an aboriginal artwork, rendering the 
two strands in yellow, red and orange dots (Invest Australia 4). Another Australian 
biotechnology organization merged the double helix with an abstract rendering of the 
country’s beloved Sydney opera house (“AusBiotech”).  
 Thus, since 1953, the double helix has grown to be one of the most powerful 
metaphors in the world of science, becoming an effortless substitution for the concept of 
life itself. As visual rhetoric, it presents a far more unique and forceful image than a 
penicillin tablet. If we position pharma in competition with bio, it is bio that surely has 
the advantage of primary association with the rhetorical helix. As a rhetorical tool 
proprietary to the biotechnology industry, the double helix gives bio a distinct edge over 
big pharma because it has become, to use Lakoff and Turner’s words, “a matter of 
thought, not merely language” (107). 
 Along with the entity itself—that is, the double helix as visual and rhetorical 
icon—the story behind the discovery has also become infused with meaning whereby the 
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drama of Crick and Watson is one with the drama of biotechnology. And while this 
drama can largely be interpreted as positive for bio, it is also quite clear that the 
pharmaceutical industry is not ready to capitulate on the ultimate prize of public 
ingratiation. Rhetorical tensions between bio and pharma—i.e., the rhetorical helix—
continue to be in play to pull the two industries together and to pull them apart. As will 
be discussed in the next chapter, the strategies for union (or division) are deliberate and 
active products of the composing process. 
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CHAPTER VI 
 
WOOING THE PUBLIC IN NORTH CAROLINA: 
BIOTECHNOLOGY AS A TRANSFORMING AND LIFE-BASED ENDEAVOR 
 
 
In The Making of Meaning, Ann E. Berthoff tells teachers of writing that “the 
character of the composing process [is] one in which everything happens at once—
forming/thinking/writing” (6). She writes: 
 
After reading several accounts of the discovery of the structure of the DNA 
molecule, I constructed for my own amusement a model of the composing process 
as a double helix, trying to let the relationships articulated in that form help me 
discover those of composing. I had heard Francis Crick remark that you know a 
model is working for you when you get more out of it than you had put in – and I 
was delighted to see this happen. Although the process begins at the bottom and 
works its way upward, in each of the units, the four acts of mind, whether 
perceptual, conceptual, or rhetorical, can be read from top down as well as from 
bottom up. (7) 
 
 
Berthoff’s model is particularly apt for describing the activities of those who are 
charged with “making meaning” for the biotechnology industry or biotechnology 
activities. Meaning encompasses not only the facts and figures of definition and the 
feelings and impressions of description, but personal meaning as well. In crass terms, 
personal meaning (i.e., that which is meaningful to an individual) is the “what’s in it for 
me” question, with the answer often a product of wish fulfillment. A better economy, 
more jobs, elevated community status, and effective therapies can all be elements that are 
meaningful on a personal level. 
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In her double helix of composition, Berthoff lists several sets of what she calls 
“acts of mind,” including the following: seeing in context, establishing a perspective, 
looking, and responding (8). It is context and perspective that establish relative positions 
for pharma and bio. As Berthoff describes it, context and perspective are dynamic and 
changeable. While the general context for pharma and bio could be considered the health 
care industry or perhaps life sciences, the context could also be industries that use 
animals for research.  Thus bio and pharma could be thrust into the same positive, 
negative or neutral bucket. Bio and pharma can also be positioned in opposition to one 
another, with one wearing the proverbial white hat and the other the black. If bio is new, 
it is because its oppositional element, pharma, is old. If pharma makes enormous profits, 
it is a useful construction to say that bio has yet to make a profit. As circumstances 
change (that is, as the general context changes), perspective changes with it. For example, 
in 2006, the biotechnology industry turned 30; whether 30 is old or young depends upon 
one’s point of view—and one’s motivation for describing it thusly. 
North Carolina presents an excellent case study of the biotech rhetorical helix as 
composition in action. It also serves to demonstrate both senses of the rhetorical helix: 
composition of definition and description, in juxtaposition to one another; and 
composition of a public climate that will favor one industry over another. In the past few 
decades, state-sponsored agencies and others have introduced biotechnology to the public 
at large. They have articulated its merits and classified it vis a vis other industries in the 
state. They have substantiated their position through the use of positive examples. They 
have employed metaphors to facilitate meaning. And, most strategically, they have placed 
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North Carolina biotech within a context of critical economics and have established a 
perspective of achievable competition. All of this has been accomplished within a 
Berthoff-style framework that recognizes “how you construe is how you construct” 
(Berthoff 10). In North Carolina, biotechnology has been constructed as both life-giving 
and life-changing. 
The North Carolina Biotechnology Center, located in Research Triangle Park, was 
founded by the state in 1984 to drive biotechnology development and to foster 
appreciation for the sector. In a 2004 publication subtitled “Moving Biotechnology from 
the Mind to the Marketplace,” the NC Biotech Center says that its mission is to “provide 
long-term economic and societal benefits to North Carolina through support of 
biotechnology research, business and education statewide.” The pamphlet says the 
Center’s 50-member staff pursues six goals: 
 
• Strengthen North Carolina’s academic and industrial research capabilities 
• Foster North Carolina’s biotechnology industrial development 
• Enhance the teaching and workforce-training capabilities of North Carolina’s 
educational institutions 
• Work with business, government and academia to move biotechnology from 
research to commercialization in North Carolina 
• Inform North Carolinians about the science, applications, benefits and issues 
of biotechnology 
• Establish North Carolina as a preeminent international location for the 
biotechnology industry. 
 
 
All of the goals listed above have a counterpart rhetorical mission that is manifested in all 
communication from the center including documents, interviews, publications, 
newsletters, meetings, seminars, lobbying efforts, and more. It is a grand plan for wooing 
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the public, for persuading state citizens and others that positioning biotechnology in 
North Carolina is consubstantial with their interests. 
The messages directed at those considering relocation to North Carolina 
emphasize themes such as the state’s excellent infrastructure, trained workforce, 
incentive package, and attractive living environment. For the internal audience (North 
Carolinian citizens), the most powerful and transformational message lies in 
biotechnology’s capability to change North Carolina from a state built on traditional 
industries—agriculture, textiles, and tobacco—to one with all of the new, young, and 
innovative qualities of biotech. The underlying message is that it is not only the state that 
is acquiring these characteristics, but its citizens as well. 
One theme employed by the North Carolina Biotechnology Center hearkens back 
to the concept of “winning the race.” In a pamphlet entitled “Biotechnology Works in 
North Carolina,” the Center references “North Carolina Firsts,” which include the first 
public university (the University of North Carolina) and the first successful powered 
airplane flight (by the Wright Brothers). The reference to the Wright Brothers in 
particular is a strategic move because, as with Crick and Watson, it puts a human face to 
a technological achievement and emphasizes the fact that this notable achievement took 
place in North Carolinians’ own backyard. The North Carolina Biotechnology Center 
also, strategically, includes itself in the list of firsts, saying that it was the “world’s first 
government-sponsored initiative in biotechnology.” Just as the Wright Brothers showed 
initiative in aviation, the NC Biotech Center and, by extension, the citizens of North 
Carolina are driven to be first in biotechnology. 
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Biotechnology is not only a field of science, it is—in rhetorical terms—a 
community as well. To make the concept of biotechnology feel local and friendly, 
BioSpace, a provider of web-based information, established a successful marketing 
campaign that organizes clusters of biotech organizations into what BioSpace calls 
“hotbed communities.” The BioSpace maps visually depict, within a particular 
geographic region, those companies that define themselves as biotechnology related. 
The underlying message of the hotbed map is that unlike the pharmaceutical 
industry with its century of history and major barriers to entry, biotech is accessible. 
Becoming a major pharmaceutical company requires substantial resources for research 
and development, large-scale manufacturing and marketing. A biotechnology 
organization, on the other hand, can be as intimate as two people with an idea. For cities 
or states that wish to infuse life into their stagnant communities, biotech provides a 
feasible option. The names on each BioSpace map underscore the folksiness of the 
biotech communities. Notable examples include “Biotech Beach” (Southern California), 
“BioGarden” (New Jersey), “Genetown” (Massachusetts) and “BioForest” (Northwest 
United States and Canada). 
The BioSpace website says that the hotbed maps have “highlighted thriving 
clusters of life science industry, helping to attract investment, talent and additional 
resources to specific geographic areas.” The site also says that the original hotbed map— 
“Biotech Bay” (the San Francisco Bay Area)—is on permanent display in the 
Smithsonian Institution’s National Museum of American History. 
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In essence, the BioSpace maps compress all three stages of the rhetorical helix. 
They define, in scientistic style, what biotechnology is in any given area; they describe 
the biotechnology community in a folksy way; and they ingratiate the local community 
by establishing shared aims (e.g., successful economic development). 
Like the other BioSpace communities, North Carolina has defined itself on a 
hotbed map, as shown in Figure 2.  Again, keeping the connection with first flight, the 
map features several forms of air transportation: a Wright-style biplane, jet, hot air 
balloon and zeppelin. 
 
 
 
Figure 2. BioSpace North Carolina Hotbed Map. Manasquan, NJ: BioSpace, 2007. 
Reproduced by permission. 
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North Carolina biotechnology companies themselves also employ the language of 
competition and speed. In a double-page ad in Fortune magazine, Quintiles Transnational 
Corporation, a contract research company that provides services to biotech, shows a large 
photo of a North Carolina city with a biplane flying overhead. The caption reads, “Great 
innovations have always had a way of taking off in North Carolina.” The text reads, 
 
Today it’s biotechnology. North Carolina is home to more than 170 fast-moving 
biotech companies, dozens of academic research facilities and Quintiles 
Transnational—the company that helped speed 9 of the top 10 best-selling biotech 
products to market.  
 
 
W. Steven Burke, Senior Vice President for Corporate Affairs at the North 
Carolina Biotechnology Center, says the center is “communicationally intensive,” which 
is necessary in “a world peppered with biotechnology expectations triggered by nations, 
states, governors, and agencies” (personal interview). The NC Biotech Center publishes 
the newsletter BT Catalyst on a bimonthly basis, and sends it free to any member of the 
public who requests to be on the mailing list. It is also published in an electronic format. 
The Center also publishes Fast News, a weekly e-mail digest that reports on 
biotechnology developments across the state and is linked to other articles about 
biotechnology from the general media and biotech sources. 
Burke, who described himself as one of the Center’s first employees, said the 
driving question for the organization has been “how to bring biotech to the life of a 
place.” Burke says that the words he would use to describe biotechno logy are 
“responsible,” “transforming,” and “life-based.” “Life is everything,” Burke asserts. “If 
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you have a technology that can manifestly understand, shape, and presume to shape life, 
you have the most significant endeavor ever in hand.” 
Burke says that he prefers the term endeavor over the term industry because it 
implies more than simply being a tool of capitalism. Although a biotechnology industry 
provides a source of jobs and represents the business of manufacturing, the biotechnology 
concept is larger than that. An endeavor, on the other hand, encompasses a business 
message, but also suggests that which has “profound societal and civic importance,” he 
says. 
Burke says that while biotechnology has proven key to changing the nature of 
pharmaceuticals, it also affects every other aspect of life, from plant and animal 
agriculture to forestry to biofuels. However, the aspect of biotechnology related to drugs 
receives the most emphasis because it is achievable and profitable. 
Biotechnology is a complicated story to tell, Burke says, and given the emotional 
connotations of language, it is not easy to counter the voices of skeptics. As an example, 
he says that those who speak on behalf of biotechnology have not come up with a tool of 
language half as effective as Frankenfood (a pejorative term for genetically modified 
foodstuffs). 
“People like easy, incisive connotations,” Burke says. “When people accuse 
biotech of ‘playing God,’ these words together have an easy shorthand resonance, but no 
logic. What we’re doing is ‘playing man’—tinkering, evolving, making mistakes.” 
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But the concept of playing man cannot be easily explained, Burke says. With such 
a complicated story as biotech, unless people are interested, they don’t stay engaged for 
long, says Burke. And those who are skeptical won’t listen in the first place.  
However, this is not to suggest that there are many skeptics when it comes to 
biotechnology. In fact, biotech is generally well regarded in the United States, Burke 
says. “Biotechnology is affected by our ambient culture more than we know,” he says. 
“Americans have traditionally been a society very tolerant of—and for growth, dependent 
on—new technology,” starting with the telegraphs, new construction, ships, and railroads 
of the last century. 
Burke says that a good deal of effort is made to define biotechnology because 
giving “utterance to definition is comforting and revealing.” Only the things that can’t be 
defined are the things to be afraid of, Burke says. He notes that when he first came to 
work for the NC Biotech Center 20 years ago, he came across 47 different definitions for 
biotechnology. Each definition, in its own way, struggled to capture the concept of “life-
changing technology,” Burke says. 
Those who are in a biotechnology audience in North Carolina are usually 
“engaged and attentive,” Burke says. Language directed to the public about the 
biotechnology community is usually not highly scientific and is usually kept at a general 
college level. Burke says he likes the term biotechnology community since it implies 
working together for positive outcomes, saving lives and creating a civil society. “This is 
human activity,” he says. “The key is human spirit.” 
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The messages from the North Carolina Biotechnology Center are, in a sense, an 
extension of earlier efforts by the state to develop a major technology center in Research 
Triangle Park (which encompasses Durham, Raleigh, and Chapel Hill). The park, known 
as RTP, was developed in the 1960s to transform an economy dependent on textiles and 
farming into the modern age. In a 1999 video about the endeavor (North Carolina’s 
Research Triangle Park: An Investment in the Future), former North Carolina governor 
Jim Hunt says, “Forty years ago we were a poor state. North Carolina was one of the 
poorest states of our area and we just didn’t see how it was gonna change.” Hunt 
continues by saying that textiles and farming were “not sufficient to keep our young 
people at home and provide the economic base we needed.” 
Narration from a Department of Commerce film, made in 1954 and embedded 
into the RTP video says, “Every year, some of our best educated young people leave to 
find a living elsewhere. Of all our state’s resources, these young people are most valuable 
and we’re still losing them by the thousands.” 
Youth and vitality, it was determined, could be recaptured through the recruitment 
of high technology initiatives such as telecommunications, environmental sciences, 
chemical companies, pharmaceutical companies and biotechnology. “RTP has 
transformed North Carolina’s economic landscape,” the narration says. 
Tales of personal transformation are told in the video as well, such as the story of 
Judy Watkins, who had been a textile operator until 1987 when her company closed its 
doors and she was out of a job. Watkins later got a job in biotechnology as a media 
preparer. She is quoted as saying, “It’s a different world here than at the textile mills.” 
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Also, significantly, the video touches on the transformation of tobacco, which had 
traditionally been the state’s most important cash crop. In the video, Dorcas Green, a 
science teacher at a Kinston (NC) high school, says: 
 
In this area, historically, tobacco has been the number one crop. If we use 
biotechnology in making new products out of tobacco, I know that we are going 
to improve the economy here. Our students already see that we can generate 
cosmetics from tobacco and a cure for cancer. Of course with their minds they can 
come up with all the things that we haven’t even thought of. (“North Carolina’s 
Research Triangle Park”) 
 
 
In a few short sentences, Green touches on all of the messages that resonate most clearly 
with public sentiment and lay the foundation for embracing biotechnology in the state. 
These messages are as follows: 
 
• An old economy of tobacco and textiles can be transformed into a new 
economy of biotechnology and health care 
• Tobacco, an old product criticized for its deleterious health effects, can be 
transformed into new, health-enhancing products 
 
 
Green’s statement contains elements of hyperbole (“cure for cancer”; “they can 
come up with all the things that we haven’t even thought of”) that resonated earlier in the 
Watson and Crick representative anecdote for biotechnology. Similarly, she also 
privileges newness, quest for knowledge, and youth, with its inherent characteristics of 
quickness, agility, and innovation. 
In a recent supplement of The Scientist magazine, focused solely on North 
Carolina, an article described all of the “villages” in the state that grew into “technology 
giants with the right combination of rural roots and corporate investment” (Macek 66). 
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Towns that had been previously best known for Christmas tree farms, furniture 
manufacturing, poultry farming, and tobacco crops are now being resurrected as seats of 
biotechnology that produce immunotherapy products, biofuels, and other biotech 
products. 
For North Carolinians, the tobacco story touches on deep-seated emotions. 
According to the North Carolina Department of Agriculture and Consumer Services, 
tobacco’s historical importance cannot be underestimated. Feelings about the crop still 
run high, especially since well over one-third of all tobacco-related employment in the 
United States is in North Carolina. A passage on the department’s website reads, 
 
Tobacco has always been an important part of North Carolina’s economy and a 
vital crop to our producers. Many people raised in this state can find a heritage 
relating to some area of the tobacco industry. The golden leaf is a bedrock to 
North Carolina. (“NCDA&CS Marketing Division”) 
 
 
The site notes that the tobacco industry “has been in a transition period” since October 
2004, when a tobacco quota buyout was put into law by the federal government, thus 
ending federal farm price support. 
A strong indication of the winds of change for tobacco came in spring 2007, when 
both chambers of the North Carolina General Assembly proposed bills that called for a 
smoking ban in all public places and worksites, for reasons of health. Elon University, a 
North Carolina-based school, conducted a poll to determine support for these bills and 
found that sixty-five percent of respondents in favor of the law, with thirty-one percent 
opposed. Hunter Bacot, director of the poll, said that “It appears that the historical ties to 
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tobacco in this state are now essentia lly severed, as anti-smoking sentiments prevail 
among North Carolinians” (“Elon University Poll”). 
Even tobacco manufacturers acknowledge the reality of change. In a press release 
dated March 21, 2007, Reynolds American Inc. and its largest subsidiary, R. J. Reynolds 
Tobacco Company, said that the company supports “reasonable public smoking 
restrictions with common-sense exemptions for places such as private homes and adult-
only facilities like bars” (“Reynolds American”). On April 3, 2007, a North Carolina 
House committee took a step closer to a total tobacco ban when it passed a bill to 
establish no-smoking zones around most buildings in the University of North Carolina 
system. 
Clearly, the North Carolina public has acknowledged that tobacco does not 
represent the future of North Carolina. At the same time, the scenario of “rehabilitated” 
tobacco is appealing and lends itself to messages of new, human-driven science that takes 
nature and improves upon it. In an interview with UNC-TV, a public television station, 
Dr. Charles E. Hamner, who led the North Carolina Biotechnology Center from its 
inception in 1984 until his retirement in 2002, spoke to the possibility of inserting genes 
into tobacco plants, thus causing them to produce specific proteins which could then be 
used for pharmaceuticals, blood replacements, enzymes for industrial use, and “a number 
of potential valuable food products, all from tobacco.” Hamner said that rather than 
seeing tobacco as a health risk through its use in smoking, it is possible to see it as a 
“value-added plant” (“Interview”). 
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One of the most compelling tales of transition can be found in Targacept, Inc., a 
biopharmaceutical company located in Winston-Salem, North Carolina—one of several 
communities throughout the South that was built on the strength of the tobacco industry.  
Targacept originally started out as a research program at R. J. Reynolds Tobacco 
Company (RJR) which, according to its website, is the second- largest tobacco company 
in the United States, manufacturing one of every three cigarettes sold in America. As a 
financial powerhouse, RJR not only gave rise to its headquarters skyscraper located in the 
heart of the city, but it also contributed liberally to numerous educational, economic 
development and human-service programs through its private foundation. As industry 
critics describe it, “Cigarette makers are America’s 20th-century Medicis, sponsoring 
symphonies, art exhibits, dance, and theater troupes” (Mollenkamp, Levy, Menn, and 
Rothfeder 15). The same authors write: 
 
Winston-Salem, North Carolina, population 144,000, is one of the largest cities 
tobacco built. Thousands work at RJR, which has dominated the town for a 
century. On warm summer days the musk of drying tobacco hangs in the air. 
There’s even a nearby community called Tobaccoville, named in the 1870s after 
the town’s lone landmark: a chewing- tobacco factory. (Mollenkamp et al. 16) 
 
 
In the mid-1980s, R. J. Reynolds Tobacco embarked upon a mission to 
understand everything about nicotine, the active ingredient in tobacco, including its 
pharmacology, chemistry, and toxicology. Thus, RJR established the Nicotine Research 
and Analogue Development Program (NRADP) at a cost of tens of millions of dollars. 
The company was looking for possible new products, includ ing a “reduced risk 
cigarette,” but what it found was a series of nicotinic compounds that “appeared to have 
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potential therapeutic applications for a wide variety of ailments, including Alzheimer’s 
and Parkinson’s diseases, ulcerative colitis, and Tourette’s syndrome” (Lord, Mandel, 
and Weger 117).  
As Targacept’s website explains: 
 
 
During our incubation within RJRT [R.J. Reynolds Tobacco], RJRT’s researchers 
published hundreds of scientific papers and abstracts. Many of the publications 
focused on neurona l nicotinic receptors (NNRs), a unique class of molecular 
targets in the body that maintain and adjust central nervous system (CNS) 
activity.  
 
The findings from RJRT’s researchers, as well as numerous investigations into the 
biological effects of nicotine reported in the scientific literature, suggested a role 
for NNRs in the treatment of human disease and led to the creation of Targacept. 
(“Targacept”) 
 
 
Targacept, which became a wholly owned subsidiary of RJRT from 1997 to 2000, 
was ultimately spun out as an independent company in 2000. A “best practice” study in 
Harvard Business Review described the events leading up to the spinout: 
 
(B)y the mid-1990s, pressure on the tobacco industry was intensifying, and RJR’s 
parent company, RJR Nabisco Holdings, was in the midst of a corporate breakup. 
RJR Tobacco was forced to retrench and focus on defending its core business; its 
top managers could no longer afford to lavish time and resources on one of the 
company’s more-promising, if surprising, areas of new product development. As 
one of the NRADP researchers puts it: “RJR’s core product is an agricultural 
product that comes rolled in paper; it’s manufactured very simply. An R&D-
intensive pharmaceutical business was hardly a strategic fit.” Internal interest in 
NRADP evaporated, its funding dried up, and despite its promising discoveries, 
its future within RJR looked bleak. (Lord et al. 117) 
 
 
The debate within RJRT was whether to axe the research program, support it 
minimally, or sell it off completely. RJRT felt that the unit had the capability to transition 
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from a wholly owned subsidiary to an independent company, and thus took the decision 
to spin out Targacept in 2000. 
This transition to independent company status was an act of wooing in itself, 
particularly on the part of J. Donald deBethizy, then-head of RJR’s product research and 
development group. DeBethizy, who shouldered the mantle of champion of the new 
company, had to convince RJR that the spin-off could generate substantial value for the 
parent corporation and that RJR should continue to provide the necessary resources to 
Targacept until the new company could stand on its own, financially and otherwise. He 
also had to embark on a strategy to pursue and attract outside partners and investors. In 
this effort, deBethizy presented the typical business arguments: Targacept had a 
substantial patent portfolio; advanced research capabilities, including a proprietary 
discovery platform; and an experienced staff—all of which translated into tremendous 
commercial viability and potential return on investment. 
These are the traditional arguments that Burke would call an act of persuasion 
“for the purpose of causing the audience to identify itself with the speaker’s interests” 
(ROM 570). As an example, a potential investor would be attracted to Targacept because 
of a shared interest in achieving good financial return. At the same time, deBethizy also 
engaged in another Burkean strategy: drawing on “identification of interests to establish 
rapport between himself and his audience” (ROM 570). In other words, deBethizy had to 
convince potential investors and partners that not only were Targacept’s interests the 
same as their interests, but that Targacept’s attitude and style matched theirs, too. To a 
great extent, this meant distancing Targacept from the “good old boy” profile of the 
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harmful big tobacco industry and embracing the notion of Targacept as a new 
organization devoted to therapeutic advancements for the well-being of humankind. 
DeBethizy recalls a visit to one high-powered investment firm to present a five-
minute overview of Targacept. At the meeting, one of the general partners acted 
impatient from the start, interrupting deBethizy and instructing him to skip parts of the 
presentation. “In his mind, I was a stereotypical tobacco hack,” recalled deBethizy 
(personal interview). DeBethizy explained that not only did most people see the field in 
general as ethically questionable; they did not view data from the tobacco industry as 
scientifically credible. 
For deBethizy, a primary challenge was learning how to ingratiate himself and 
company with the audience at hand. He understood that his company’s affiliation with the 
big tobacco industry posed a major credibility problem and intuitively understood that the 
way to overcome the problem was to emphasize the company’s transition from old to 
new. He was able to accomplish that rhetorical mission, in part, through the powerful use 
of metaphor. 
DeBethizy did not skip any parts of his presentation. Instead, he relied on an 
image of transformation that overtly acknowledged the negative while offering the 
promise of something positive. It was the image of a phoenix, of a beautiful and healthy 
golden bird that spread its wings to take off to new skies. This metaphor struck a 
responsive chord with investors as well as the media, who were quick to notice the irony 
in the imagery of “rising from the ashes.” The Financial Times wrote about the 
“surprising virtues” of nicotine (Cookson 13), while The Wall Street Journal reported that 
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“Some top nicotine researchers applaud Reynolds’ efforts with Targacept, saying it 
represents an opportunity for the nation’s No. 2 cigarette marketer to put its nicotine 
savvy to socially responsible uses” (Hwang F3). 
The phoenix was a useful metaphor to represent the idea of good emerging from 
bad; of youth from age; of rebirth from death. It is what Lakoff would describe as “a 
device of the poetic imagination and the rhetorical flourish” (Lakoff and Johnson 3). The 
idea of the phoenix rising is an orientational metaphor, a deep-seated notion that good 
(including health and life) is associated with up and bad (including sickness and death) is 
associated with down. Just as Lazarus rose from the dead, the phoenix rises from its own 
dead ashes to spring forth young and powerful. 
DeBethizy said he also relied on his down-to-earth personality to woo and 
connect with his audiences. While deBethizy described himself as proud and confident, 
he said he also made a consistent effort to be honest and genuine in his interactions with 
the general public. He recalled one time seeing a highly placed executive from Pfizer 
speak in an arrogant manner and thinking to himself, “You sound just like a tobacco 
executive.” DeBethizy noted that the pharmaceutical industry, like the tobacco industry, 
does little to address issues of pricing and profits. Big tobacco, he said, had historically 
always been on the defensive, emerging in the public eye only if there was a threat to the 
business. “Realists saw no value in going out and getting beaten up,” deBethizy said.  He 
said that big industries like tobacco, oil, and pharmaceuticals all place themselves well 
above the common man. “That’s what happens when you get power,” deBethizy noted. 
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Thus, in a compressed time frame of five years, deBethizy and his Targacept 
colleagues engaged in the rhetorical process of self-definition, description and 
ingratiation. This was a rhetorical helix of activity that the pharmaceutical and 
biotechnology industries had also engaged in, albeit over the course of decades. 
To a great extent, deBethizy’s task was to “make meaning”—that is, to construct 
an account of Targacept through written materials, speeches, one-on-one meetings, and 
even through the physical appearance of Targacept’s shiny new headquarters building. 
Just as Berthoff speaks of the process of written composition as a “continuum . . . by 
which we make sense of the world” (69), deBethizy and his colleagues had to make sense 
of Targacept by finding and forming meaning for their new company. DeBethizy’s 
efforts tracked with what Berthoff calls “interpretive paraphrase,” or “the means by 
which meanings are hypothesized, identified, developed, modified, discarded, or 
stabilized” (72). 
Although the science platform for Targacept was based on medicinal chemistry 
and small molecule development, both of which are traditionally associated with the 
pharmaceutical industry, the leadership at Targacept chose to identify the company as 
biotech. “We were an emerging growth company, so we called ourselves bio,” recalled 
deBethizy. “It was a way to differentiate ourselves from the larger pharmaceutical 
companies. As a small growth company, it put us into a class with others like us.” In this, 
deBethizy and his peers employed Burke’s concept of reduction, whereby the activities in 
which Targacept is employed are reduced from the grand heading of science to the very 
specific grouping of biotechnology. It is an intentional selection that emphasizes certain 
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properties that the company has in common with others. As Burke writes, “any 
generalization is necessarily a reduction in that it selects a group of things and gives them 
a property which makes it possible to consider them as a single entity” (GOM 96). 
In addition to size, the designation bio also allowed Targacept to distinguish itself 
by high potential growth rate, along with high potential risk. Whereas pharma, in 
deBethizy’s words, are “old drugs being defended from generics,” bio represented 
“innovation” and “promise.” 
Another metaphor deBethizy offered up is the idea of the biotech industry as a 
child and pharma as “cranky, self-centered adults.” He stated that “people love children” 
and that the “child- like metaphor works for us” because it allows the company’s 
representatives to be wide-eyed, enthusiastic and emotional. The idea of family 
underscores a basic conceptual metaphor which Lakoff and Turner define as “part of the 
common conceptual apparatus shared by members of a culture” (51). In fact, Lakoff 
writes extensively of the metaphorical concept of parents and children in Moral Politics, 
in which the “strict father” family is associated with metaphors of moral strength, order, 
and authority (99), and the “nurturant parent” family is associated with metaphors of 
empathy, self-development, and happiness (136-137). 
The imagery of parent, child and family is used widely throughout the business 
community to conceptualize everything from mergers, which are often described as 
marriages, to spinouts, which are frequently portrayed as births. If we consider 
biotechnology as an offspring of pharmaceuticals, we have what Burke calls “the paradox 
of substance” whereby “(t)he offspring is “substantially one” with the parent: its history 
 
 
186 
thus being a development from merger (during the Edenic conditions of the foetus in the 
womb) to division (at the first “biological revolution,” experienced by the offspring at the 
time of parturition” (GOM 405). 
In other words, biotechnology (as the child) is one with pharmaceuticals (as the 
parent) and, at the same time, separate from it. As Burke puts it: 
 
the bursting of the bonds that has been made necessary by the growth of the 
foetus to the point where the benign circle of protection, the “enclosed garden,” 
had threatened to become a malign circle of confinement; and its status as 
offspring of this parent rather than that keeps it consubstantial with the familial 
source from which it was derived. (GOM 405-6) 
 
 
 For Targacept, the “ambiguity of starting points” (GOM 406) is doubled since 
its historical status makes it substantially one with big tobacco, and its rhetorical 
positioning as a biotech company makes it substantially one with pharmaceuticals. 
Association with strong “parental” business units can be advantageous. Targacept found 
that the press releases it issued that incorporated references to R. J. Reynolds or to large 
pharmaceutical companies were picked up much more readily by news organizations than 
those that did not. On the other hand, it can be argued that positioning oneself as a 
“child” business unit can be equally, if not more, advantageous for Targacept or any other 
biotech company because it assumes all of the characteristics of youth, including promise 
and potential. 
 After six years as an independent company, Targacept successfully completed 
an initial public offering in 2006, now becoming what deBethizy describes as “an older 
adolescent.” The move to metaphorical adulthood does not necessarily sever rhetorical 
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relationships with the parent, not does it necessarily create an autonomous identity. This 
is particularly true given Targacept’s new ventures into strategic partnerships with 
pharmaceutical companies. Such relationships can be considered as “ambiguities of 
substance” that Burke describes as follows: 
 
In being identified with B, A is “substantially one” with a person other than 
himself. Yet at the same time he remains unique, an individual locus of motives. 
Thus he is both joined and separate, as once a distinct substance and 
consubstantial with another. (ROM 545) 
 
In keeping with the metaphor of biotechnology as a child- into-adolescent, those 
who analyze the industry are given to saying that biotechnology has “come of age.” The 
transition of the industry as a whole can be tracked rhetorically by the report titles and 
introductory language used by Ernst & Young, a financial services firm that has tracked 
biotech progress since 1986. Per the messages extracted below, it is clear that industry 
analysts place biotech in an ambiguous position—distinct from pharmaceuticals insofar 
as its science is concerned, but similar to the pharma industry in terms of pressure for the 
need to provide products and deliver a return on investment. Table 4 shows some of the 
descriptions applied to biotech as it has evolved over two decades, with metaphors of 
movement, family, and self-composition clearly in play. 
The success of the communications efforts made by the North Carolina 
Biotechnology Center and others exemplify the last bulleted item in Table 4—that is, that 
biotech is now moving into the public mainstream. The biotechnology industry’s public 
relations initiatives have taken root, with articles in the public press largely in favor of the 
new industry. People are for biotechnology and the characteristics that seem to be 
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associated with it, although some admit that they really don’t understand the science 
behind it. As one reporter expresses it: 
 
Once it was easy to understand what we made in our factories in North Carolina. 
Furniture. Socks. Blue jeans. But now we’re becoming known for making 
biological products such as drugs, diagnostics, vaccines, vitamins, amino acids 
and enzymes. If we’re lucky, we soon will be known as a world leader in the 
field. Perhaps by then North Carolinians will know a little bit more about this 
strange new industry. (Rafferty 49-50) 
 
 
Table 4 
 
Cross-section of Introductory Language from Ernst & Young Biotech Reports, 1986-2001 
 
Title Messages (bolding mine) 
Biotech 86: At the Crossroad - A survey of an industry in evolution, including 
interviews with industry pioneers  and the new 
generation of managers 
- The crossroad is a place for questioning , but 
also a place that calls for confidence 
(No report issued for 1987)  
Biotech 88: Into the Marketplace - Biotech products are not yet reaching the market 
routinely, but the experience curve pitched 
upward in 1987. 
- Biotech will be the answer to AIDS 
- Biotechnology will have enormous positive 
impact on agriculture 
Biotech 89: Commercialization - The title of this year’s survey…speaks to what 
the industry has centrally cared about and 
achieved: staying on course in the journey that 
leads from the laboratory to the marketplace 
Biotech 90: Into the Next Decade - The first wave of technology with which the 
industry made its start is now fully developed, and 
new waves of technology are coming in behind 
faster than before. 
- It is certain that biotechnology is fundamental . 
- This industry is necessary and permanent. 
Biotech 91: A Changing Environment - …just as biotechnology is transforming  its 
environment, so, too, is the environment 
transforming biotechnology 
- Hoffman-La Roche’s acquisition of a majority 
stake in Genentech took many by surprise, but in 
retrospect, it has an inescapable logic. Genentech 
faced an integral dilemma of a technology 
company coming of age – the conflict between 
funding new product development versus Wall 
Street’s demand for quarterly earnings’ growth. 
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Biotech 92: Promise to Reality - The year contains its own drama – almost two 
billion dollars in new capital raised within the first 
six months of calendar 1991. 
- This is also a story of products and alliances, and 
of an industry growing up. 
- In retrospect, it is the story of the promise of an 
industry being fulfilled 
Biotech 93: Accelerating Commercialization - From its birth, the industry’s progress has been 
governed by a unique confluence of factors. 
Massive breakthroughs in science and technology. 
Enormous capital needs with a long horizon to 
payback. Financial markets that turn alternatively 
hot and cold. The heavy hand of regulation…. 
- No other major industry has had to grow up 
with so many hurdles  to surmount in order to 
bring value-added products to its customers and 
earn commensurate profits  
Bitoech 94: Long-Term Value, Short-Term 
Hurdles 
- BIO now has more than 520 members in 47 
states. 
- Our member companies are not only the current 
leaders in all facets of the industry…they are the 
foundation of the industry’s future, the startup 
companies and the innovators who will turn 
today’s dreams into tomorrow’s successful 
products. 
Biotech 95: Reform, Restructure, Renewal - Biotech companies are aligning with big pharma 
companies and with each other – in the U.S. and 
overseas – in a complicated web of 
interdependence. 
Biotech 96: Pursuing Sustainability - …the truth is, that many of this year’s events 
mark the industry’s passage into greater 
maturity . 
- The biotechnology investment climate has moved 
from passion to panic. The passion began with 
Genentech’s public offering, because every 
potential investor could identify with biotech’s 
mission of addressing serious diseases such as 
Alzheimer’s, cancer, and ALS. 
- However, the capital markets were operating 
under the fallacious assumption that, because 
biotechnology dealt with molecules that were 
natural, biotech’s products would be safer than 
traditional pharmaceuticals and would get through 
the FDA regulatory process faster. 
Biotech 97: Alignment - Twenty years ago, the industry known as 
biotechnology sprouted roots  in our academic and 
medical institutions. 
- However, these are new times for our industry, 
and the challenge now is adapting to the new 
healthcare environment. Our industry cannot sit 
back and be content with resting on our success. 
The healthcare industry is a tough one, the dollars 
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are limited, and the solutions are great. 
New Directions 98 - The issue of genethics , which came to the 
forefront this year, could significantly impact the 
direction of research, depending on which route 
public and political opinion takes.  
- The public and political response to Dolly, the 
cloned sheep, provided a wake up call, indicating 
how imp ortant genethics will be as the profile of 
the biotech industry increases in years to come. 
Biotech 99: Bridging the Gap - A significant gap has emerged as investors, 
especially in the public equity markets, are 
increasingly unwilling to recognize and reward 
value being created during the development 
process of a biotechnology product. 
(2000) Convergence: The Biotechnology Industry 
Report 
- In our last report, Bridging the Gap, we lamented 
that the market has not recognized the value being 
created in the biotechnology industry. That all 
changed as the year turned, with genomics stocks 
leading the way to often dizzying heights. 
- Biotechnology advances are working to turn 
into reality what sounded so futuristic in the 
last century. They are creating a world which, in a 
sense, is more “living” than ever… 
Biotech 2001: Focus on Fundamentals  Biotech’s high profile moves it more into public 
mainstream 
 
 
In other words, people like what biotechnology seems to stand for, although they 
may not precisely know what biotechnology is. Such a paradox is the rhetorical helix at 
play, with definition and description winding around each other en route to the 
destination of ingratiation. 
Targacept, meanwhile, has now firmly entrenched itself in the biotechnology 
community in the Piedmont Triad of North Carolina, an area becoming known as the 
“research triangle” of the western part of the state. The local chamber of commerce and 
other economic development agencies have frequently offered up Targacept as a 
representative anecdote for the Triad’s transition from an old economy to new. 
Several stories have featured Regina Whitaker, a medicinal chemist at Targacept, 
who had once been employed as a textile worker in the agrarian community of 
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Yadkinville, as an example of how students and other young people are being retrained 
for biotech. As one reporter describes it, “Regina Whitaker represents a voice of hope for 
the state’s displaced workers” (Craver A12). The government, too, has jumped on the 
old-to-new economy transformation by offering Whitaker up as an example of a 
biotechnology industry success story (“Biotechnology Industry Success Stories”). 
Whitaker acts as what Lakoff, in Don’t Think of an Elephant, calls a “person 
metaphor,” where, in this case, transformation from old technology to new is 
conceptualized in terms of a single person (69). In explaining the negative sense of a 
person metaphor, Lakoff discusses the use of Saddam Hussein as a representative of the 
war in Iraq. Here, in the positive sense, Whitaker can be thought of as a representative of 
biotechnology and the notion of a community becoming economically healthy and fully 
able to compete. 
The transformation of Whitaker, and others like her, underscores what Burke calls 
the “realm of the idealistic” whereby “a sense of consubstantiality is symbolically 
established between beings of unequal status” (ROM 570). From the perspectives of pay, 
opportunity and job challenge, the mundane world of farming or textile manufacturing is 
not equal to the sophisticated world of biotechnology and medicinal science. But from an 
idealistic perspective, a textile- or tobacco-based community could aspire to a rise in 
status through local biotech training programs and the infusion of new high-tech 
businesses into the area. As a result, virtually everyone located near biotech companies 
like Targacept has a symbolic opportunity to share in the new-economy vision. Those in 
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low-paying factory jobs, for example, can now dream of being retrained as skilled 
professionals in biotech. 
Ironically, tobacco profits are being used to transition workers out of the tobacco 
industry and into biotechnology. The Golden LEAF Foundation, a nonprofit organization 
that distributes funds from a 1999 master settlement agreement with cigarette 
manufacturers, is facilitating this change. In describing its activities, the foundation said 
that in 2003 it initiated a $60 million biotechnology initiative that “immediately focused 
national attention on North Carolina.” In this, the foundation added, “the Golden LEAF 
biotech initiative already is providing to be transformational” (“In the Spotlight”). 
The golden leaf, it should be noted, is a nickname that had been bestowed on the 
tobacco leaf for its once-golden opportunity to bring its growers and manufacturers great 
prosperity. In a potent metaphor of birth, death, and rebirth, the dead leaves of tobacco 
have reblossomed into a new golden leaf of life. The capitalist gold of tobacco has 
transformed into the prosperous gold of biotech therapeutics.  
As biotechnology companies such as Targacept engage in self-definition and 
description, and as they are defined and described by others, they fulfill the first sense of 
the rhetorical matrix. The second sense of the matrix—biotechnology companies and the 
industry at large interacting in competition with the pharmaceutical industry—is far more 
complex. Not only can biotechnology (as the “child”) never fully disassociate itself from 
the parent, in many instances, mergers and other affiliations act to push the strands of the 
matrix back together. As described in Ernst and Young’s 1995 annual report, biotech 
companies are now aligning with big pharma “in a complicated web of interdependence.” 
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In other words, the new interwoven structure of biotechnology and pharmaceuticals 
brings a new twist to the rhetorical matrix whereby the two entities fuse to form a new 
rhetorical entity: the biopharmaceutical industry. 
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CHAPTER VII 
 
CONCLUSION 
 
 
At the heart of the rhetorical helix is an examination of language that presents 
itself as solid and unchanging, language that presents itself as fluid and malleable, and the 
relationship between the two. It is an important helix, this definition/description swirl, 
because it traverses between the liberating, yet perhaps threatening, concepts of 
possibility and change, and the confining, yet perhaps comforting, concepts of 
standardization and stasis, and makes us question our reaction to each.  
The rhetorical helix is also a way to understand how industries and businesses 
compose themselves, and how they create meaning as a means to attain ingratiation. The 
helix is a metaphor for understanding that development is not linear and that multiple 
forces are always at play. The rhetorical helix highlights the way in which the 
pharmaceutical and biotechnology industries, as the primary example, move through 
rhetorically constructed illusions of independence and interdependence. As a construct of 
movement and transition, the rhetorical helix is inherently unstable and ambiguous – a 
postmodern image for a postmodern world. 
A physical example of the ambiguity that a double helix presents can be found in 
the courtyard of the Piedmont Triad Research Park (PTRP) in Winston-Salem, North 
Carolina. There stands a sculpture of three gleaming, stainless steel strands of DNA that 
appear to intertwine as they reach upward (see Figure 3).  
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Figure 3. Triple Helix Sculpture at Piedmont Triad Research Park 
 
 
A report from the National Center for Biotechnology Workforce describes the 
imagery thusly: 
 
Spiraling into the sky, the curves of a triple-helix sculpture stand near an 
entranceway to the Piedmont Triad Research Park. With the remarkable  
biotechnological breakthroughs being made in the field—from advances in 
Alzheimer’s disease to capabilities for growing new body organs—this shining 
sculpture also marks a gateway to the future. (“Addressing the Need” 1) 
 
 
In the human body, DNA has a distinctive spiral shape that some have compared 
to a gently twisting ladder, with each “ladder” having two rails connected by multiple 
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rungs, and each rung having two basic chemicals that are called base pairs. In order for 
DNA to duplicate itself, the chemicals in the rungs “unzip” from one another. 
But in the PTRP sculpture, the rungs do not unzip. Instead, as the ladder climbs 
toward the sky, the rungs get shorter and the rails come closer to one another until, 
ultimately, the rails converge to a point. It is an artistic liberty, one without foundation in 
biological reality. It is also, perhaps, an artistic liberty that speaks to a desire for closure. 
While some individuals, particularly entrepreneurs, are highly tolerant of 
ambiguity (Gladstone and Gladstone), others simply cannot cope with the conflicting and 
multi- layered messages that bombard our modern world. In his study of media literacy, 
W. James Potter states that the stronger our “emotional intelligence,” the more we can 
appreciate different perspectives. He writes: 
 
If we have a low tolerance for ambiguity, we will likely choose to ignore those 
messages that do not meet our expectations; we feel too confused or frustrated to 
work out the discrepancies. 
  
In contrast, if we are willing to follow situations into unfamiliar territory that go 
beyond our preconceptions, then we have a high tolerance for ambiguity. Initial 
confusion does not stop us. Instead, this confusion motivates us to search harder 
for clarity. We do not feel an emotional barrier that prevents us from examining 
messages more closely. (53) 
 
The “unfamiliar territory” that Potter speaks of is just what Burkean dramatism 
forces us to encounter. However, what dramatism has illuminated in the pharmaceutical 
and biotechnology helix is an affinity for that which seems eternal and true. Through the 
mythologies of Fleming and Watson and Crick, we demonstrate our willingness to return 
to that which is familiar, and that which we value. 
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When we accept the myth of Fleming as a young Scottish scientist who, by good 
fortune (or destiny, or Providence) accidentally discovered penicillin through mold 
spores drifting into an open window, we are essentially agreeing to assign significance to 
the values of fortune, destiny, and God. When we accept the myth of Crick and Watson 
as smart, bold, innovative, and brash, and validate these traits in anthologies and 
children’s books, we as a society are saying we value these qualities as well. 
If the story of Fleming has come to be associated with the pharmaceutical 
industry, and the story of Crick and Watson has come to be associated with the 
biotechnology industry, it is because we as a society have allowed for it to be so. As 
Barthes writes, “the meaning of the myth has its own value, it belongs to a history” and 
that meaning “postulates a kind of knowledge, a past, a memory, a comparative order of 
facts, ideas, decisions” (117). 
In this regard, the myth is a sort of crystallization. It is an attempt to rid ourselves 
of ambiguity through collective agreement that God and nature are responsible for 
penicillin, not corporations and chemicals. As a society, we comfortably lock in our 
version of the events, and it all works very well until we are forced to rethink our 
position. 
As the industry’s first blockbuster product, penicillin transformed the big 
pharmaceutical players into extraordinarily wealthy entities. But in a world that expects 
its saviors and heroes to work for free, the concept of excessive profit did not reconcile 
well. Horror stories like thalidomide, which caused grievous birth defects, and Vioxx, 
which was linked to cardiac arrests, increased public skepticism of pharmaceutical 
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products, and the myth of the pharmaceutical industry as life-giving saviors began to be 
rewritten. The pharmaceutical industry lost public goodwill. In movies and novels, 
pharmaceutical executives were frequently cast as evildoers, unscrupulously testing 
dangerous drugs on an unwary public. By then, it was very easy for the public to place 
the “black hat” on pharmaceuticals. The pharmaceutical industry as the bad guy became 
the new myth, the newly accepted collective agreement. 
The rhetorical matrix is the means by which an industry such as pharma can fight 
pigeonholing. In an unambiguous world, one could place the black hat squarely on 
pharma and the white hat on bio. However, in the ambiguous world of the rhetorical 
double helix, pharma and bio both wear grey, with the potential always there to “spiral 
upward” (using the metaphor that up is good) or spiral downward. 
In the rhetorical helix, definition is in constant interaction with description. 
Definition seeks to lock in the truth through a scientistic approach that affirms whether “it 
is, or it is not.”  Definition, on the other hand, has more dramatistic play, posing the 
option of whether something should or should not be, and providing for alternative 
scenarios. Whether we accept or reject these scenarios speaks to our values as a society. 
Over the course of their histories, the pharmaceutical and biotechnology 
industries have strategically defined and described themselves—within their own 
industries, in relation to the other, and in relation to the public. 
These ongoing rhetorical exercises are the essence of what Kenneth Burke would 
describe as dialectic or “the employment of the possibilities of linguistic transformation” 
(GOM 402). The debates represent a continuum: always pushing and pulling, and always 
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in connection to each other. When Burke speaks to merger and division he notes the 
danger of treating one aspect of a thing as indicative of the essence of that thing and notes 
that “there are always ways whereby, in searching for the “essence” of a thing, we can 
consciously or unconsciously choose to seek either the “specific” essence or the 
“generic” essence” (GOM 409). This is precisely the dilemma for the pharmaceutical and 
biotechnology industries as they go forward, and can be a subject of interest for 
rhetoricians who wish to observe how this drama plays out in the decades to come. Do 
bio and pharma belong together, should their self-definitions and descriptions be merged, 
or should distinctions continue to be drawn between the two?  Or is there an entirely 
different alternative that makes these polarities moot? 
Considered in isolation, pharmaceutical and biotechnology industry rhetoric 
essentially communicates each industry’s ability to transform us in some way—to 
provide jobs for our communities; to bring therapeutics to our medicine cabinets; to make 
us, by association, innovative and heroic. 
Penicillin’s discovery (or invention, depending on one’s point of view) was 
integrally linked with the world of pharmaceuticals. It was a product that represented 
transformation at its most figurative—and literal. Taken by mouth, one small penicillin 
tablet had the power to transform a human being from the near-dead to the recalled-to-
life. Penicillin was a product that was desperately needed by humankind, transforming its 
manufacturers into saviors and heroes. 
Biotechnology, meanwhile, also communicated its capability to transform, 
particularly in sleepy communities whose industries were become less viable. In the early 
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history of North Carolina, those in the Piedmont Triad made their living from the earth. 
In High Point, they turned trees into beds, tables, and chairs, making that city the 
“furniture capital of the world.”  In Greensboro, they spun denim and rayon into useful 
fabrics, making that city an important textile hub. And in Winston-Salem, they picked 
tobacco leaves and turned them into cigarettes, with a portion of the profits directed 
toward city growth. All were examples of transformation, both in terms of the products 
that took shape from raw materials, and the life those products then gave to their 
communities. 
Those in biotechnology have attempted to imbue their industry with a 
mythological power of transformation that can affix itself to anything it touches. Gwyn 
Riddick, director of the Piedmont Triad office of the North Carolina Biotechnology 
Center likens biotech to a nucleus that is at the core of life. He says: 
  
Every cell has a nucleus, and that nucleus is at the core. It’s driving the rest of the 
cell. The core circle is biotechnology, which is the driver—the lowest common 
denominator . . . The next circle is life sciences, which revolves around biology 
and biochemistry and includes more stuff than biotechnology. The bigger circle is 
bioscience, which includes fields like environmental science and marine science   
. . . And then there’s health care where hospitals and many other institutions fall, 
comprising an even bigger circle which includes all things that affect the health of 
humans. (Rogoski B15) 
 
 
What this imagery does is turn the genesis of biotechnology and pharmaceuticals 
upside down. Instead of biotechnology being a subset of pharmaceuticals, or the child of 
pharmaceuticals, it is the seed from which all else springs. It is a hierarchical relationship, 
but one that makes it impossible for pharmaceuticals and biotechnology to be adversaries 
since they are all part and parcel of the biggest circle of life itself. 
 
 
201 
In a double helix, although the two strands appear to twist and weave first closer 
and then apart from one another, in reality they maintain a consistent distance, separated 
by base pairs. By contrast, as the distinctions between the pharmaceutical and 
biotechnology industries grow murkier, their strands move so closely to one another as to 
be nearly indistinguishable. While biotech grows bigger and more pharma-like, pharma, 
by adopting biotech language and absorbing bio technology, becomes more bio- like. In 
fact, the term biopharmaceutical is now emerging to capture the generic essence of that 
which is bio and that which is pharma. 
In its 2005 annual report, the industry group PhRMA noted that the 
pharmaceutical industry has brought under its wing a number of biotechnology advances. 
The organization writes, “The convergence of traditional pharmaceutical chemistry and 
biotechnology has led the pharmaceutical and biotechnology industries, once thought of 
as being distinct and independent, to become more similar than dissimilar” (5). In 
appropriating bio references, the pharmaceutical organization seeks to increase its 
acceptability quotient with the public at large. 
Dr. Frank Baldino, Jr., Chairman and CEO of Cephalon (which calls itself a 
“biopharmaceutical” company), makes light of the distinction between biotechnology and 
pharmaceuticals, saying that he has been in the biotechno logy industry for close to 20 
years and still doesn’t know what biotechnology means. Tongue firmly in cheek, he 
writes: 
 
So what then is biotechnology? Maybe it is a process. Maybe it is how we do 
business. We say a lot of odd things to describe our business, after all we are 
forever telling everyone that we focus on innovative products for unmet medical 
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needs that address large under-served markets using of course (and my personal 
favorite) validated targets. 
 
I guess that by definition then the pharmaceutical industry uses only invalidated 
targets for medical needs that have already been fully satisfied and, perhaps, they 
use no innovation at all. (“Cephalon”) 
 
 
As the biotechnology matures, observers are beginning to question the essence of 
this industry. A recent Forbes article describes how Amgen “started life in California as a 
biotech boutique obsessed with the new science of genetic engineering” and how, 25 
years later, “it is a teenage hippie trapped inside the musclebound body of a $10 billion-a-
year behemoth” (Langreth, “Biotech Behemoth” 130).  
Similarly, an article in The Wall Street Journal says that Amgen, “the world’s 
largest biotech company by sales” is now facing “big-company woes” (Chase A1). As 
biotech products find their way through the FDA approval process to market, biotech 
companies are now facing the same safety and efficacy scrutiny of their products that 
their pharmaceutical counterparts have dealt with for years. 
 In terms of Burkean dialectic, the concept of merger would imply that both 
biotech and pharma have their flaws and their successes. Examples of the positive-to-
negative continuum for big pharma range from: 
 
• “Pharma provides much-needed medical products” to “Pharma pushes drugs” 
•  “Pharma’s drugs are safe” to “Pharma’s drugs are pushed out of research too 
quickly; they aren’t safe” 
•  “Pharma’s drugs are fairly priced” to “Pharma is simply out to make money” 
 
 
 A similar continuum can also be constructed for bio, ranging from: 
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• “Biotechnology is biology; it’s natural” to “Biotechnology is not natural; it’s 
fooling around with nature” 
• “Biotechnology is ethical; it offers new approaches to healthcare” to 
“Biotechnology is unethical; it manufactures Frankenfoods; it promotes 
eugenics” 
 
 
The concept of division, on the other hand, would mean that certain aspects of 
pharma are flawed while aspects of bio are heroic (or the converse).  
Judging from the popular press, a middle ground is emerging whereby bio and 
pharma are both acknowledged as having flaws that are lessened when the two industries 
combine. One industry writer says that “Biopharmaceutical companies have emerged as 
an ideal hybrid combining both the technology platforms of traditional biotech companies 
and the drug development expertise and capabilities of mainstream pharma companies” 
(Viswanathan 20).  
If dramatism is, as Burkean David Blakesley expresses it, “the systematic method 
for articulating these strategic spots, those eddies of meaning where it is possible for 
rhetoric to prove opposites” (22), what then does it mean when two entities weave so 
closely together that opposition no longer applies?  If biotechnology has been synthesized 
(or is synthesizing) into pharmaceuticals and vice versa, then the dialectic (or rhetorical 
matrix) between the two has come to rest. If this is the case, then we can rid ourselves of 
ambiguity once and for all by fusing the helix into a single, unambiguous 
biopharmaceutical (or perhaps “life science”) strand. 
And yet, try as hard as we may to solidify our ideas, the rails of the helix separate 
and we once again move from a scientistic is/is not basis of comfort to a dramatistic 
impetus for inquiry and potential instability. In the world of the DNA double helix, 
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although the “unzipping” of DNA’s base pairs is biologically programmed for 
consistency (thymine can only be paired with adenine; guanine can only be paired with 
cytosine), mistakes can and do happen, causing mutations. In the world of the bio and 
pharma rhetorical helix, separation of the rails (and, for that matter, integration of the 
rails) can also be cause for instability. 
Attempts to merge biotech and pharma strands into one have been met with great 
resistance in some camps. In fact, some industry observers are attempting to deconstruct 
bio and pharma into smaller components, with the pharmaceutical industry positioned not 
merely as one giant big pharma entity, but several different entities, such as “little 
pharma,” “generic pharma,” and “specialty pharma.” The same phenomenon is also 
occurring in the biotechnology arena. 
Ronald A. Rader, president of the Biotechnology Institute, notes that the term 
biopharmaceutical—as in the intersection of the terms biotechnology and 
pharmaceuticals—and other related terms “are so misused and abused that they are losing 
their meaning” (“Part 1” 60). He writes that because the term biopharmaceutical “is used 
inconsistently, other pharmaceutical sectors—including the R&D services and 
mainstream drugs (Big Pharma) industries—are co-opting it for their own uses” (“Part 1” 
61). 
Rader notes that “(i)n the biotechnology business view, anything that appears 
high-tech and involves pharmaceuticals (or life sciences), particularly if it is about small 
companies, is described as biopharmaceutical (and/or bio-technology)” (“Part 2” 43). He 
continues by saying that “hundreds of small drug discovery and related service 
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companies that have no involvement in or use of biotechnologies are called 
biopharmaceutical” (“Part 2” 43).  
Rader suggests that biopharmaceutical and biotechnology are “buzzwords that 
attract audience attention and evoke warmer, more positive images than alternatives such 
as drugs” (“Part 2” 44)  He complains that “both companies and journalists often seem to 
care more about attracting attention and exploiting biotech’s positive image than about 
precise use of particular terms” (“Part 1” 60). 
Rader is right, of course, from a scientific perspective. Arbitrary use of the bio 
modifier does confuse issues such as industry reporting and financial analysis. But from a 
rhetorical perspective, Rader’s observations merely serve to underscore how powerful 
and attractive the notion of bio is in American society. The media, the pharmaceutical 
and biotech industries, and individuals all seem to be jumping on the bio bandwagon. 
When billionaire David H. Murdock, senior chairman, CEO and owner of Dole 
Food Company was looking to transform the old textile town of Kannapolis, North 
Carolina into a new biotechnology research campus, he described the new place as a 
“biopolis,” noting that “(t)he dictionary might say there isn’t such a word, but it’s a new 
term that will be used extensively about our town. I want to make this entire town into a 
think tank” (McCurry 2). 
But in the unstable helix of bio-pharma rhetoric, the terms bio or even biopharma 
may not necessarily be a safe haven. Just as there are scores of people who point fingers 
at the evils of pharmaceuticals, so too are there others, like Adam Wolfson, writing for 
the New Atlantis, who are highly concerned about biotech. Wolfson writes, 
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First, the continued development of biotechnology in certain directions will 
require the violation of truly basic moral strictures. Second, biotechnology will 
initiate a revolution in how we think about family, parenthood, the relation 
between the generations, work and achievement, and many other areas of human 
life. And third, biotechnology could bring about a fundamental rupture in human 
history, leading us into a “posthuman”age. (55) 
 
 
Wolfson characterizes certain aspects of biotechnology—eugenics, cloning, 
embryonic research—as moral and biblical issues. As rhetoric, such shalt or shalt not 
edicts act dramatistically by pushing and pulling at our emotions. If the public sees 
cloning, for example, as contrary to its interests then—in Burkean terms—the interests of 
the public will not be consubstantial with that of the biotechnology industry (or at least 
that sector of the biotechnology industry). 
Similarly, if the public sees the need for new and better therapeutics as critical to 
its interests, then both the pharma and bio industries will find ways to highlight their 
responses to the public’s perceived need. Public ingratiation with pharma, bio, or 
biopharma is always a construction and always in play. Public ingratiation is dynamic; 
one needs only look at the history of pharmaceuticals to see how reaction to an industry 
can advance from negative to positive to negative. 
Meir Statman discusses the process of “creative destruction” in the 
pharmaceutical industry whereby “entrepreneurs constantly look for opportunities to 
compete by improving their products and production processes and by introducing new 
products” (1). The result, he says, is “competition through creative destruction 
(replacement) of existing products and forms of organization” (1). 
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Ultimately, both pharma and bio may need to engage in creative destruction as the 
idea of therapeutics is now interacting in an entirely new rhetorical helix with the concept 
of prevention as the opposite rail. 
Historically, pharmaceutical companies promoted the notion that in order to be 
healthy, we simply needed to ingest a pill and all would be well. Even as the 
pharmaceutical companies appropriated language from biotechnology, the message was 
still the same: new, entrepreneurial drugs can help address mankind’s medical needs. 
The appeal of biotechnology was to take the body’s own naturally produced 
proteins and harness them for medicinal purposes (as Genentech did with the body’s anti-
clotting protein). Bio, therefore, was equivalent to natural, innovative, and even 
personalized. Bio also linked itself with newness and potential for the future. As the 
official voice for the biotechnology industry, BIO develops the content of its web site in a 
way that is most favorable to its interests. On BIO’s web site, biotechnology as a word 
and a concept takes the front row seat, with more mentions than the common word the. 
The future-focused words potential and opportunity are more prevalent on the site than 
present- focused words such as profit and responsibility. And yet, although the 
biotechnology industry emerged as a new way to develop drugs, those drugs are also 
largely based on curing disease. 
“The pharmaceutical and biotechnology industries project themselves as solving 
the world’s problems,” stated Vincent Henrich, Director of the Center for Biotechnology, 
Genomics and Health Research at the University of North Carolina at Greensboro 
(personal interview). “This is an error of enthusiasm.” 
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Henrich stated that instead of antidotes, the real health care paradigm shift will be 
an increased focus on pre-symptomatic diagnosis, early detection, and monitoring 
techniques. Although therapeutics may extend people’s lives, they do not prevent the 
trauma of the disease itself, he said. “Curing cancer is a noble goal and has captured a lot 
of young imaginations,” Henrich said. “But there are two questions: (a) Is it cost-
effective, and (b) Isn’t it better for the patient if he didn’t get cancer in the first place?” 
If Henrich is right, then the rhetorical helix of the biotechnology and 
pharmaceutical industries may be shifting completely, as their combined categorization 
as therapeutics may be newly positioned, through definition and description, in 
opposition to pre-therapeutic approaches. As one Forbes writer expresses it, 
 
The pharmaceutical industry, despite a golden age of biology that has unraveled 
mysteries of the genetic code and yielded miracle drugs that save thousands of 
lives, may be on the brink of a backlash. Millions of us are popping prescription 
pills for innocuous ills, when simple lifestyle changes of diet and exercise—
harped on by physicians for decades—are more effective and a lot cheaper. 
(Langreth, “Just Say No” 103). 
 
 
Perhaps these two new rails—biopharmaceuticals and pre-therapeutic 
approaches—will attempt to reconcile with each other, through a new post-
pharmaceutical, post-biotech world of health. Whatever this new world of health may be, 
and however it may be defined or described, it will certainly be part of a new, always-
ambiguous, always-interacting rhetorical helix. 
 
 
209 
 
WORKS CITED 
 
“Abbott History.” Abbott Laboratories. 2007. 10 March 2007. 
<http://abbott.com/global/url/content/en_US/10.30:30/general_content/ 
General_Content_00069.htm>. 
 
“About Pfizer: Vision and Values.” Pfizer Inc. 2007. 18 March 2007. 
<http://www.pfizer.com/pfizer/are/mn_about_vision.jsp>. 
 
“ADL Denounces PETA for its ‘Holocaust on Your Plate’ Campaign.” Press release. 
Anti-Defamation League. 24 Feb. 2003. 8 Oct. 2006. 
<http://www.adl.org/PresRele/HolNa_52/4235_52.htm>. 
 
“Addressing the Need for Manpower in Biotechnology: A Report from the National 
Center for the Biotechnology Workforce: A Biomanufacturing/Bioprocessing 
Training Panel Discussion.” Biotech Resource Line: A Newsletter Tracking 
Trends in Biotechnology. Plattsburgh, NY: Medical Frontiers International Inc. 2 
Feb. 2006. 1 March 2007. <www.bio- link.org/pdf/resourceline030706.pdf >. 
 
“Administration Introduces New Industry Classification System: Press Release.” Office 
of Management and Budget. Executive Office of the President. 8 Apr. 1997. 1 
Dec. 2006. <http://www.census.gov/epcd/naics/pressrel.html>. 
 
Alexander, Amy. “His Messy Desk Sparked the Discovery of Penicillin; An Eye for 
Observation.” Investor’s Business Daily. 15 June 2006: A03. 
 
“All About the Human Genome Project (HGP).” National Human Genome Research 
Institute. 6 June 2007. <http://www.genome.gov/10001772>. 
 
Almy, Gary L. How Christian is Christian Counseling. Wheaton, IL: Crossway Books, 
2000. 
 
“American and Briton Report Solving Molecular Pattern of Vital Nucleic Acid.” The 
New York Times. 13 June 1953: 17. 
 
Amundsen, Darrel W. and Gary B. Ferngren. “Medicine.” The History of Science and 
Religion in the Western Tradition: An Encyclopedia. Ed. Gary B. Ferngren. New 
York: Garland P, 2000: 485-490. 
 
Anderson, Eric G.  “Here’s to the Giants of Medicine.” Medical Economics. 20 Dec. 
1999: 64. 
 
 
210 
Anderson, J. Brady. “Biotechnology: Reducing World Hunger.” USAID. 15 Sep. 2000. 1 
Dec. 2006. <http://www.usaid.gov/press/spe_test/speeches/2000/sp000915.html>. 
 
AusBiotech: Australia’s Biotech Organisation. 2007. 7 May 2007. 
<http://www.ausbiotech.org/>. 
 
Aventis. Advertisement. “So that Health Doesn’t Depend on Age.” Scrip. October 2002: 
43. 
 
Bankston, John. Alexander Fleming and the Story of Penicillin. Unlocking the Secrets of 
Science Series: Scientists.  Bear, DE: Mitchell Lane P, 2001. 
 
Barnes, Fred. “Politics.” Vogue. Sept. 1989: 542. 
 
Barthes, Roland. Mythologies. Trans. Annette Lavers. New York: Hill and Wang, 1972. 
 
“Bayer.” The Pharmaceutical Century: Ten Decades of Drug Discovery. American 
Chemical Society. 2007. 29 April 2007. 
<http://pubs.acs.org/journals/pharmcent/company5.html>.  
 
Bayer AG Communications. Science for a Better Life: The Mission Strategy of the Bayer 
Group. Leverkusen, Germany: 2004   
 
Bell, Adam. “Billionaire on a Mission.” The Charlotte Observer. 11 Sept. 2005: 1D.  
 
Berthoff, Ann E. The Making of Meaning: Metaphors, Models, and Maxims for Writing 
Teachers. Upper Montclair, NJ: Boynton/Cook, 1981. 
 
Betz, Fredrick. Managing Technological Innovation: Competitive Advantage from 
Change. 2nd ed. Hoboken, NJ: Wiley-IEEE, 2003.  
 
“BioSpace: Hotbed Campaigns.” BioSpace, Inc. 2007. 7 May 2007. 
<http://www.biospace.com/biotechhotbeds.aspx.>. 
 
“Biotech Career Profiles.” Biotechnology Institute. 2005. 7 May 2007. 
<http://www.biotechinstitute.org/careers/career_profiles.html>. 
 
Biotech Primer. The Primer: a Biotechnology Guide for Non-Scientists. 
Carlsbad, CA: Biotech Primer, Inc., 2005.  
 
“Biotechnology.” The Columbia Encyclopedia. 6th ed. 28 April 2007. 
<http://www.bartleby.com/65/bi/biotech.html>. 
 
 
 
211 
“Biotechnology.” Wikipedia. 7 Sept. 2006. 1 Dec. 2006. 
<http://en.wikipedia.org/wiki/Biotechnology>. 
 
“Biotechnology: A Collection of Technologies.” Biotechnology Industry Organization. 7 
May 2007. <http://bio.org/speeches/pubs/er/technology_collection.asp>. 
 
Biotechnology Industry Organization. Editors’ and Reporters’ Guide to Biotechnology. 
Washington, DC: BIO, 2002. 
“Biotechnology Industry Success Stories.” U.S. Department of Labor, Employment and 
Training Administration. 7 May 2007.  
<http://www.doleta.gov/Brg/Indprof/BioSuccess.cfm>. 
Birch, Beverley. Alexander Fleming: Pioneer with Antibiotics. Giants of Science Series. 
Detroit: Blackbirch P, 2002. 
Blakesley, David. The Elements of Dramatism. The Elements of Composition Series. 
New York: Longman, 2002. 
Boettcher, Jennifer. “Challenges and Opportunities Presented by NAICS.” Journal of 
Business & Finance Librarianship. Vol. 5(2) 1999: 3-13. 
 
Booth, Martin. Opium: A History. New York: St. Martin’s Griffin, 1996. 
Bowker, Geoffrey C. and Susan Leigh Star. Sorting Things Out: Classification and Its 
Consequences. Cambridge, MA: MIT P, 1999.  
Bozanich, Ante. “Animal Rights Quotes.” Online posting. Animal Rights Community 
Online. Animal Rights Concerns. 2005. 8 Oct. 2006 
<http://www.animalsuffering.com/forum/viewtopic.php?t=4094>. 
 
Brian, Denis. The Voice of Genius: Conversations with Nobel Scientists and Other 
Luminaries. Cambridge, MA: Perseus Books Group, 2001. 
 
“Bristol Myers Squibb: A Brief History.” Bristol Myers Squibb. 2007. 22 Sept. 2006.  
<http://www.bms.com/aboutbms/content/data/ourhis.html>.  
 
“Bristol Myers Squibb: Working Together. Bristol Myers Squibb. 2007. 10 Mar. 2007. 
<http://www.bms.com/alliances/working_together/content/data/ 
fg_alliances_working_together_4541.html>. 
Bud, Robert. “Antibiotics: The Epitome of a Wonder Drug.” British Medical Journal. 6 
Jan. 2007. 7 May 2007. <http://www.bmj.com/cgi/content/full/334/suppl_1/s6>. 
 
 
212 
---. The Uses of Life: A History of Biotechnology. Cambridge: Cambridge UP, 1993. 
---.  “Biotechnology in the Twentieth Century.” Social Studies of Science. Aug. 1991: 
415-457. 
Burke, Kenneth. A Grammar of Motives and A Rhetoric of Motives. 1945 and 1950. 
Reprint. 2 vols. in 1. A Meridian Book. Cleveland : World P, 1962.  
---. Language as Symbolic Action: Essays on Life, Literature and Method. Berkeley: U of 
California P, 1968. 
---. Permanence and Change: An Anatomy of Purpose. 1954. Afterword Kenneth Burke. 
Berkeley: U of California P, 1984.  
Burke, W. Steven. Personal interview. 7 Mar. 2007. 
Burrill, G. Steven. Foreword. Biotech 86: At the Crossroad. San Francisco: Arthur Young 
High Technology Group, 1986. 
Burroughs Wellcome & Co. Wellcome’s Excerpta Therapeutica. London: Burroughs 
Wellcome & Co, 1908. 
 
“Cannery Row: The Good Life.” Cannery Row Company. 2004. 1 Mar. 2007. 
<http://www.canneryrow.com/theme/goodlife.html>. 
 
Carter, Estanislao. The Last Prophet: A Nove l. Lulu P, 2006. 
 
Ceccarelli, Leah. Shaping Science with Rhetoric: The Cases of Dobzhansky, 
Schrodinger, and Wilson. Chicago: U of Chicago P, 2001.  
 
“Celera: Our History.” Celera. 2007. 7 Mar. 2007. 
<http://www.celera.com/celera/history>. 
 
“Cephalon: Leadership.” Cephalon, Inc. 2006. 7 Mar. 2007. 
<http://www.cephalon.com/Our_business/leadership.aspx>. 
 
“Change of Attitude Needed on Antibiotics.” Editorial. South Morning Post. 15 Feb. 
2006: 14. 
 
Chan, Mark L.Y. “Homo Geneticus or Imago Dei? Beyond Genetic Reductionism.” 
Beyond Determinism and Reductionism: Genetic Science and the Person. Eds. 
Roland Chia and Mark L.Y. Chan. Adelaide, Australia: ATF P, 2003. 
 
 
 
213 
Chase, Marilyn. “Amgen’s Star Fades Amid Safety Questions.” The Wall Street Journal. 
10 April 2007: A1. 
 
Clark, Ronald W. The Life of Ernst Chain: Penicillin and Beyond. New York: St. 
Martin’s P, 1985. 
 
“Clinton’s Grand Jury Testimony, Part 4.” Washington Post. 1998. 7 May 2007. 
<http://www.washingtonpost.com/wp-
srv/politics/special/clinton/stories/bctest092198_4.htm>. 
 
 “Clue to Chemistry of Heredity Found.” The New York Times. 13 June 1953: 17. 
ProQuest Historical Newspapers. Proquest. UNC Greensboro Lib. 7 May 2007. 
<http://www.proquest.com>. 
 
Coe, Fred A. Burroughs Wellcome Co., 1880-1980: Pioneer of Pharmaceutical Research. 
New York: Newcomen Society in North America, 1980.  
 
Cookson, Clive. “The Surprising Virtues of the Evil Weed: HEALTH: Nicotine can be 
good for you. Clive Cookson on the benefits of tobacco-based therapies.” 
Financial Times. 27 June 2003: 13. 
 
Coonan, Clifford. “China’s Green Pigs Aid Stem-cell Study.” The Irish Times. 30 Dec. 
2006: 13. LexisNexis. UNC Greensboro Lib. 7 May 2007. 
<http://www.lexisnexis.com>. 
 
Cooper, Porus P. “Biotechnology? Well, It’s…” Philadelphia Inquirer. 22 June 2005: 
C06. 
 
Corner, John. New Challenges for Documentary. 2nd Ed. Manchester, UK: Manchester 
UP, 2005.  
Craver, Richard. “Big Leap: Biotechnology Industry Happy Choice.” Winston-Salem 
Journal. 30 April 2006: A12. 
“Credo.” Johnson & Johnson. 31 Aug. 2004. 15 Apr. 2007. 
<http://www.jnj.com/our_company/our_credo_history/beginnings/index.htm>. 
 
Crick, Francis. What Mad Pursuit: A Personal View of Scientific Discovery. Alfred P. 
Sloan Foundation Series. New York: Basic Books, 1988. 
 
---. The Astonishing Hypothesis : The Scientific Search for the Soul. New York: 
Touchstone, 1994. 
 
 
 
214 
Crosby, Alfred W. America’s Forgotten Pandemic: The Influenza of 1918. Cambridge: 
Cambridge UP, 1989. 
 
deBethizy, J. Donald. Personal interview. 22 May 2007. 
 
“Dog.” Merriam-Webster’s Collegiate Dictionary. 10th ed. 2000. 
 
Economic Classification Policy Committee. “Issues Paper No. 1: Conceptual Issues.” 
U.S. Census Bureau. 8 Feb. 1993. 1 Dec. 2006. 
<http://www.census.gov/epcd/naics/issues1>. 
Economic Classification Policy Committee. “Issues Paper No. 2: Aggregation Structures 
and Hierarchies.” U.S. Census Bureau. 8 Feb. 1993. 1 Dec. 2006. 
<http://www.census.gov/epcd/naics/issues2>. 
Ede, Andrew and Lesley B. Cormack. A History of Science in Society: from Philosophy 
to Utility. Toronto: Broadview P., 2004.  
“Elon University Poll Finds Support for N.C. Smoking Ban at 65 Percent.” Elon 
University. 3 Oct. 2006. 7 May 2007. <http://www.elon.edu/e-
web/elonpoll/100306.xhtml>. 
Engström, A. “Presentation Speech: The Novel Prize in Physiology or Medicine, 1962.” 
Nobelprize.org. 5 May 2007. <http://nobelprize.org/nobel-
prizes/medicine/laureates/1962/press.html>. 
 
Environmental Commissioner of Ontario. 2004-2005 Annual Report: Planning Our 
Landscape. 29 Apr. 2007 <www.eco.on.ca/english/publicat/ar2004.pdf>. 
“Famous Scots: Sir Alexander Fleming.” Rampant Scotland. 7 May 2007. 
<http://www.rampantscotland.com/famous/blfamfleming.htm>. 
Fancher, Lynn. “Aristotle and the Great Chain.” College of DuPage. 25 Sept. 2004. 7 
May 2007. <http://www.cod.edu/people/faculty/fancher/Aristotl.htm>. 
Farland, Donna. It Takes Two: The Story of the Watson & Crick Team. Oxford, MA: 
Authentic Perceptions P, 2002.   
“Federal Agency Directory: Hierarchical Directory of Agencies.” Louisiana State 
University Lib. 1 Dec. 2006. <http://www.lib.lsu.edu/gov/tree>. 
Ferriman, Annabel. “BMJ Readers Choose Sanitation as Greatest Medical Advance since 
1840.” British Medical Journal. 20 Jan. 2007: 111. 
 
 
 
215 
“Fleming Museum.” St. Mary’s NHS Trust.  2006. 7 May 2007. <http://www.st-
marys.nhs.uk/ fleming_museum.html>. 
Fox, Michael W. Inhumane Society: The American Way of Exploiting Animals. New 
York: St. Martin’s P, 1992. 
Fox Keller, Evelyn. “Physics and the Emergence of Molecular Biology.” Journal of the 
History of Biology 23 (1990): 389-409. 
“Franklin, Rosalind.” CWP at UCLA. 30 April 1997. 7 May 2007. 
<http://cwp.library.ucla.edu/Phase2/Franklin,_Rosalind@841234567.html>. 
 
Friedman, Meyer and Gerald W. Friedland. Medicine’s 10 Greatest Discoveries. New 
Haven: Yale UP, 1998. 
“Fur Facts: FAQ & Quotes.” Furs.com. 8 Oct. 2006. <http://www.furs.com/faq.html>. 
Gambardella, Alfonso. Science and Innovation: The U.S. Pharmaceutical Industry during 
the 1980s. Cambridge: Cambridge UP, 1995. 
 
Garrett, Laurie. Betrayal of Trust: The Collapse of Global Public Health. New York: 
Hyperion, 2000. 
 
“Genentech: The Science of Biotechnology.” 7 May 2007. 
<www.gene.com/gene/research/biotechnology/index.jsp>. 
 
“Get Smart: Know When Antibiotics Work.” Centers for Disease Control and Prevention. 
9 Feb. 2007. 7 Mar. 2007 
<http://www.cdc.gov/drugresistance/community/faqs.htm>. 
Gilchrist, Jim. “Will We See His Like Again? Sir Alexander Fleming’s Work Made 
History, But Is Such Scottish Scientific Discovery Now Under Threat.” The 
Scotsman. 18 March 2005: 31. 
Gladstone, David J. and Laura Gladstone. Venture Capital Investing: The Complete 
Handbook for Investing in Private Businesses for Outstanding Profits. London: 
Financial Times Prentice Hall, 2003. 
 
Glaser, Vicki and John Hodgson. “Before Anyone Knew the Future Nature of 
Biotechnology.” Nature Biotechnology 16 Mar. 1998: 240. 
Glasner, Peter R. and Harry Rothman. Splicing Life? The New Genetics and Society. 
Cardiff Papers in Qualitative Research. Aldershot, Hants, England: Ashgate P, 
2004. 
 
 
216 
GlaxoSmithKline. Forward Thinking. King of Prussia, PA: GlaxoSmithKline World 
Wide Bsiness Development. 7 May 2007. 
<www.gsk.com/about/downloads/busdev-brochure.pdf>. 
 
Glick, Bernard R. and Jack J. Pasternak. Molecular Biotechnology: Principles and 
Applications of Recombinant  DNA. 2nd ed. Washington, DC: ASM P, 1998. 
 
Goldsworthy, Peter D. and Alexander C. McFarlane. “Howard Florey, Alexander 
Fleming and the Fairy Tale of Penicillin.” Medical Journal Australia. 18 Feb. 
2002: 176-178. 
 
Gollop, Frank M. “Heterogeneity Index: A Quantitative Tool to Support Standard 
Industrial Classification.”  U.S. Census Bureau. Aug. 1994. 7 May 2007. 
<http://www.census.gov/epcd/naics/ecpcrpt2>. 
 
Goss, Stephen C. “Testimony of the 108th Congress: The Future of Human Longevity: 
How Important Are Markets and Innovation. Hearing of the Senate Special 
Committee on Aging.”  Social Security Administration Online. 3 June 2003. 7 
May 2007. <http://www.ssa.gov/legislation/testimony_060303.html)>. 
Graft, Donald. “[Answer to] Do You Really Believe That ‘A Rat Is a Pig Is a Dog Is a 
Boy’?” Animal Rights Frequently Asked Questions. 29 April 1995. 8 Oct. 2006 
<http://selenasol.com/selena/struggle/animal_faq.html>.graf 
“Guide to Biotechnology.” Biotechnology Industry Organization. 1 Dec. 2006. 
<http://bio.org/speeches/pubs/er/technology_collection.asp>. 
 
Hantula, Richard. Alexander Fleming. Trailblazers of the Modern World. Milwaukee, 
WI: World Almanac, 2003. 
Harmon, Amy. “A Revolution at 50; Twist and Shout! The Double Helix Replicates Itself 
in Popular Culture.” New York Times 25 Feb. 2003, (Late Edition (East Coast)): 
A1. 
Harrison and Star. Advertisement. “Making Science Sexy.” Pharmaceutical Executive. 
April 2006: 65. 
 
Haught John F. Science and Religion: From Conflict to Conversation. Mahwah, NJ: 
Paulist P, 1995. 
 
Hawthorne, Fran. The Merck Druggernaut: The Inside Story of a Pharmaceutical Giant. 
Hoboken, NJ: John Wiley & Sons, 2003. 
 
Henrich, Vincent. Personal interview. 15 Mar. 2007. 
 
 
217 
Higby, Gregory. “A Brief Look at American Pharmaceutical Education before 1900.” 
American Journal of Pharmaceutical Education. Fall 1999: 1-16. 
 
---. “Introduction: American Pharmacy before 1852.” American Pharmacy (1852-2002): 
A Collection of Historical Essays. Eds. Gregory Higby and Elaine Stroud. 
Madison, WI: American Institute of the History of Pharmacy, 2005. 
 
Hird, Ed. “Sir Alexander Fleming: Countless Millions Saved.” Feb. 2000. St. Simon’s 
Anglican Church. 7 May 2007. < http://www3.telus.net/st_simons/cr0002.htm>. 
 
“Historic Figures: Alexander Fleming.” British Broadcasting Company. 7 May 2007. 
<http://www.bbc.co.uk/history/historic_figures/fleming_alexander.shtml>. 
 
“History of BIO.” Biotechnology Industry Organization. 31 Jan. 2005. 1 Dec. 2006. 
<http://www.bio.org/aboutbio/history.asp>.   
 
“History of the Royal Pharmaceutical Society.” Royal Botanic Gardens, Kew. 9 Sept. 
2006. <http://www.kew.org/collections/ecbot/materia_history.htm>. 
 
Ho, David. “Alexander Fleming.” Time. 29 March 1999: Time 100: 117-120. 
 
Hovland, Michael A. and Jason G. Gauthier. History of the 1997 Economic Census. U.S. 
Census Bureau, July 2000. 
 
“The Human Genome Project Completion: Frequently Asked Questions.” National 
Human Genome Research Institute. Dec. 2006. 7 May 2007. 
<http://www.genome.gov/11006943>. 
 
Hwang, Suein L. “A New Twist to Tobacco: R.J. Reynolds Using Its Research on 
Nicotine to Venture into Drug-Making.” Wall Street Journal. 6 July 1999: F-3. 
“In the Spotlight: A Bright Future in Biotechnology.”  2006. Golden Leaf Foundation. 7 
May 2007. <http://www.goldenleaf.org/spotlight06c.html>. 
Inglis, John and Joseph Sambrook and Jan Witkowski, eds. Inspiring Science: Jim 
Watson and the Age of DNA. Foreword by Matt Ridley. New York: Cold Spring 
Harbor Laboratory P, 2003. 
“Interview with Dr. Charles E. Hamner, Jr.” North Carolina People. Lou Dobbs, prod. 
William Friday, host. UNC-TV, Research Triangle Park, N.C. 13 Feb. 2000. 
“Inventor of the Week Archive: Penicillin.”  Sept. 2003. Lemelson-MIT Program. 7 May 
2007. <http://web.mit.edu/invent/iow/fleming.html>. 
 
 
 
218 
Invest Australia. Advertisement. Biotechnology Investors’ Forum. Worldwide Issue 2, 
2002: 4. 
 
“Invitrogen: Passion at Work for a Healthier Tomorrow.” 27 April 2006. The Scientist.  7 
May 2007. <http://careers.the-
scientist.com/index.cfm?attributes.fuseaction=news.display&article_id=791>. 
 
Jonson, Ben. The Alchemist. Ed. Alvin B. Kernan. New Haven: Yale UP, 1974. 
 
Kaye, Judith. The Life of Alexander Fleming. Pioneers in Health and Medicine. New 
York: Twenty-First Century, 1993. 
Kinsinger, Stuart. “Beware of ‘Big Pharma’.” Lindsay Daily Post (Ontario). 2 June 2006: 
C3. 
Kistler, John M. People Promoting and People Opposing Animal Rights: In Their Own 
Words. Westport: Greenwood P, 2002. 
 
Koehn, Philipp. “Data Intensive Linguistics — Lecture 13; Semantics and Discourse.” 
School of Informatics; University of Edinburgh. 20 February 2006. 7 May 2007. 
<http://www.inf.ed.ac.uk/teaching/courses/dil/> 
 
Kuchment, Anna. “The More Social Sex.” Newsweek. 10 May 2004: 88. 
 
LaFee, Scott. “Cultural Revolution: Why the Petri Became Science’s Favorite Dish.” The 
San Diego Union-Tribune. 25 Jan. 2007: E-1.  
 
Lakoff, George. Don’t Think of an Elephant! Know Your Values and Frame the Debate. 
Foreword by Howard Dean. Introduction by Don Hazen. White River Junction, 
VT: Chelsea Green P, 2004. 
 
---. Moral Politics: How Liberals and Conservatives Think. 2nd ed. Chicago: U of 
Chicago P, 2002. 
 
Lakoff, George and Mark Johnson. Metaphors We Live By. Chicago: U of Chicago P, 
1980. 
 
Lakoff, George and Mark Turner. More than Cool Reason: A Field Guide to Poetic 
Metaphor. Chicago: U of Chicago P, 1989. 
 
Langreth, Robert. “Biotech Behemoth.” Forbes. 20 Jan. 2005: 130.  
 
---. ”Just Say No!” Forbes. 29 Nov. 2004: 102+. 
 
 
 
219 
Langreth, Robert and Matthew Herper. “Germ Warfare.” Forbes. 19 June 2006: 60+. 
 
Lewis, Sinclair. Arrowsmith, Elmer Gantry, Dodsworth. 3 vols. in 1. New York: Literary 
Classics, 2002. 
 
“Lighten Up, Doc.” Editorial. Chicago Sun-Times. 21 Jan. 2004: 63. 
 
Loft, Kurt. “The Stuff of Life.” Tampa Tribune. 21 June 2004: 6. 
 
Lord, Michael D., Stanley W. Mandel and Jeffrey D. Wager. “Spinning Out a Star.” 
Harvard Business Review. 1 June 2002: 115-121. 
 
Macek, Catherine. “Biotech Transition Towns.” The Scientist. Supplement. April 2007: 
66. 
 
Macfarlane, Gwyn. Alexander Fleming, the Man and the Myth. Cambridge, MA: Harvard 
UP, 1984. 
 
Mahoney, Tom. The Merchants of Life: An Account of the American Pharmaceutical 
Industry. New York: Harper, 1959. 
 
Mailer, John S. and Barbara Mason. “Penicillin: Medicine’s Wartime Wonder Drug and 
Its Production at Peoria, Illinois.” Illinois History Teacher. Vol. 8, No. 1: 39-47. 
 
Marx, Christy. Watson and Crick and DNA. New York: Rosen Publishing Group, 2005. 
 
Maurois, Andre. The Life of Sir Alexander Fleming, Discoverer of Penicillin. Trans. 
Gerard Hopkins. Introduction by Robert Cruickshank. New York: EP Dutton, 
1959. 
 
McCabe, Katie. “Who Will Live, Who Will Die?” Washingtonian Aug. 1986: 115. 
 
McCurry, John. W. “Billiona ire Doles Funding for N.C. ‘Biopolis’.” Site Selection. Nov. 
2005: 2.  
 
McKinnell, Hank A. “Healthier Americans, Wealthier America.” 27 Jan. 2004. Pfizer: 
Public Policy. 7 May 2007. 
<http://www.pfizer.com/pfizer/policy/hank_mckinnell.jsp>. 
 
“Milestones in Merck History.” Merck. 2007. 10 March 2007. 
<http://www.merck.com/about/feature_story/01062003_penicillin.html>. 
 
Mollenkamp, Carrick and Adam Levy, Joseph Menn, and Jeffrey Ro thfeder. The People 
vs. Big Tobacco. Princeton: Bloomberg P, 1998. 
 
 
220 
Morgan, William. “Monument to a City’s Past Could Save the City’s Future.” Providence 
Journal 8 Aug. 2003: Commentary, B5. 
 
Morris, Betsy and Doris Burke and Patricia Neering. “The Best Place to Work Now.” 
Fortune. 23 Jan 2006: 78-86. 
 
Murray, Joseph E. “Perspective on Medical Research; Animals Hold the Key to Saving 
Human Lives; We Can’t Let Arguments about Equivalent ‘Rights’ Impede the 
Search for a Cure for AIDS and Other Diseases.” Los Angeles Times. 5 Feb. 
1996: 5. 
 
Nathan, Barry R. and Jessica Turvey. Skills and Competencies Needed by Arizona’s 
Workforce: The Bioindustry. Phoenix, AZ: Advancing Employee Systems, 2001.  
 
Newkirk, Ingrid. “Apology for a Tasteless Comparison.” Israel Insider. 5 May 2005. 8 
Oct. 2006. <http://web.israelinsider.com/views/5475.htm>. 
 
---. Letter. Commentary.  Jul/Aug. 2001: 4. 
 
Nill, Kimball. Glossary of Biotechnology Terms. 3rd ed. Boca Raton: CRC P, 2002. 
 
“The Nobel Prize in Physiology or Medicine 1945.” Nobel Foundation. 2007. 7 March 
2007. <http://nobelprize.org/nobel_prizes/medicine/laureates/1945/press.html>. 
 
“The Nobel Prize in Physiology or Medicine 1945: Sir Alexander Fleming; Banquet 
Speech.” Nobel Foundation. 2007. 7 March 2007. 
<http://nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-
speech.html>. 
 
“North American Industry Classification System – 1987 Standard Industrial 
Classification Replacement, 1997 Final Rule.” Federal Register. 9 Apr. 1997. 24 
Apr. 2007. <http://www.census.gov/epcd/www/naicsdoc.htm>. 
 
“North American Industry Classification System, Updates for 2007, Final Rule.” Federal 
Register. 11 Mar. 2005. 24 Apr. 2007. 
<http://www.census.gov/epcd/www/naicsdoc.htm>. 
 
“North American Industry Classification System, Revision for 2007, Final Rule.” Federal 
Register. 16 May 2006. 1 Dec. 2006. 
<http://www.census.gov/epcd/naics07/index.html>. 
 
“North American Industry Classification System Public Comments by Document 
Number.” U.S. Census Bureau. 1 December 2006. 
<http://www.census.gov/epcd/naics07/DOCKET.HTM>. 
 
 
221 
“North American Industry Classification System, ECPC Decisions on Public Comments 
Regarding Changes.” U.S. Census Bureau. 10 Mar. 2005. 10 May 2007. 
<http://www.census.gov/epcd/naics07/DOCKET.HTM>. 
 
“North American Industry Classification System, Updates for 2007.” U.S. Census 
Bureau. 11 Mar. 2005. 10 May 2007. 
<http://www.census.gov/epcd/naics07/naics07fr2.htm>. 
 
“North American Industry Classification System: Professional, Scientific, and Technical 
Services. Docket Page 37.” U.S. Census Bureau. 10 May 2007. 
<http://www.census.gov/epcd/naics07/NAICS07docketPage37.html>. 
 
North Carolina Biotechnology Center. Annual Report Fiscal Year 1984-1985. Research 
Technology Park, N.C.: NC Biotechnology Center, 1985. 
 
North Carolina Biotechnology Center. Annual Report 1992. Research Technology Park, 
NC: N.C. Biotechnology Center, 1992. 
 
North Carolina Biotechnology Center. Annual Report 1995. Research Technology Park, 
N.C.: NC Biotechnology Center, 1995. 
 
North Carolina Biotechnology Center. Annual Report 1997. Research Technology Park, 
N.C.: NC Biotechnology Center, 1995. 
 
North Carolina Biotechnology Center. Annual Report 1998. Research Technology Park, 
N.C.: NC Biotechnology Center, 1998. 
 
North Carolina Biotechnology Center.  Annual Report. Research Triangle Park, N.C.: 
North Carolina Biotechnology Center, 2006. 
 
North Carolina Biotechnology Center. Moving Biotechnology from the Mind to the 
Marketplace. Research Triangle Park, N.C.: July 2004. 
 
North Carolina Biotechnology Center and North Carolina Department of Commerce. 
Biotechnology Works in North Carolina. Research Triangle Park, N.C., n.d. 
“NCDA&CS Marketing Division: Field Crops – Tobacco.” North Carolina Department 
of Agriculture & Consumer Services. 7 May 2007. 
<http://www.ncagr.com/markets/commodit/horticul/tobacco/>. 
North Carolina’s Research Triangle Park: An Investment in the Future. Narr. Carl Castle. 
John Wilson, 1999. 
 
 
 
222 
O’Keefe, Cati. “All Aboard: A Public/Private Partnership Helps a Declining New Jersey 
Shore Town Reinvent Itself as a Transit-Oriented Community Village.” Builder. 
June 2003: 67-8. 
 
Olby, Robert. The Path to the Double Helix: The Discovery of DNA. Foreword by 
Francis Crick. Seattle: U of Washington P, 1974. 
 
Oliver, Richard W. The Biotech Age: The Business of Biotech and How to Profit from It.  
New York: McGraw-Hill Professional, 2003. 
 
Olshansky, S. Jay and Robert N. Butler and Bruce A. Carnes. “What if Humans Were 
Designed to Last?  The Scientist. March 2007: 28+. 
 
Olson, Maynard V. “Clone by Clone by Clone.” Nature. 15 Feb. 2001: 816-819. 
 
Oxford University Press. The Third Man of the Double Helix: Publisher’s Description. 
2005. 7 May 2007. 
<http://www.us.oup.com/us/catalog/general/?view=usa&cp=25347&ci=97801928
06673>. 
 
Parker, Steve. Alexander Fleming. Groundbreakers. Chicago: Heinemann Library, 2001. 
 
Paugh, John and John C. Lafrance. Meeting the Challenge: U.S. Industry Faces the 21st 
Century: The U.S. Biotechnology Industry. U.S. Department of Commerce, 
Office of Technology Policy. Darby, PA: Diane P, 1997.  
 
 “Penicillin and the Age of Miracles Part 2: The Rise of a Wonder Drug.” Community 
Reporter: A Publication of the Community Advisory Council of Bristol-Myers 
Squibb. Fall 2003. 
 
“PETA’s History: Compassion in Action.” PETA Media Center. People for the Ethical 
Treatment of Animals. 25 May 2007. 
<http://www.peta.org/factsheet/files/FactsheetDisplay.asp?ID=107>. 
 
“PETA’s Mission Statement.” About PETA. 2006. People for the Ethical Treatment of 
Animals. 4 Oct. 2006. <http://www.peta.org/about>. 
 
Peters, Janet and Scott Slotterbeck. Under the Microscope: Biotechnology Jobs in 
California.  Employment Development Department, Labor Market Information 
Division, Information Services Group, Occupational Research Unit, 2004. 
 
Peters, Pamela. “Biotechnology: a Guide to Genetic Engineering.” Access Excellence. 1 
Dec. 2006. 
<http://www.accessexcellence.org/RC/AB/BC/what_is_biotechnology.html>. 
 
 
223 
“Pfizer: 2005 Corporate Citizenship Report.” Pfizer. 2007. 7 May 2007. 
<http://www.pfizer.com/pfizer/subsites/corporate_citizenship/report/index.jsp>. 
 
“Pfizer: Exploring Our History 1849-1899.” Pfizer. 2007. 7 May 2007. 
<http://www.pfizer.com/pfizer/history/1849.jsp>. 
 
“Pfizer: Exploring Our History 1862 – The Civil War.” Pfizer. 2007. 7 May 2007. 
<http://www.pfizer.com/pfizer/history/1862.jsp>. 
 
“Pfizer: Exploring Our History 1900-1950.” Pfizer. 2007. 7 May 2007. 
<http://www.pfizer.com/pfizer/history/1941.jsp>.  
 
“Pharmaceutical.” Encyclopaedia Britannica Online. 2007. 29 Apr. 2007. 
 <http://search.eb.com/eb/article-9059583>. 
 
“Pharmaceutical Industry.” Britannica Concise Encyclopedia. Encyclopædia Britannica 
Online. 2007. 29 Apr. 2007. <http://search.eb.com/ebc/article-9375069>. 
 
“Pharmaceutical Industry.” Encyclopaedia Britannica. Encyclopaedia Britannica Online. 
2007. 20 April 2007. <http://search.eb.com/eb/article-9108560>. 
 
“Pharmaceutical Industry.” The Oxford Encyclopedia of Economic History. 30 April 
2007.  <http://libproxy.uncg.edu:2273/views/ENTRY.html?subview=Main&entry
=t168.e0341.s0003>. 
 
Pharmaceutical Research and Manufacturers of America. Pharmaceutical Industry Profile 
2005. Washington, DC: PhRMA, 2005. 
 
Pollack, Robert. The Missing Moment: How the Unconscious Shapes Modern Science. 
Boston: Houghton Mifflin, 1999. 
 
Potter, W. James. Media Literacy. 3rd ed. London: Sage P, 2005. 
 
Quintiles. Advertisement. “North Carolina: The State of Minds.” Fortune. 19 Sept. 2005: 
S5.  
 
Race for the Double Helix. Dir. Mick Jackson. Perf. Jeff Goldblum, Tim Pigott-Smith, 
Alan Howard, Juliet Stevenson. A&E Television Networks, British Broadcasting 
Corporation (BBC), Horizon Films, 1994. 
 
Rader, Ronald A. “What is a Biopharmaceutical? Part 1: (Bio) Technology-Based 
Definitions.” BioExecutive International. March 2005: 60-65. 
 
 
 
224 
---. “What is a Biopharmaceutical? Part 2: Company and Industry Definitions.” 
BioExecutive International. May 2005: 42-49. 
 
Radford, Tim. “Forgotten Man of DNA Dies at 88.” The Guardian. 7 Oct. 2004: 8.   
 
Rafferty, Heidi Russell. “Breaking the Mold: Biotech, That Strange Industry Few 
Understand, Is Reshaping Our Economy and Our Schools.” North Carolina. Nov. 
2003: 48+. 
 
Ratcliff, J.D. Yellow Magic: The Story of Penicillin. New York: Random House, 1945. 
 
Rathman, George B. “Biotechnology Startups.” Biotechnology: The Science and the 
Business. Derek Springham, Vivian Moses, and Ronald E. Cape, eds. Amsterdam: 
Harwood Academic P, 1991. 
 
Read, John. From Alchemy to Chemistry. New York: Courier Dover P, 1995. 
 
Reingold, Jay. “Industry Alphabet Soup: Decoding the Identifiers.” 2 May 2003. 
Standard & Poor’s. 1 Dec. 2006. 
<www.library.cornell.edu/abld/abld03/sicnaicgic.ppt>. 
 
“Reynolds American, R.J. Reynolds Oppose N.C. Smoking Ban.” PR Newswire. 21 
March 2007. 
 
Robins, Edwin Claiborne. “Making Today’s Medicines with Integrity…Seeking 
Tomorrow’s with Persistence”: The Story of the A.H. Robins Company. New 
York: Newcomen Society in North America, 1966. 
 
Rogoski, Richard R. “What’s in a Name: Context Often Determines Meaning of 
Biotechnology.” Triad Business Journal. Special Edition: Growing Life Science 
Ventures. 19 May 2006: B7+. 
 
Romano, Terrie. Making Medicine Scientific: John Burden Sanderson and the Culture of 
Victorian Science. Baltimore: Johns Hopkins UP, 2002. 
 
Rosen, Michael S. “Biotechnology Flourishes in 2005, While Big Pharma Flounders” 
MidwestBusiness.com. 3 Jan. 2006. 7 May 2007. 
<http://www.midwestbusiness.com/news/viewnews.asp?newsletterID=13380>. 
 
---. “Eat Your Heart Out, Big Pharma: Top 10 Biotech Companies Explode.” 
MidwestBusiness.com. 6 Mar. 2006.  7 May 2007. 
<http://www.midwestbusiness.com/news/viewnews.asp?newsletterID=13902>.  
 
 
 
225 
Runco, Mark A. Creativity: Theories and Themes: Research, Development, and Practice. 
Burlington, MA: Elsevier Academic P, 2007. 
 
Russell, William and Rex Burch. The Principles of Human Experimental Technique. 
London: Methuen, 1959. 
 
Sanders, Robert. “Nobelist James Watson Headlines Celebration of DNA & Biotech.” 
UC Berkeley News. 30 September 2003. 7 May 2007. 
<www.berkeley.edu/news/media/releases/2003/09/30_helix.shtml>.   
 
Sawyer, Robert J. Frameshift. New York: Tor, 1997. 
 
Sayre, Anne. Rosalind Franklin and DNA. New York: WW Norton, 2000; originally 
published in 1975. 
 
Schenley Laboratories. Advertisement. Life. 14 Aug. 1944.  
 
Schrödinger, Erwin. What Is Life?: with Mind and Matter and Autobiographical 
Sketches. Cambridge: Cambridge UP, 1967. First published 1944.  
Seabrooke, Kevin, ed. “Francis Crick and James Watson Figured out the Structure of 
DNA, Opening Up a New Era in Biology.” The World Almanac for Kids 2004. 
New York: World Almanac Education Group, 2003.   
Segerstrale, Ullica. Defenders of the Truth: The Sociobiology Debate. Oxford: Oxford 
UP, 2000. 
Shreeve, James. The Genome War: How Craig Venter Tried to Capture the Code of Life 
and Save the World. New York: Knopf, 2004. 
Smith, Leland L.  Critical Issues in Biomedical Science: a Guide for Biochemistry and 
Molecular and Cell Graduate Students, Postdoctoral Fellows, and Junior Faculty. 
West Conshohocken, PA: Infinity P, 2002. 
Sokoloff, Boris. The Story of Penicillin. Chicago: Ziff-Davis, 1945. 
Spilker, Bert. Multinational Pharmaceutical Companies: Principles and Practices. 2nd ed. 
New York: Raven P, 1994. 
 
Stanley, Alessandra. “Where Has Escapism Gone?” The New York Times. 18 Jul. 2003: 
E-1. 
 
Starko, Alane Jordan. Creativity in the Classroom. 2nd ed. Mahwah, NJ: Lawrence 
Erlbaum, 2001. 
 
 
226 
Statman, Meir. Competition in the Pharmaceutical Industry: The Declining Profitability 
of Drug Innovation. Washington: American Enterprise Institute for Public Policy 
Research, 1983. 
 
Sternberg, Steve. “Double Helix Unlocked Key to Life. USA Today. 24 Feb. 2003: 1D. 
Stevenson, Karen. “1900-2000: Changes in Life Expectancy in the United States.” 23 
Mar. 2006. Elder Web. 7 May 2007. 
<http://www.elderweb.com/home/node/2838>. 
Stich, Stephen P. and Peter Carruthers and Michael Siegal, eds. The Cognitive Basis of 
Science. Cambridge: Cambridge UP, 2002. 
“Stop Animal Exploitation NOW!”  S.A.E.N. 11 Feb. 2007. 24 Apr. 2007. 
<http://www.all-creatures.org/saen/about.html>. 
Tansey, Bernadette. “Biotech Gathering Celebrates 25 years; ‘H & Q,’ Begun with about 
14 Presenters, Now Has about 310.” San Francisco Chronicle. 7 Jan. 2007. 7 May 
2007. <http://www.sfgate.com/cgi-
bin/article.cgi?file=/chronicle/archive/2007/01/07/BUGH4NDCB41.DTL&type=
business>. 
“Targacept: Our History.” Targacept, Inc. 7 May 2007. 
<http://www.targacept.com/wt/page/history>. 
 
Thagard, Paul. “The Passionate Scientist.” The Cognitive Basis of Science. Stephen P. 
Stich, Peter Carruthers and Michael Siegal, eds. Cambridge: Cambridge UP, 
2002. 
 
Tocci, Salvatore. Alexander Fleming: The Man Who Discovered Penicillin. Great Minds 
of  Science. Berkeley Heights, NJ: Enslow, 2002. 
 
Toth, Julius. Letter to the author. n.d. Received 4 April 2007. 
 
Truelove, Christiane. “Word to the Wise.” Med Ad News. Feb. 2007: 3. 
 
Turner, Tyya N. Vault Guide to the Top Pharmaceutical and Biotech Employers. New 
York: Vault, Inc., 2004. 
 
Tweedale, Geoffrey. “Archives of the Pharmaceutical Industry: Their Scope and Use.” 
The Pharmaceutical Industry: A Guide to Historical Records. Lesley Richmond, 
Julie Stevenson and Alison Turton, eds. London: Ashgate P, 2003. 
 
 
 
227 
U.S. Department of Labor, Bureau of Labor Statistics. “North American Industry 
Classification System (NAICS) at BLS.” 17 June 2004. 1 Dec. 2006. 
<www.bls.gov/bls/naics.htm>. 
 
U.S. Department of Labor, Occupational Safety and Health Administration. “SIC Major 
Group 87.” 1 Dec. 2006. 
<http://www.osha.gov/pls/imis/sic_manual.display?id=73&tab=group>. 
 
---. “SIC Major Group 28.” 1 Dec. 2006. 
<http://www.osha.gov/pls/imis/sic_manual.display?id=21&tab=group>. 
 
Vagelos, Roy and Louis Galambos. The Moral Corporation: Merck Experiences. New 
York: Cambridge UP, 2006. 
  
Viswanathan, Sangita. “Poised for Attractive Growth.” Pharmaceutical Formulation & 
Quality. Nov. 2004: 20+. 
 
Vizard, Liza. Foreword. Thrifty Scots?: Steps to Improve Financial Literacy. Jim 
McCormick, Mike Chapman and Deirdre Elrick, eds. Edinburgh: Scottish Council 
Foundation, 2005. 
 
Wallis, T.J.  “Careers in Biotech: Inventing the Future; Want to Help Feed the World, 
Develop New Medications, Cure Diseases, Help Keep our Environment Clean, 
and Help Solve Crime? Then a Career in Biotechnology Just Might Be for You. 
Career World. April 2002: 6+. 
 
Watson, James D. The Double Helix. New York: Atheneum, 1968. 
 
---. “Succeeding in Science: Some Rules of Thumb.” Science. 24 Sept. 1993: 1812.  
 
Weatherall, M. In Search of a Cure: A History of Pharmaceutical Discovery. Oxford: 
Oxford UP, 1990. 
 
West, D. Sean. “Review of DNA The Secret of Life.” Amazon. 7 Jan. 2005. 7 May 2007. 
<http://www.amazon.com/DNA-Secret-James-D-
Watson/dp/0375710078/ref=pd_bbs_sr_2/104-3172230-
4599905?ie=UTF8&s=books&qid=1180902330&sr=8-2>.  
 
Wilkins, Maurice. Maurice Wilkins: The Third Man of the Double Helix. Oxford UP, 
2003. 
 
Wilson, David. In Search of Penicillin. New York: Knopf. 1976.  
 
 
 
228 
Winstead, Edward R. “Humans and Mice Together at Last: Scientists Compare Mouse 
Chromosome 16 to the Human Genome.” Genome News Network. 31 May 2002. 
8 Oct. 2006. <http://www.genomenewsnetwork.org/articles/05_02/ 
mouse_053102.shtml>. 
 
Wolff, George. The Biotech Investor’s Bible. New York: John Wiley and Sons, 2001. 
 
Wolfson, Adam. “Why Conservatives Care About Biotechnology,” The New Atlantis. 
Summer 2003: 55. 
 
Worthen, Dennis B. “The Pharmaceutical Industry, 1852-1902.” American Pharmacy 
(1852-2002): A Collection of Historical Essays. Eds. Gregory J. Higby and Elaine 
C. Stroud. Madison, WI: American Institute of the History of Pharmacy, 2005.   
 
Wright, Robert. “James Watson & Francis Crick” Time: The 100 Most Important People 
of the Century: Scientists and Thinkers. 29 Mar. 1999. 7 May 2007. 
<http://www.time.com/time/time100/scientist/profile/watsoncrick.html>. 
 
Young, Frank E. “Biotechnology: the view from the FDA. Health Matrix. Fall 1986. 1 
Dec. 2006. 
<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed& 
list_uids=10279339&dopt=Abstract>. 
 
Zilinskas, Helen. ”Anne Sayre Collection of Rosalind Franklin Materials.” American 
Society for Microbiology. Aug. 1990. 7 May 2007. 
<http://www.asm.org/Membership/index.asp?bid=16414>. 
 
 
 
229 
APPENDIX A 
 
APOLOGY FOR A TASTELESS COMPARISON 
 
 
Newkirk, Ingrid. “Apology for a Tasteless Comparison.” 5 May 2005. Israel Insider. 8 
Oct. 2006. <http://web.israelinsider.com/Views/5475.htm>. 
 
Apology for a tasteless comparison 
By Ingrid Newkirk  May 5, 2005 
 
When the investigative footage of the violations at the AgriProcessors glatt kosher 
slaughterhouse was released last December, an observant Jewish staff member here at 
PETA (People for the Ethical Treatment of Animals) suggested that we consider 
referencing the classic Yiddish song “Dona, Dona” to convey the horror of the calves 
who are transported to slaughter, and perhaps use its haunting music to accompany the 
video images.  
 
When I consulted with other Jewish staff and PETA advisors, some thought that this was 
an offensive and inappropriate use of the song, which alludes to the journey to 
concentration camps.  
 
This renewed the heated debates that were provoked during the “Holocaust on Your 
Plate” Campaign, taking me back to the mental wrangling that we have experienced here 
over the profound conflicts that comparisons to the Holocaust generate, and the diversity 
of complex positions on these issues within the Jewish community. Even among Jews 
who are aligned with animal rights, the melancholic song incited a spectrum of passionate 
and visceral reactions.  
 
We decided not to use the song in connection with the AgriProcessors case, and I have 
decided to apologize for the pain caused by the “Holocaust on Your Plate” 
Campaign.  
 
When “Holocaust on Your Plate” was originally launched, we knew that it would be 
emotionally charged and intellectually provocative. Even if we had used more 
conventional tactics, people don't like to have it pointed out to them that they¹re causing 
unnecessary pain and suffering by eating meat. We did aim to be provocative. We did 
not, however, aim simply to provoke.  
 
Hard as it may be to understand for those who were deeply upset by this campaign, I was 
bowled over by the negative reception by many in the Jewish community. It was both 
unintended and unexpected. The PETA staff who proposed that we do it were Jewish, and 
the patronage for the entire endeavor was Jewish. We were careful to use Jewish authors 
and scholars and quotes from Holocaust victims and survivors. And since Judaism has 
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some of the strongest teachings regarding compassion for animals among the 
monotheistic faiths, I truly believed, as did the Jewish staff members who proposed the 
exhibit, that a large segment of the Jewish community would support it.  
 
We had also seen the positive response to Holocaust scholar Charles Patterson's book, 
‘Eternal Treblinka: Our Treatment of Animals and the Holocaust,’ and felt that our 
exhibit was very much in keeping both with the spirit and goals of his book, as well as 
the history that he documents, which finds more and more Jews opting for vegetarian 
diets as a part of their response to the Holocaust applied to humans and other animals.  
 
The Orthodox Jewish Press wrote, “Charles Patterson’s book gives us pause for thought, 
and if killing and consuming our animal protein is a societal cause of homicide and 
genocide then we must stop to give some consideration. After all, foods of animal origin 
are especially prone for causing most of our major illnesses, such as cancer and heart 
disease.”  
 
A member of the editorial staff at the daily Israeli paper, Ha’aretz wrote, “this is a 
thorough and thought-provoking book. If the linkage of animal rights and the Holocaust 
seems startling at first, it begins to make perfect sense as one reads on. Some might see 
this as trivialization of the Holocaust; it isn’ t. Instead, the chilling parallels Patterson 
exposes seem to offer even more reason to despair of the human race.”  
 
Another daily paper from Israel, Maariv opined, “the moral challenge posed by 'Eternal 
Treblinka' turns it into a must for anyone who seeks to delve into the universal lesson of 
the Holocaust... .”  
 
The Jerusalem Post stated, "Even if you are not persuaded to give up meat meals for 
moral reasons, at least you will never be able to say of the suffering behind them: “I 
didn't know... .”  
 
Similar responses have been published in Jewish papers all over the world.  
 
The “Holocaust on Your Plate” Campaign was designed to sensitize people to different 
forms of systematic degradation and exploitation, and the logic and methods employed in 
factory farms and slaughterhouses are analogous to those used in concentration camps. 
We understand both systems to be based on a moral equation indicating that “might 
makes right” and premised on a concept of other cultures or other species as deficient and 
thus disposable. Each has its own unique mechanisms and purposes, but both result in 
immeasurable, unnecessary suffering for those who are innocent and unable to defend 
themselves.  
 
As with the song “Dona, Dona,” we had hoped to draw attention to the common, 
terrifying experience of the condemned en route to their horrible and unnecessary 
slaughter. We recognize that the analogy made in “Dona Dona” resonates as more than a 
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rhetorical or literary comparison, especially to those for whom the experience is still too 
personal to universalize. The differences cannot be translated or reduced to a metaphor, 
particularly for the victims and survivors who still bear physical and emotional scars of 
persecution and for the Jewish community still so horribly vulnerable to continued acts of 
anti-Semitism.  
 
We sincerely wished to bridge these different forms of systematic abuse. By showing 
how humans were treated “like animals” it was never our goal to humiliate the victims 
further.  
 
We believe that we humans can and should use our distinctive capacities to reduce 
suffering in the world. Even the vegan diet that we endorse out of concern for animal 
suffering promotes human health, protects the environment, and liberates us from violent 
practices, as Dr. Richard Schwartz makes so clear in his book Judaism and 
Vegetarianism. These are all goals directed at alleviating human suffering as well as that 
of other beings.  
 
Our mission is a profoundly human one at its heart, yet we know that we have caused 
pain. This was never our intention, and we are deeply sorry. We hope that you can 
understand that although we embarked on the “Holocaust on Your Plate” project with 
misconceptions about what its impact would be, we always try to act with integrity, with 
the goal of improving the lives of those who suffer. We hope those we upset will find it 
in their hearts to work toward the goal of a kinder world for all, regardless of species. 
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APPENDIX B 
 
NEW SECTORS IN NAICS 
 
 
 “New Sectors in NAICS.” 3 June 1998. U.S. Census Bureau. 7 May 2007. 
<http://www.census.gov/epcd/www/naicsect.htm>. 
 
New Sectors in NAICS 
 
NAICS groups the economy into 20 broad sectors, up from the 10 divisions of the SIC 
system. 
 
11 Agriculture, Forestry, Fishing and Hunting 
21 Mining 
22 Utilities 
23 Construction 
31-33 Manufacturing 
42 Wholesale Trade 
44-45 Retail Trade 
48-49 Transportation and Warehousing 
51 Information 
52 Finance and Insurance 
53 Real Estate and Rental and Leasing 
54 Professional, Scientific, and Technical Services 
55 Management of Companies and Enterprises 
56 Administrative and Support and Waste Management and 
Remediation Services 
61 Educational Services 
62 Health Care and Social Assistance 
71 Art, Entertainment, and Recreation 
72 Accommodation and Food Services 
81 Other Services (except Public Administration) 
92 Public Administration 
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APPENDIX C 
 
1997 U. S. NAICS CODES AND TITLES 
 
 
 “1997 U.S. NAICS Codes and Titles.” July 1998. U.S. Census Bureau. 7 May 2007.  
<http://www.census.gov/epcd/naics/naicscod.txt>. 
 
1997 U.S. NAICS Codes and Titles 
 
325: Chemical Manufacturing 
3254:      Pharmaceutical and Medicine Manufacturing 
32541:      Pharmaceutical and Medicine Manufacturing 
325411:      Medicinal and Botanical Manufacturing 
325412:      Pharmaceutical Preparation Manufacturing 
325413:      In-Vitro Diagnostic Substance Manufacturing 
325414:      Biological Product (except Diagnostic) Manufacturing 
 
541: Professional, Scientific, and Technical Services 
      5417:      Scientific Research and Development Services 
54171: Research and Development in the Physical, Engineering, and Life 
Sciences 
           54172: Research and Development in the Social Sciences and Humanities 
